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SUMMARY
Hammerhead ribozymes are RNA motifs found in a number of plant viroids which 
possess an autocatalytic function for cleaving intramolecular phosphodiester bonds. The 
hammerhead m otif consists of a conserved catalytic core of 22 nucleotides which is flanked 
by sequences of varying length which hybridise to the target region of the substrate RNA 
through W atson-Crick base-pair interactions. The flanking sequences can be manipulated to 
enable the hammerhead motif to function in a trans-conformation and cleave any RNA 
molecule after a triplet motif with the consensus sequence ‘N U X ’, where N can be any 
nucleotide and X any nucleotide with the exception of guanosine. There has been 
considerable interest in the potential of hammerhead ribozymes as therapeutic gene silencing 
agents for the treatment of dominant-negative genetic disorders, tumours and chronic viral 
infections. The current study has focused on hammerhead ribozymes targeted against 
hepatitis B virus (HBV). The ribozyme-mediated cleavage reaction has been split into two 
components: hybridisation and phosphodiester bond cleavage. The influence of substrate 
RNA secondary structure on both of these steps has been investigated.
A potential stem-loop in the HBV core protein open reading frame was identified by 
computer modelling. Five hammerhead ribozymes with total flanking sequences of 16 bases 
were targeted against NUX triplets in this stem-loop. Ribozyme-substrate hybridisation was 
studied by gel-shift assay utilising radiolabelled ribozymes with an unlabelled excess of 
either a 60-base truncated substrate corresponding to the stem-loop, or a 639-base substrate 
corresponding to the entire core protein open reading frame. The ribozymes were shown to 
bind more strongly to the 639-base substrate. This was thought to be due to the 60-base 
substrate forming aggregates in which the ribozyme binding sites were inaccessible. 
Increasing the length of the ribozyme flanking sequences from 16 to 59 bases increased the 
strength of binding. The strength of ribozyme-substrate hybridisation was not related to the 
predicted extent of double-stranded RNA in the target region of the substrate.
The rate of ribozyme-mediated cleavage was determined under single-turnover 
conditions, with radiolabelled 60-base substrate and an excess of unlabelled ribozyme. 
Strong hybridisation did not necessarily confer a rapid rate of cleavage. Two ribozymes, 
RZ572 and RZ572B, targeted against the same NUX triplet, had different flanking 
sequences (RZ572, total flanking sequence of 16 bases; RZ572B, total flanking sequence of 
59 bases). Although RZ572B has a seven-fold higher affinity for the substrate than RZ572, 
RZ572 has a five-fold higher cleavage rate. It is thought that this is due to changes in the 
substrate secondary structure influenced by the binding of the ribozyme flanking sequences. 
It is proposed that a highly structured substrate RNA promotes rapid ribozyme-mediated 
cleavage as a result of increased torsional stress within the phosphodiester bonds. However,
the substrate secondary structure should not prevent the ribozyme and substrate from 
hybridising.
The activity of the ribozymes in the rabbit reticulocyte lysate cell-free translation 
system was determined. Only one ribozyme, RZ534, when transcribed in situ , induced a 
decrease of 20% in core protein production relative to a luciferase control. This ribozyme 
did not demonstrate any cleavage activity in the earlier in vitro studies. Primer extension 
analysis of RNA extracted from the reticulocyte lysate reactions showed that no cleavage 
products were generated by any of the ribozymes used, suggesting that the inhibition seen 
with RZ534 was the result of an antisense mechanism. Repeating the experiment with in 
vitro synthesized ribozyme RNA did not result in any inhibition of protein synthesis, 
suggesting that the antisense inhibition previously seen was caused by the RZ534 DNA 
transcription template.
The disparity between the results obtained with the 60-base and 639-base substrates, 
and between the purified RNA and cell-free translation experiments, and the large 
inaccuracies seen in the techniques used raises concerns about the validity of this and many 
other earlier in vitro studies, and their relevance to in vivo  conditions. It may be better to 
discard such methodologies, replacing them with intracellular screening and in vitro 
evolution of RNA libraries.
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Basic research is what I am doing when I don’t know what I ’m doing.
W em her von Braun.
The most exciting phrase to hear in science, the one that heralds the most discoveries, is not 
‘Eureka!’ (I found it!), but ‘That’s funny ’
Isaac Asimov.
CHAPTER 1 INTRODUCTION
1.1 HEPATITIS B INFECTION
The World Health Organisation estimates that approximately two billion people have 
been infected with hepatitis B virus (HBV). Most of these patients have an acute infection, 
defined as clearing the virus in less than six months after infection. However, approximately 
350 million persons are chronically infected, with infection lasting more than six months. 
Fifty percent of these patients will eventually clear the virus or suffer a subclinical infection, 
but the other fifty percent will die prematurely from viral-induced cirrhosis or primary 
hepatocellular carcinoma. HBV is the prototype virus of the family Hepadnaviridae, which 
also includes viruses which infect duck, heron, ground squirrel and woodchuck. 
Hepadnaviruses are not thought to be cytopathic; both acute and chronic hepatitis B result 
from the immune response eliminating HBV infected cells. The pathogenesis of chronic 
carriage is explained by an individual’s immune status; note that neonates and the 
immunocompromised develop a chronic infection. Despite an intensive vaccination 
programme, over one million people a year die as a result of HBV infection. Current 
antivirals have limited efficacy either because of specific immune deficits or because of viral 
resistance. They are also too expensive for widespread use in the developing world. To 
understand their antiviral mechanisms, we first need to examine the molecular biology of the 
virus.
1.2 HEPATITIS B VIRUS
HBV is the smallest known human virus. The virion, or Dane particle, has a diameter 
of 42nm, containing within its 7nm thick outer lipid envelope an icosahedral capsid with a 
diameter of 21nm and a partially double stranded circular genome of 3.2kb (figure 1.1). The 
genome contains four overlapping open reading frames (ORFs) encoding the viral 
polymerase, the surface envelope glycoproteins (LHBs, MHBs and SHBs), the core capsid 
protein (HBc), the secreted e-antigen (HBeAg), and the poorly characterised X protein 
(HBx). In addition to the viral proteins, the virion also includes a cellular protein kinase 
(Kann et a l ,  1993).
1.2.1 HBV polymerase
The 90kDa HBV polymerase can be divided into four domains.
1) The N-terminal primase domain. This region is covalently linked via a tyrosine residue to 
the 5 ’ end of the minus-strand of the virion DNA and is necessary for priming minus- 
strand synthesis.
2) The spacer or tether domain which, despite being necessary for polymerase function, has 
no specific function of its own.
1
virus
Figure 1.1a. The HBV virion (or Dane particle) and non-infectious filaments. The 
nucleocapsid (consisting of HBcAg) contains the relaxed, circular DNA and polymerase, 
which are covalently linked via the polymerase terminal (primase) domain. The 
nucleocapsid is surrounded by a lipid envelope derived from hepatocytes, in which is 
embedded the L, M and S forms of HBsAg. The non-infectious filaments and spheres are 
composed of just the three surface proteins. Taken from Gerlich, (1993a)
HBV 
3182 bp
x>
Figure 1.1b HBV genome organization. The outer lines represent the various classes of 
RNA transcripts, with the encapsidation signal, e, indicated. The viral promoters are 
indicated as triangles The inner lines represent the partially double-stranded DNA genome, 
with the repeats DR1 and DR2 indicated as boxes 1 and 2 respectively. The central 
arrows represent the four major ORFs, pre-core (pre-C)/core (C), surface (pre-S1/preS- 
2/S), polymerase (P) and X. Taken from Gerlich, (1993a).
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3) The reverse transcriptase domain, encoding the nucleic acid-dependent polymerase 
activity.
4) The C-terminal RNase H domain, responsible for digesting the RNA strand of the 
pregenomic (pg) RNA-minus strand DNA hybrid (Radziwill et a l., 1990).
Although recombinant polymerase is active in the absence of pgRNA and HBc 
(Seifer & Standring, 1993), the polymerase is only packaged in the presence of pgRNA 
which only carries one functional encapsidation signal. It is thought that only one 
polymerase molecule is packaged per virion. However, it is possible that the polymerase 
could be packaged as a multimer. The polymerase has been targeted with a range of antiviral 
nucleoside analogues (see section 1.8).
1.2.2 Envelope proteins
The pre-Sl/pre-S2/S ORF encodes three glycoproteins, translated from three 
different start codons, but all having identical carboxy termini. The small HBs (SHBs) 
protein (24 kD) is encoded by the S region of ORF S and is translated from the third AUG. 
The N termini of the large (LHBs, 39 kD) and medium (MHBs, 33 kD) surface proteins are 
encoded by the pre-Sl and pre-S2 regions respectively (Heermann et a l., 1984, Stibbe & 
Gerlich, 1983a). In carriers with high viraemia, non-infectious particles composed of excess 
HBsAg can be found in the serum. The morphology of these particles varies from spheres 
with a diameter of 17 to 25 nm to less numerous filaments with a 20 nm diameter and 
variable length. When the LHBs protein is overexpressed relative to the two smaller 
proteins, HBsAg accumulates in the ER (endoplasmic reticulum). The ER dilates and the 
hepatocytes appear opaque when examined by light microscopy, becoming known as 
‘ground glass’ cells (Chisari et al., 1987, Gallina et al., 1994).
SHBs is very rich in hydrophobic residues. Computer modelling suggests that these 
hydrophobic domains form four a-helica l transmembrane domains (Berting et al., 1995, 
Stirk eta l., 1992). Helices HI and IV are amphipathic. It is predicted that this polarity will 
allow SHBs to multimerize within the lipid bilayer, potentiating the budding of HBs particles 
into the ER lumen (Simon et al., 1988). This is supported by studies which have shown that 
HBs with helices ID and IV deleted cannot escape from the ER. It also has an unusually 
high number of 14 cysteines, all of which are crosslinked. Treatment of SHBs particles with 
dithiothreitol breaks the disulphide bonds and can render these particles non-immunogenic . 
A signal for N-linked glycosylation is found at asparagine-146 (Peterson et al., 1982).
The MHBs protein is a minor virion component, with its N-terminal 55 amino acids 
being derived from the pre-S2 domain. The pre-S2 domain is exposed on the outside of the 
virion and is susceptible to protease degradation (Stibbe & Gerlich, 1983b). The asparagine 
at position 4 is glycosylated. The epitopes in this region are not conformation dependent, 
suggesting this region is very flexible (Heermann et a l ,  1987). Peptides with the N-terminal
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pre-S2 sequence have been shown to induce protective immunity. This has led to 
considerable interest in incorporating the pre-S 1 and pre-S2 regions into the HBV vaccine, 
which only comprises of the SHBs protein in commercially available vaccines.
In the LHBs protein, the pre-S 1 domain masks the pre-S2 domain. This prevents the 
glycosylation of asparagine 4 in pre-S2. However, the pre-S 1 domain becomes
myristoylated at the N terminus, anchoring it in the membrane. Myristoylation is essential 
for virus infectivity in vitro (Bruss et a l ,  1996b). Although LHBs is inserted into the 
membrane cotranslationally, its topology is believed to alter after translation is complete 
(Bruss et a l., 1994)
1.2.3 HBc protein
The HBc protein has either 183 or 185 amino acids, depending on the virus 
genotype. Translation begins from the second start codon of ORF C, 29 codons 
downstream of the f ir s t . This upstream region is termed pre-core, and forms the N-terminal 
of the secreted form of HBc, called the e antigen (HBeAg).
HBc contains many charged amino acids. The only post-translational modification is 
phosphorylation when it is expressed in eukaryotic cells (Machida eta l., 1991, Roossinck & 
Siddiqui, 1987). The dynamics of capsid assembly have been studied in Xenopus  oocytes 
(Zhou eta l., 1992, Zhou & Standring, 1991). Once synthesised in the cytoplasm, HBc is 
translocated to the nucleus where it first dimerizes (Zhou & Standring, 1992a). Once the 
concentration of dimers reaches 0.8(iM, they self-assemble into isometric particles with T3 
symmetry containing 180 HBc subunits. These particles contain the pgRNA, the viral 
polymerase and a cellular protein kinase C, though empty particles are also observed (Pasek 
et a l ., 1979). Once assembled the particles are stabilised by disulphide bonds (Nassal, 
1992b, Zhou & Standring, 1992b).
HBc contains two distinct domains which have been defined by mutational analysis. 
The first 147 or 149 amino acids form a protease resistant hydrophobic domain which is 
necessary for core particle formation (Seifer & Standring, 1995). The key motif in this 
region is thought to be a heptad repeat of hydrophobic residues which may form a leucine 
zipper-like domain. Deletion analysis has shown that a minimum of the first 139 amino 
acids is required for core particle formation. The final 36 residues are protease sensitive, and 
are therefore not thought to have any tight structure; this protamine-like domain is extremely 
arginine-rich (Gallina et a l ., 1989). The arginines are clustered in four blocks, three of 
which have the sequence SPRRR(R), and are thought to be involved in binding nucleic acids 
(Nassal, 1992a). Effective encapsidation requires at least the first 164 amino acids. 
However, virus variants in which the core polypeptide ends at residue 164 have severely 
impaired ability to complete positive strand DNA synthesis, making HBc a vital component 
in virus genome replication. Deletion of the first 10 residues at the N-terminal end prevents
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formation of core particles, though substitution of core sequence at the C-terminal and in the 
epitope regions does not impair particle formation (Seifer & Standring, 1995). The minimal 
assembly domain lies between residues 10 and 144 (Birnbaum & Nassal, 1990).
A number of deletions in the central portion of the core ORF have been detected in 
clinical samples. The importance of these deletions is unclear; they are unable to form hybrid 
particles with wild-type HBcAg (Williams, 1997). The presence of these deletions is 
sometimes associated with increased severity of disease. Wild-type HBcAg shows cell-cycle 
dependent intracellular localisation. The protein is present in the nucleus in G1 and G2, but 
is found in the cytoplasm during S phase. The deletions described here show distribution 
throughout the nucleus and cytoplasm, possibly resulting from the deletion lying just 
upstream of the nuclear localisation signal. Although the relevance of these observations is 
unclear, they may be linked to the severe chronic disease seen in these patients.
1.2.4 HBe antigen
The pre-core region of ORF C encodes a hydrophobic a-helix which functions as a 
secretion signal, allowing HBeAg to be translocated into the ER lumen in its unprocessed 
form as p25e (Ou et al., 1986). Following translocation, 19 of the 29 pre-core amino acids 
are removed by host signal peptidase to give p23e. The remaining 10 amino acids prevent 
HBeAg assembling into particles (Wasenauer et al., 1992). p23e is either secreted, becomes 
embedded in the plasma membrane (Bruss & Gerlich, 1988), or undergoes further cleavage 
in the C-terminal protamine-like domain to give three truncated proteins, p l6 e , p l8 e  and 
p20e, all of which are secreted . Sometimes uncleaved p25e can be found remaining in the 
cytoplasm (Garcia et al., 1988).
HBeAg is not essential for the viral life cycle (Schlicht & Schaller, 1988). Mutations 
in the pre-core region can yield viable virus which does not produce HBeAg during chronic 
or acute infection (see section 1.4.2) (Carman et al., 1989). This can complicate monitoring 
of disease progression, as HBeAg has been used as a marker of viral replication, with loss 
of HBeAg along with the appearance of anti-HBe antibodies being taken as an indicator of 
resolution of disease (loss of HBeAg indicates a good prognosis during interferon 
treatment). However, there are patients, particularly of Far Eastern or Mediterranean origin, 
for whom loss of HBeAg leads to more severe disease. It is also important to note that 
patients who are anti-HBe positive fail to respond as well to interferon as HBeAg positive 
patients. There have been reports of patients in which HBeAg was undetectable by 
serological methods following interferon treatment, but DNA sequencing revealed wild-type 
virus. It is speculated in these cases that HBeAg is still being produced, but is contained 
entirely within immune complexes.
HBeAg is believed to induce tolerance (Milich et al., 1993b), particularly in neonatal 
infections, by stimulating a Th2 response, which downregulates the CTL response which
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would otherwise cause disease (see section 1.4.2). It has also been suggested that HBeAg 
may enter the thymus of neonates, and promote the deletion of HBeAg/HBcAg reactive T- 
helper clones. However, the role of HBeAg in adult infections, of which only 5% become 
chronic, is unclear (Aldershvile etal., 1980). Transient overexpression of HBeAg has been 
shown to suppress viral replication through the interaction of p23e with HBeAg, to form 
hybrid core particles which are unable to support encapsidation (Guidotti et al., 1996b, 
Scaglioni eta l., 1997).
1.2.5 HBx protein
The HBx protein is produced at extremely low abundance. Its role has yet to be 
determined in HBV. It has been thought that it may play no useful role in infection, as avian 
hepadnaviruses lack an equivalent to HBx. In vitro experiments with HBV HBx have 
implied that HBx is not necessary for infectivity (Blum et al., 1992). However, experiments 
in the woodchuck, using viruses in which the X ORF is disrupted by a nonsense mutation, 
show that the X protein is essential for the establishment of infection (Zoulim et al., 1994).
In vitro experiments have suggested a role for HBx in gene transactivation (Arii et 
al., 1992), with interactions with ras and rel signalling proteins having been reported (Klein 
& Schneider, 1997). HBx has been shown to bind indirectly to HBV enhancer I (Enh-I) via 
the AP-1 and CREB transcription factors (Benn et al., 1996). Over-expression experiments 
in cell culture have suggested interactions with p53 (Truant et al., 1995) and protein kinase 
C, as well as suggesting HBx may induce apoptosis (Su & Schneider, 1997). Other cell 
culture experiments have implied that HBx is tumourigenic (Seifer et al., 1991), whilst 
transgenic mice over-expressing HBx develop hepatocellular carcinoma (Koike et al., 1994). 
However, the implications of these experiments must be carefully considered, as they all 
involve levels of HBx many times greater than that found in a normal infection. Other 
activities attributed to HBx include serine/threonine kinase (Wu et al., 1990), AMP kinase 
(Dopheide & Azad, 1996) and kunitz-type serine protease inhibitor activities. The latter 
activity may be significant when the interaction between HBx and the proteasome complex is 
considered (Fischer eta l., 1995).
1.3 VIRAL LIFE CYCLE
The HBV lifecycle can be split into several stages (figure 1.2). These are attachment 
to the host cell surface, penetration of the host cell, viral gene expression, genome replication 
and the production and release of new virion particles.
1.3.1 Attachment to the cell membrane
This is the first stage in determining the host range and tissue tropism of a virus 
(Gerlich et al., 1993b). Identification of the HBV receptor has been slowed by the lack of a
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Figure 1.2. A diagrammatic representation of the HBV lifecycle, with key stages indicated. 
(1) Binding to the receptor; (2) penetration of the hepatocyte; (3) entry into the nucleus; 
(4) formation of cccDNA; (5) transcription of viral RNAs; (6) translation of viral mRNAs; (7) 
encapsidation of pgRNA; (8) DNA synthesis; (9) release of new virions from the 
hepatocyte; (10) retention of some genomes in the nucleus for further rounds of replication. 
Taken from Nassal & Schaller, (1996)
tissue culture system. Human hepatocellular carcinoma (HCC) cell lines have been used to 
show that the pre-S domains bind to the membranes of these cells, but not to animal 
hepatocytes or human carcinomas from outside the liver. SHBs is indispensable for viral 
infectivity (Neurath et a l., 1986). It has recently been shown to bind in a Ca2+ dependent 
fashion to a phospholipid binding protein, annexin V, which is present on human liver
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plasma membranes (Leenders et al.,- 1992, Debruin et al., 1995). Despite 90% sequence 
homology, rat liver annexin V does not bind SHBs. Transfection of a non-permissive rat 
HCC cell line with annexin V allows these cells to be infected with HBV, lending more 
support to annexin V being the receptor for HBV (Gong et al., 1997). A role for serum 
proteins has been implied, as both interleukin-6 (Neurath et al., 1992) and monomeric and 
polymerized serum albumin have both been shown to bind HBs (Ishihara et al., 1987, Hu & 
Peterson, 1988, Krone et al., 1990).
1.3.2 Penetration of the host cell
Although there is evidence from DHBV that the capsid enters cells by pH 
independent mechanisms (Rigg & Schaller, 1992), it is still unclear how hepadnaviruses 
penetrate hepatocytes. In DHBV, covalently closed circular (ccc) DNA has been found in 
the nucleus 24 hours after infection (Tuttleman et al., 1986). Although core particles are 
found in the nuclei it is not known if they deliver the DNA or if free DNA enters the nucleus 
on its own. HBc does have a nuclear localisation signal (Yeh et al., 1990), and the diameter 
of core particles is at the functional limit of the nuclear pore (Feldherr et al., 1984).
1.3.3 Viral gene expression
Viral transcription occurs from a limited number of cccDNAs in the host cell nucleus. 
Expression is controlled from two enhancers, with mRNAs being initiated from four 
promoters, but all terminating at the same polyadenylation signal (Schaller & Fischer, 1991) 
(Siddiqui et al., 1987). Note that the quoted nucleotide positions in this thesis are measured 
from the HBV unique EcoRl restriction site in pre-S2.
1) 3.5kb RNAs. This is the major transcription product, and covers the entire genome, with 
some redundancy at the ends (Seeger et al., 1991). Transcription is driven from the core 
promoter to generate two RNAs (Yaginuma & Koike, 1989). The slightly shorter 
pgRNA (initiating at nt 1818) functions as the template for the viral reverse transcriptase, 
as it generates new viral genomes, as well as mRNA for the core and polymerase genes. 
The pre-core RNA initiates 20 to 30 bases upstream of the pre-core ORF (between nts 
1783 and 1790) and serves as mRNA for HBeAg (Yaginuma et al., 1987).
2) 2.4kb RN A. A  low abundance RNA, which functions as the mRNA for LHBs. 
Transcription is controlled from the SP-I promoter element.
3) 2 .1 kb RN A s. These RNAs with heterogeneous 5’ ends serve as the mRNAs for 
production of MHBs and SHBs. Transcription is controlled from the SP-II promoter 
(Cattaneo eta l., 1983).
4) 0.9kb RN A. The mRNA for X-gene expression. Transcription is repressed under 
conditions supporting viral growth, reflecting the extremely low abundance of HBx.
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The typical eukaryotic promoter has a TATA-box approximately 30 nt upstream of 
the transcription initiation point. This motif binds transcription factor IID, which forms the 
core of the transcription pre-initiation complex which recruits RNA polymerase II to a 
precise point for starting transcription. Therefore transcripts produced from TATA-box 
promoters have a precise 5' end. Only the SP-I promoter in HBV has a TATA-box; the 
remaining three promoters are TATA-less and produce mRNAs with variable 5' ends 
(Schaller & Fischer, 1991).
All four HBV promoters are more active in liver cells than in non-liver cells, with the 
SP-II and X promoters being active in all mammalian cell types (Seifer et a l., 1990). 
Maximum transcriptional activity requires binding of hepatocyte-specific transcription 
factors. SP-I requires hepatocyte nuclear factor-I (HNF-I), whilst the pre-core/core 
promoter requires HNF-III (Chen et al., 1994) and C/EBP (CCAAT/enhancer binding 
protein) for its activation (Yuh & Ting, 1991).
Promoter activities are frequently controlled by enhancers. These are elements which 
are usually situated upstream (though also occasionally downstream) of promoters which 
also bind transcription factors to increase the activity of the promoters under their control. 
HBV has two enhancers. The first, Enh-I, is located 450nt upstream of the pre-core/core 
promoter between nts 1080 and 1234 (Dikstein et al., 1990a). It has been shown to 
upregulate the activity of the pre-core/core, surface and X promoters, and to also increase the 
tissue specificity of the surface promoter (Bulla & Siddiqui, 1988, Roossinck & Siddiqui, 
1987). A number of factors bind to Enh-I, though only C/EBP (Dikstein et al., 1990b) and 
the poorly defined hepatitis B liver factor (Guo et al., 1993) are hepatocyte specific. 
Amongst the other factors are AP-1 and CREB , which mediate transactivation of Enh-I by 
HBx (Jameel & Siddiqui, 1986).
A second enhancer is located between nts 1685 and 1773, overlapping the core 
promoter (Yuh & Ting, 1990, Yuh et al., 1992). This is highly tissue specific, having only 
been shown to function in highly differentiated hepatoma cell lines (Yuh & Ting, 1993). It 
has been shown to drive both the SP-I and SP-II promoters. Clusters of mutations have 
been found in Enh-II which are associated with fulminant hepatitis (Yasmin, 1997). Gel 
shift experiments have shown that these mutations prevent the binding of an uncharacterised 
nuclear component, whilst reporter gene assays show that the mutated Enh-II has an 
increased transactivational ability. This has led to the hypothesis that these mutations 
prevent the binding of an inhibitory factor, or disrupt a negative regulatory element in Enh-II 
(Lo & Ting, 1994), leading to increased viral transcription which contributes to the 
development of fulminant hepatitis.
The transcription termination signal is situated just after the pregenomic RNA 
initiation site (Ganem & Varmus, 1987). However, it can only function as a terminator 
when it is more than 400 bases away from the start of transcription (Cherrington et al.,
9
Chapter 1 Introduction
1992), enabling RNA polymerase II to ignore it during the first pass from the 3.5kb RNA 
start point. All HBV RNAs are capped and polyadenylated. Some splice variants have been 
observed in HCCs and infected livers, though their function is unknown in humans (Su et 
al., 1989). Site-directed mutagenesis of these splice sites does not affect viral replication in 
cell culture. A novel genetic element similar to the rev response element from HIV-1 has 
been found 3’ to the S gene, which is believed to suppress splicing (Huang & Yen, 1995). 
However, in ducks, it has been shown that splice variants are needed for the production of 
LHBs (Obert et al., 1996).
1.3.4 Genome replication
The hepadnaviruses are similar to retroviruses in that both groups use reverse 
transcriptase in the replication of their genomes. Whilst retroviruses have an RNA genome 
and replicate via a DNA intermediate (the provirus, which must be integrated into the host 
cell DNA), the hepadnaviruses have a DNA genome and replicate via an RNA intermediate, 
the 3.5kb pgRNA. Although the pgRNA is generated in the cell nucleus, DNA synthesis 
does not occur until the pgRNA has been encapsidated. This process is described in figure
1.3 and reviewed in detail by Nassal & Schaller, (1996).
1.3.5 Formation of new virions
Formation of new virions begins with the association of the polymerase with the e 
encapsidation signal at the 5' end of the pgRNA (Bartenschlager et al., 1990, Bartenschlager 
& Schaller, 1992). The e signal is a highly structured region which is sensitive to mutations. 
This region lies in the pre-core region of the mRNA. Mutations in this region are very 
important during HBeAg to anti-HBe seroconversion in chronic infection (section 1.4.2). 
Because the structure must be maintained, only a limited number of mutations can occur 
(figure 1.4) (Knaus & Nassal, 1993, Pollack & Ganem, 1993).
Core particle assembly and genome maturation occur in the cytoplasm. As described 
previously core particles spontaneously dimerize and when at a sufficiently high 
concentration these dimers assemble around the pregenomic RNA and polymerase to form 
capsids, or core particles.
As the surface proteins are translated the two signal peptides in the S domain insert 
the growing polypeptides into the ER membrane. Core particles show an affinity for ER 
membranes containing LHBs protein (Bruss et al., 1996a), and bud through the ER 
membrane picking up a membrane envelope containing a mixture of all three surface 
proteins. As the virions pass through the Golgi apparatus the glycoside chains on the 
surface proteins are modified and the HBc and LHBs subunits are linked by disulphide 
bridges (Ganem, 1991). Release of the finished virion particles does not require any specific 
signals.
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Figure 1.4. The predicted secondary structure of the HBV encapsidation signal. The 
HBeAg start codon (AUG) is highlighted in bold and boxed. The bulge above codon 15 is 
where the negative strand primer is synthesised (section 1.3.4). This structure must be 
maintained for effective encapsidation of the pgRNA; only mutations which do not disrupt 
the structure can be selected for. Commonly observed mutations are G1896A and 
G1899A. (Kindly supplied by D. Williams, Institute of Virology.)
1.4 HBV PATHOLOGY
1.4.1 Epidemiology and transmission
HBV infection has a broad spectrum of outcomes, ranging from subclinical infection 
to acute, self limiting hepatitis and rarely fulminant hepatitis, which is frequently fatal (figure 
1.5). 50% of infected adults develop a subclinical infection with no visible symptoms. 90% 
of adults with a clinical infection develop acute hepatitis, with only 10% becoming chronic 
carriers. This situation is reversed in patients infected perinatally. There are over 350 
million chronic carriers unevenly distributed around the world. In Northern Europe only
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0.1-0.2% of the population are HBsAg carriers. This rises to 3% in the Mediterranean and 
10-15% in Africa and the Far East. Even higher rates of incidence can be found in some 
communities of Inuit and Australian Aborigines. In endemic areas with carrier incidence of 
up to 20%, over 85% of the population are positive for anti-HBs and/or anti-HBc antibodies.
ADULT EXPOSURE TO HBV
No infection Infection
50% 50%
Subclinical infection Clinical
(no symptoms) infection
90%
Acute HBV Chronic HBV
infection infection
Asymptomatic 
HBsAg carrier
Figure 1.5. HBV infection disease phenotypes. Disease progression can be represented 
as a series of pairs of possible outcomes through which a patient may progress.
Chronic
hepatitis
The main route of transmission is by percutaneous exposure. Before the introduction 
of HBsAg screening infection commonly occurred following blood transfusion or the 
administration of blood products. Today a more common transmission route is via needles 
shared by intravenous drug abusers. Transmission can also occur via acupuncture, tattooing 
and body piercing as well as by seemingly innocuous routes such as sharing razors and 
toothbrushes.
Many adult infections in low prevalence countries occur sexually. Experiments in 
non-human primates have demonstrated infection with contaminated semen, but not with 
saliva. Homosexual men are at particularly increased risk (Karayiannis et al., 1985).
The most important mechanism in endemic areas is from mother to child. 
Transmission does not usually occur in utero, but during birth and the period immediately 
after in Asia, whilst in Africa infection usually occurs in early childhood. Almost all women 
who are HBeAg positive infect their child, whilst transmission is less common from mothers 
who are anti-HBe positive (Delcanho e ta l ,  1994, Zhu et al., 1997).
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1.4.2 Immunopathogenesis
Acute hepatitis is characterised by viral clearance as a result of CTL-mediated killing 
or apoptosis of infected hepatocytes. Although there is evidence from transgenic mouse 
models that CTL can block HBV replication by a non-cytolytic mechanism mediated by 
tumour necrosis factor (TN F)-a and interferon-y (Guidotti et al., 1996a), the high levels of 
serum ALT observed during active hepatitis tie in with the cytolytic mechanism. The acute 
response is broad, strong and polyclonal, and possibly involves natural killer cells. 
Clearance may never be 100% as virus can be found peripherally which can restimulate CTL 
(Michalak eta l., 1994a, Michalak et al., 1994b). It is not clear if this residual virus comes 
from a reservoir in the lymphocytes (StollBecker et al., 1997). A strong memory T-cell 
response is also found after clearance (Penna et al., 1996, Rehermann et al., 1996). In 
contrast to the acute infection, what little CTL response there is in a chronic infection is weak 
and limited to a small number of epitopes.
What factors are involved in producing a chronic infection? It is obviously to the 
virus's advantage to persist in the host for as long as possible. HBV is believed to induce 
tolerance by producing high levels of serum HBeAg and HBsAg (Milich et al., 1993a). The 
hypothesis that HBsAg induces tolerance is based on circumstantial evidence (Mishra et al., 
1992); the long period of HBsAg positivity that is observed following seroconversion to 
anti-HBe does suggest some degree of tolerance. HBeAg has been shown in mice to cross 
the placenta and induce tolerance in the foetus . This parallels what is observed in babies 
born to HBeAg positive mothers, where there is a 90% rate of establishment of chronicity 
(Milich eta l., 1993b). However this tolerance is eventually lost in both mice and humans, 
though it is not known why this occurs. How does HBeAg induce tolerance and prevent 
active disease? HBeAg preferentially stimulates Th2 cells, which mediate the antibody 
response, and downregulates Thl cells, which mediate CTL activity. This is puzzling as 
HBeAg, which shares many epitopes with HBeAg, does not induce tolerance, but instead 
stimulates the T hl response, leading to active disease (Franco et al., 1996). This is probably 
due to the different structures of HBeAg and HBeAg, and the key epitopes being 
conformational (Milich et al., 1995). This observation also explains why patients infected 
with viruses which do not produce HBeAg often go on to develop severe acute, and 
sometimes fulminant, hepatitis. However, it does not explain the large number of cases in 
adults of acute hepatitis caused by HBeAg producing strains. It is believed that the 
establishment of chronic infection in adults is primarily a result of host factors.
HLA class II alleles have been associated with viral clearance; a study in the Gambia 
showed a link between the class II alleles DR1301/1302 and the ability to clear virus (Thursz 
et al., 1995). This link is not perfect, and other factors such as mannose binding protein 
(which binds to the carbohydrate moieties on the viral particles) (Summerfield et al., 1995) 
and T N F-a alleles may also be important (Thursz, 1997).
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As chronic infection proceeds, the virus accumulates mutations (Marinos et al.,
1996). At an early stage pre-core mutants appear which lead to an inability to produce 
HBeAg. The most frequently observed is the G to A substitution at position 1896, which 
produces a stop codon. HBeAg is lost from 5% of chronic carriers per year, resulting either 
in remission or more severe disease. This dichotomy is linked to further mutations arising in 
HBeAg. HBeAg-negative strains have occasionally been reported in patients with non- 
fulminant acute hepatitis. Evidence from sequence analysis has shown that such HBeAg- 
negative viruses are transmissible (Mphahlele et al., 1997). Patients with continuing disease 
show an accumulation of amino acid substitutions in the B-cell epitopes (Carman et al., 
1995, Carman e ta l., 1997a). This is proposed to lead to an ineffective anti-HBc B-cell 
response. In contrast, those patients who enter clinical remission carry viruses with amino 
acid substitutions in the T-helper epitopes of HBeAg. This is thought to permit immune 
escape and reduces immune-mediated disease, with mutant epitopes perhaps acting as 
antagonists against T-cells responsive to wild-type epitopes (Bertoletti et al., 1994).
More and more mutations are selected by the constantly evolving host immune 
response, leading ultimately to the virus being overwhelmed, and full seroconversion 
occurring. The viruses in the late stage of a chronic infection are believed to be considerably 
weaker in terms of infectivity and replication competence than the original wild-type strain. 
Some patients with no serological markers indicating HBV infection have been found to be 
carrying replication-defective HBV genomes (Hiller et al., 1995). It is believed that most 
transmission usually occurs in the acute or HBeAg positive phases of an infection. Although 
this ongoing evolution suggests that the immune system will eventually defeat the virus, 
50% of patients die before this can happen from cirrhosis or primary hepatocellular 
carcinoma.
1.5 VACCINATION
The original HBV vaccine consists of HBsAg particles taken from the plasma of 
chronic carriers. This vaccine is still widely used in Africa and the Far East, but has been 
superseded by a recombinant vaccine in Europe and North America as a result of safety 
concerns. The recombinant vaccine is produced in yeast and is currently the only 
recombinant vaccine licensed for use in humans (Bitter et al., 1988). Both vaccines are 
equally efficacious, though the plasma derived vaccine has the advantage of possibly 
containing small amounts of LHBs and MHBs, as well as having the proper post- 
translational glycosylation. The presence of these components may help to recruit T-cell help 
for antibody production.
The vaccine is administered in three doses at 0, 1 and 6 months and has an 85% 
seroconversion rate. This rises to 90 to 95% after non-responders have received a fourth 
booster shot. There is some controversy as to whether booster shots are required. This is
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due to disagreement over what is a protective level of anti-HBs antibodies, as well as 
discordance between the variety of diagnostic tests available for measuring anti-HBs titres. 
Although an anti-HBs titre of lOmlu/ml will give protection, such low titres may favour the 
selection of escape mutants.
A number of vaccine escape mutants have been observed, with the best characterised 
being the G145R (Carman et al., 1990a, Carman et al., 1990b). This is situated in the ‘a’ 
determinant region of HBs, a key region in determining virus serotype. This variant has 
been observed in vaccinated children with low titres of anti-HBs. Chimpanzee experiments 
have shown that high titres of anti-HBs can protect against infection with this variant. This 
is probably because other epitopes are shared between 145G and 145R, and high titres of 
polyclonal anti-HBs may be capable of responding to these other epitopes. The importance 
of these variants is under study using computer modelling to see how the variants are likely 
to spread. A key factor in this work is determining how fast the variants can spread. The 
incidence of new HBV infections is low, as the spread of HBV is dependent on chronic 
infection generating new infections over a period of decades. It is also unknown whether 
these new variants are spread sexually or vertically; this will have to wait for the cohort of 
infected children to reach sexual maturity. It is also important to know the natural incidence 
of HBsAg variants. Many examples have been reported. Studies of unvaccinated 
populations in Papua New Guinea, Sardinia and South Africa using two different HBsAg 
assays failed to detect some variants (Carman et al., 1997b). The clinical importance of 
HBsAg variants has recently been reviewed by Wallace & Carman, (1997). Initial 
mathematical models do indicate that, with current vaccination policies, vaccine escape 
mutants will become the dominant form of HBV by the mid-21st century (Wilson et al.,
1997).
In the light of the potential problems with variants a number of options are being 
considered for the next generation of HBV vaccines. In the short term the best option for 
dealing with escape mutants may be to use a hybrid vaccine containing both 145G and 145R 
HBsAg particles. The addition of pre-S and HBc epitopes to the vaccine may increase 
efficacy by recruiting T-cell help, as well as generating a broad polyclonal response similar 
to that seen in an acute infection (Kuhrober et al., 1997). Recent studies have shown that a 
vaccine containing pre-S 1 and pre-S2 produced a 64% seroconversion rate in people who 
failed to respond to the traditional vaccine (Hourvitz et al., 1996). Such vaccines will 
probably supplant the use of HBIg (hyperimmunoglobulin) in neonates born to HBeAg 
positive mothers (Delcanho et al., 1994). DNA vaccines are also being studied (Davis, 
1996, Davis et al., 1997). These are based on the surprising discovery that plasmid DNA 
injected intramuscularly can be expressed and produce immunogenic proteins (W olff et al.,
1990). DNA vaccination induces a strong CTL response as well as T-helper and B-cell 
reponses (Schirmbeck eta l., 1995). These responses are against a broad range of epitopes,
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thus mimicking the natural immune response in acute hepatitis. DNA vaccination also 
appears to bypass HLA restriction; mice which fail to respond to a protein vaccine can mount 
a good CTL response after DNA vaccination (Geissler et al., 1997). The mechanism by 
which this occurs is unknown. Another important consideration for using DNA vaccines is 
that plasmid DNA is much cheaper and easier to produce than traditional protein vaccines. 
Other recent developments include the development of oral vaccines. Approaches being 
investigated include using attenuated salmonella bacteria modified to express HBV proteins 
(Schodel et al., 1990, Schodel et a l ,  1993), and bananas engineered to produce HBsAg 
(Anon., 1997). These approaches are still at an early stage of development.
Who should receive HBV vaccine ? Over 100 countries, including the United States 
(Holland, 1996), have implemented a programme of universal childhood vaccination. The 
United Kingdom has controversially failed to follow this lead, restricting vaccination to high 
risk groups. It is generally considered that universal vaccination is the only way that HBV 
will be eventually eradicated.
1.6 CURRENT ANTIVIRAL STRATEGIES
As described earlier, most people infected with HBV develop a clinical or sub-clinical 
acute hepatitis, with the cytotoxic arm of the immune system clearing infected hepatocytes 
and the humoral response neutralising circulating virions and protecting against future 
infection. No antiviral therapies are required for these patients who usually go on to make a 
complete recovery. The situation is not as straightforward for patients with a chronic 
infection, where the host immune response is either insufficiently strong to clear the virus, 
or has been made tolerant to the virus (see section 1.4.2). Many studies have looked at 
HBeAg positive patients, where seroconversion to anti-HBe is linked to a reduction in 
hepatic inflammation and a long-lasting histological improvement in 95% of patients. 
However, many of these studies have failed to take into account the natural rate of 
spontaneous seroconversion from HBeAg to anti-HBe (approximately 5% per annum), 
making interpretation of results difficult.
The end points used to assess efficacy of treatment of chronic HBV infection are as 
follows.
1) Suppression o f  H BV replication.
Clearance of HBV DNA from serum measured by the relatively insensitive hybridisation 
assay.
Clearance of HBeAg/ detection of anti-HBe.
2) Improvement in liver disease.
Normalisation of serum aminotransferase levels.
Decrease in necroinflammatory activity on liver biopsies.
The following are long term assessments.
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3) Eradication o f HBV.
Clearance of HBsAg/ detection of anti-HBs.
Clearance of HBV DNA from serum, measured by PCR.
4) Prevention o f cirrhosis and hepatocellular carcinoma.
No data yet available. As these are the end stages of chronic HBV infection it will be 
another one to two decades before the effects of current antivirals on their development 
can be assessed.
Current antiviral agents can be divided into two groups. The first group, the immune 
modulators, includes interferon and other cytokines, as well as therapeutic vaccination. 
These agents aim to stop viral replication indirectly by directing the immune system against 
infected cells. The second group, the enzyme inhibitors, are designed to block viral 
replication directly by inhibiting the viral polymerase.
1.6.1 Model systems
Before any treatment can enter clinical trials in humans its safety must be determined 
by in vitro and animal experiments. HBV is particularly difficult to study because of its tight 
species specificity, and the difficulties in culturing primary human hepatocytes. In any 
model system a number of markers must be detected in order to establish whether HBV 
infection and replication has occurred.
1) Detection of secreted HBsAg and HBeAg.
2) Detection of HBeAg in hepatocytes.
3) Detection of RNA transcripts of the correct size (see section 1.3.3).
4) Detection of DNA replication intermediates. These include cccDNA and negative and 
positive strand intermediates.
Hepatoma cell lines grow well in cell culture. Transfection of a rat hepatoma line 
with head-to-tail dimers of the HBV genome has been shown to result in the generation of 
42nm Dane-like particles and subviral spheres and filaments of HBsAg, as well as HBV 
specific transcripts and HBV DNA polymerase activity. This work suggests that HBV 
species specificity occurs at the stage of binding and entry into the host cell. Similar work 
has been done with the human hepatoma cell line HepG2. These cells have been shown to 
permit virus entry, but there are contradictory results regarding the detection of replication 
markers. Bchini et al (1990) claimed to have detected cccDNA, viral transcripts and secreted 
particles following infection of HepG2 cells with HBV obtained from the serum of a chronic 
HBsAg carrier. In contrast Qiao et al. (1994) failed to detect any intermediates, though they 
show that virions were internalised by HepG2 cells, but the core particles failed to 
disassemble to release the genome. Infectivity of HepG2 cells has been increased by pre­
treating virions with V8 protease, which removes a portion of the pre-S domain (Lu et al.,
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1996). Many enveloped viruses require cleavage of part of a surface protein before they can 
enter their target cell. It is hypothesised that HepG2 cells lack a specific protease which 
HBV requires for entry.
It would be more desirable to use primary hepatocytes as a model system. However, 
primary hepatocytes are very difficult to grow in culture as they are not completely 
differentiated. This causes them to rapidly change phenotype and become fibroblasts after a 
short period in culture. There has been some success in maintaining primary hepatocytes in 
culture, though the exact details of how this has been achieved have not yet been published. 
Primary hepatocytes have been shown to internalise sHBsAg particles (Debruin et al.,
1995). Both foetal and adult hepatocytes have been used in infection experiments (Gripon et 
al., 1988, Ochiya et al., 1989). In both cases replication markers were detected, though the 
efficiency was low (HBeAg detected in 3% of adult cells and 12% of foetal cells). These 
results were highly variable, though the efficiency of infection can be increased by treating 
the cells with dimethylsulphoxide. An alternative is to try and identify the viral receptor and 
over-express it in cultured cells (see section 1.3.1). This has been done by transfecting 
annexin V into rat hepatocytes. This has allowed entry and replication of the virus.
Although cell systems are potentially useful for testing antivirals which directly 
inhibit a virus component, they are not useful for studying immune modulators. This 
requires an animal model. A considerable amount of work has been done using transgenic 
mice either encoding the whole virus or particular components. These mice have given many 
insights into HBV immunopathogenesis, replication strategies and the development of 
hepatocellular carcinoma (Chisari, 1996). The results of many of these studies are 
summarised in table 1.1. It is important to consider the effects of the different promoters 
used, as this could lead to changes in outcome. For example, expression of HBx from the 
HBV promoter leads to HCC, whilst expression from the a,-anti-trypsin promoter does not.
As the transgenic mouse systems are based on randomly integrated genomes, they do 
not mimic a natural infection with HBV (where integration into the host cell's DNA is not a 
necessary step in the life-cycle, and so does not always occur). Therefore an infectable 
animal model is required. The only other species which HBV infects is the chimpanzee 
(Fowler et al., 1982, Thomas eta l., 1982). However, there are strong moral and economic 
objections to the use of chimps in biomedical research, and the course of disease in 
chronically infected chimps differs from humans. There are a number of other 
hepadnaviruses in other species which can be used as model systems. Both the heron and 
the duck are infected by hepadnaviruses, though they do differ from HBV (Ishikawa & 
Ganem, 1995). Avian hepadnaviruses lack an HBx protein, and their core protein appears to 
differ functionally. Core proteins from HBV and mammalian hepadnaviruses can form 
mixed hybrid core particles, whilst avian core proteins cannot interact with human HBc in 
this way. This could have implications for encapsidation and DNA synthesis.
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P rom oter G enes ex p ressed C haracteristics R eferen ce
HBV All HBV ORFs Viral replication
CTL inhibit viral replication (non- 
cytolytic mechanism)
CTL induced hepatitis
(Araki etal., 
1989)
(Guidotti et 
al., 1996a)
(Guidotti et 
al., 1994a)
HBV SHBs Developmental and hormonal 
regulation 
CTL and cytokine regulation of HBV 
gene expression
Small S is not cytopathic 
CTL induced hepatitis
(Farza etal., 
1987)
(Guidotti et 
al., 1994a)
(Chisari et 
al., 1985)
(Moriyama et 
al., 1990)
MT + HBV LHBs and SHBs SHBs forms rapidly secretable 
spherical particles
LHBs forms HBsAg filaments that are 
retained in the ER forming 'ground- 
glass' cells
(Chisari et 
al., 1986)
ALB + HBV LHBs and SHBs HBsAg storage disease 
Cytokine induced hepatitis 
CTL induced hepatitis
HCC
(Chisari,
1989)
(Gilles etal., 
1992)
(Moriyama et 
al., 1990)
(Chisari,
1989)
HBV HBx HCC (Koike etal., 
1994)
a! AT HBx No HCC (Lee etal., 
1990)
MUP HBc Core particles do not cross the nuclear 
membrane
(Guidotti et 
al., 1994b)
MUP HBeAg HBeAg is secreted, not cytoplasmic or 
nuclear 
HBeAg is not cytopathic
(Chisari,
1996)
MT HBc Immunological tolerance (Milich etal., 
1994)
MT HBeAg Immunological tolerance (Milich etal., 
1990)
Table 1.1. HBV transgenic mice. Promoters used include; HBV (hepatitis B virus), MT 
(metallothionein), ALB (albumin), o^AT (ar anti-trypsin), MUP (mouse major urinary protein). 
Taken from (Chisari, 1996)
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The animal system most closely resembling human HBV infection is the woodchuck. 
The woodchuck is a native of the United States, and is infected by the hepadnavirus 
woodchuck hepatitis virus (WHV). This system has been well characterised and appears to 
have a similar natural history to HBV, causing a chronic infection which can progress to 
cirrhosis or hepatocellular carcinoma. WHV allows studies of infection, pathogenesis, 
superinfection with HDV and antiviral treatment, and is currently probably the most reliable 
model system (reviewed in Roggendorf & Tolle, 1995).
1.7 IMMUNE SYSTEM MODULATORS
1.7.1 Interferon
1.7.1a What are interferons?
Interferons (IFN) were first described in 1957 as proteins with the ability to interfere 
with viral infections (Isaacs & Lindenmann, 1957). The IFN family can be divided in two. 
Type I IFNs, a  and p, primarily have antiproliferative and antiviral effects, while type II, or 
y, IFN functions as an immune modulator. All three types of IFN act at the cell surface, 
with their stimulatory signals being propagated within the cell by protein kinase cascades.
The type of IFN produced during a viral infection depends on the type of cell 
involved. IF N -a  is produced primarily by leucocytes, whilst IFN -p is synthesised by 
fibroblasts. Within the groups of IF N -a  and p are numerous subtypes produced from two 
clusters of a total of 23 genes on chromosome 9. In contrast, IFN-y production is induced in 
lymphocytes by mitogenic cytokines. IF N -a  is the most widely used in therapy either 
obtained from leucocytes or in recombinant form. Recombinant, or 'consensus', IF N -a  is 
based on a consensus sequence of the commonest forms of naturally occurring IFN -a.
IFN receptors are heterodimers embedded in the plasma membrane, with a 
cytoplasmic tyrosine kinase domain. IF N -a  and p both act through the same receptor, 
whilst IFN-y has its own receptor. IFNs make the intracellular environment less hospitable 
for viruses, as well as boosting the immune response.
1.7.1b Antiviral action
Two arms of IFN ’s antiviral action involve double-stranded RNA-dependent 
enzymes (figure 1.6). Many viral RNAs, in contrast to host mRNAs, contain extensive 
double stranded regions.
The (2’-5’) oligoadenylate synthetase (2’5’OAS) is induced early in response to IFN- 
a  to generate oligonucleotides with the general structure ppp(A 2’p)nA. These 
oligonucleotides activate the latent cellular nuclease RNase L, which preferentially cleaves 
double-stranded RNA (Fischer et a l ,  1996).
A second double-stranded RNA-dependent enzyme, p l/e IF 2 a  serine/threonine 
protein kinase, or protein kinase R (PKR), is induced by IF N -a  and p in human epithelial
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cells. Following synthesis, PKR autophosphorylates, associates with the ribosome and 
goes on to phosphorylate the a  subunit of elongation initiation factor 2. This blocks any 
further protein synthesis.
IFN also has immunomodulatory effects which play an important role in limiting 
viral infection (Guidotti eta l., 1994a). Most significant of these is the upregulation of MHC 
class I expression on the surface of infected cells, thus increasing the likelihood of these cells 
being removed by the cytotoxic immune response. In addition to this, IFN also activates 
antigen processing cells and regulates the production of cytokines to enhance cytotoxic T-cell 
and natural killer cell activities (Akbar et a l,  1996).
1.7.1c IFN in the treatment of chronic HBV infection
IF N -a  obtained from buffy coat leucocytes was initially used in the mid 1970s to 
treat HBV. However studies were limited in size and number until recombinant IF N -a  
became available, though these early studies did demonstrate that IF N -a  can suppress HBV 
replication. Over the past decade it as become clear that only a third of patients with HBeAg- 
positive chronic HBV respond to treatment with a sustained loss of viral replication markers 
from serum (figure 1.7). This is accompanied by a flare in serum ALT levels which then 
return to normal, seroconversion to anti-HBe (Brunetto et al., 1991), as well as histological 
evidence of an improvement in liver disease. Successful treatment requires three to six 
months administration of thrice-weekly intramuscular or subcutaneous injection of 5 to 10 
MU of IFN -a. IFN -a is currently the most widely used therapy for chronic HBV infection.
IFN -(3 obtained from fibroblast cultures has been shown to have minimal effect on 
HBV replication (Capalbo et al., 1992). There are limited data regarding recombinant IFN- 
[3, though this is slightly more encouraging.
IFN-y does suppress HBV replication, though not to the same extent as IF N -a  
(Kakumu et al., 1991). There is no advantage in using IFN-y in combination with IF N -a  or 
p, as there is no increase in seroconversion rates and there are more serious side effects, 
such as granulocytopenia and hepatic decompensation (Gilles et al., 1992).
1.7.1d What factors influence IFN response?
Why do only a third of patients respond to IFN? It is important to answer this 
question as it could give an insight into how IFN ’s antiviral effect could be improved, as 
well as predicting which patients will not respond, thus sparing them the side effects of 
prolonged IFN treatment and being more cost effective. The most important factors 
predicting a favourable response are elevated ALT (but not too elevated, otherwise 
decompensation may occur) and low, but not negative, serum HBV DNA levels. Raised 
ALT suggests the presence of some immune response against HBV (Bayraktar et al., 1996), 
which can be boosted by IFN. Concurrent infection with HIV (Dimartino et al., 1996) or
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Figure 1.7. Serum ALT levels and viral markers in patients with chronic HBV infection 
before, during and after a four month course of IFN-a therapy. The top diagram shows a 
typical response to IFN, where HBV DNA is lost before HBeAg, whilst the lower diagram 
shows the course of a poor response. The solid bars represent the levels of three viral 
markers; HBV DNA, HBeAg, and HBsAg, which are used to follow disease progression. 
The peak of ALT in the top panel is the result of a burst of IFN-a stimulated CTL, which 
clears the bulk of the infected hepatocytes. Taken from Hoofnagle & Di Bisceglie (1997).
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HCV (Zignego et al., 1997) does not favour a good response. HBeAg-negative chronic 
carriers have a reduced response rate to IFN. Reactivation in these patients is more likely 
when cirrhosis is present, when disease has been long-term, and if the pre-core mutant of 
HBV has become the predominant circulating virus.
Some studies have looked at peripheral blood cells in non-responders. These have 
shown that levels of IFN receptors do not vary between responders and non-responders, 
though levels of 2’5’OAS do appear to be elevated in responders (Solinas et al., 1993). 
However, the relevance of these studies is questionable, as it is not known how these 
observations relate to what is happening in the liver.
A major concern clouding the use of IFN is that is has been widely reported to have 
poor efficacy in Oriental patients, who constitute over 80% of patients with chronic H B V ; 
This is likely to be because most Oriental patients are infected perinatally, leading to immune 
tolerance and the presence of integrated HBV DNA in the host genome. The development of 
immune tolerance could explain why a large proportion of Oriental patients have normal ALT 
levels. Those patients who have elevated ALT respond at rates comparable to Caucasian 
patients. The main reason for long-term failure to respond is the high frequency (47%) of 
reactivation. This could be related to the reported high prevalence of anti-IFN -a2a 
antibodies in Oriental patients compared to Caucasians treated in a multicentre trial (Lok et 
al., 1990), though other studies have failed to support this observation. Neutralising 
antibodies are not detected when IFN-a2b is used instead. It has been suggested that ethnic 
variation in the distribution of IFN -a2  alleles leads to Oriental patients recognising 
recombinant EFN-a2a as foreign. However, only 50% of patients lacking the IFN -a2a gene 
develop neutralising antibodies; HLA type may play a role in this.
1.7.1e Long term outcome in patients treated with IFN
Few studies have examined responses later than 12 to 18 months after the start of 
IFN treatment, though those that have do report good responses (Korenman et al., 1991, 
Villeneuve& Willems, 1996). However, delayed reactivation of viral replication occurs in 
up to 50% of responders. This is due to either incomplete suppression of HBV replication 
during the course of treatment, or the development of anti-IFN antibodies.
In 50 to 100% of patients who clear both HBsAg and HBeAg semm HBV DNA 
drops to levels undetectable by PCR. However it has been reported that residual HBV DNA 
can be found in peripheral blood mononuclear cells and in the liver of these patients 
(StollBecker et al., 1997). It is not certain as to whether this comes from integrated genomes 
which are incapable of replication, or whether such small quantities of HBV DNA are 
clinically relevant.
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1.7.2 Prednisolone
Acting via the glucocorticoid response element (Turkaspa et al., 1988) and indirectly 
as an immunosuppressor, prednisolone enhances HBV replication (Chou et al., 1992, Lau et 
al., 1992). It may seem strange to use such an agent to treat HBV infection, but withdrawal 
of chronic HBV patients from steroid therapy has been shown to cause an ALT flare and 
spontaneous HBe seroconversion (Daikoku et al., 1995). This has been attributed to a 
rebound increase in immune function above its previous state. This can be further enhanced 
by following prednisolone priming with IF N -a therapy, though this finding has not been 
observed in all trials (Krogsgaard eta l., 1996).
1.7.3 Thymosin
Thym osin-a, is a 28 amino acid peptide purified from bovine thymus which 
promotes IF N -a , IFN-y and IL-2 production, and enhances T-cell function and IL-2 
receptor expression. An initial pilot study showed 86% of patients responded to thymosin-a, 
treatment in the first year (measured by DNA clearance) compared to 25% of patients 
receiving a placebo (Andreone et al., 1993). 78% of the patients who responded maintained 
a response up to three and a half years after the treatment. Thym osin-a, is well tolerated, 
and has been shown to be effective when used in combination with a low dose of IFN -a. In 
this trial 55% of patients who failed to respond to the standard IFN -a treatment responded to 
the thym osin-a,-IFN -acom bination (Rasi eta l., 1996). A more recent study in China has 
showed an overall rate of HBeAg to anti-HBe seroconversion rate of 70.3% in patients 
treated with thym osin-a,-IFN -a compared to 46.3% seroconversion in patients treated with 
thym osin-a, alone. This is particularly significant as it demonstrates the successful use of 
immunomodulators in an Oriental population. A successful response requires less than 
2500pg/ml of viral DNA in serum (Naylor et al., 1996).
As well as having immunomodulatory functions, thym osin-a, has also been shown 
to inhibit the growth of non-small cell lung carcinoma and to specifically inhibit the 
anchorage-independent growth of HBV transfected HepG2 cells (Moshier et al., 1996). The 
mechanisms by which thymosin-a, does this are unknown.
1.7.4 Levamisole
Levamisole is a synthetic, orally administered T-cell stimulant. It has been shown in 
a randomised, double blind trial to increase the number of patients becoming HBV DNA 
negative (Fattovich et al., 1994). However, the rate of HBeAg loss was the same in the 
treated and control groups. Combination therapy with IF N -a  is inferior to treatment with 
IFN -a alone, and has more severe side-effects (Bosch et al., 1993).
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1.7.5 Granulocyte-macrophage colony-stimulating factor (GM-CSF)
GM-CSF is used to improve immune function in immunosuppressed patients, and 
has been shown to decrease serum HBV DNA in chronic HBV patients. The major role for 
GM-CSF is in patients with leucopenia. These patients cannot be safely treated with IFN 
alone, but can receive the normal IFN regimen when receiving GM-CSF.
1.7.6 Interleukin-12 (IL-12)
IL-12 is a heterodimeric cytokine synthesised by antigen presenting cells which 
promotes the activation of Thl cells, maximising secretion of IFN-y (Rossol et al., 1997). 
This stimulates natural killer cells, the generation of a specific CTL response and production 
of opsonizing IgG antibodies. IL-12 has been shown to have therapeutic benefit in mouse 
models of various tumours and viral infections (Cavanaugh et al., 1997). Because of the 
high species specificity of IL-12 (only the sequences of human and murine IL-12 are 
known), no trials have been performed on any of the hepadnavirus animal models. 
However, the importance of CTL in the resolution of chronic HBV is well known, and some 
evidence suggesting a role for IL-12 has been forthcoming. IL-12 has been shown to 
stimulate Kupffer cell activity and mononuclear cell infiltration in the livers of mice. The 
mononuclear infiltrates were shown to have enhanced natural killer activity and to secrete 
IFN-y in vitro without any added stimuli.
Immunisation of mice transgenic for HBeAg with an HBe peptide led to a Th2-driven 
anti-HBe autoantibody response. This could be inhibited by IL-12 treatment, which 
switched the T-helper response to T h l. This suggests that IL-12 could be used in patients 
who have an ineffective immune response to allow them to develop protective CTL 
immunity.
Human trials have begun using IL-12. The relatively long serum half-life (2-5 
hours) compared to other cytokines, and the low toxicity of IL-12, make such studies 
sensible.
1.7.7 Therapeutic vaccination
A new approach to dealing with infectious agents is that of therapeutic vaccination. 
Like conventional vaccination, therapeutic vaccination aims to trigger a protective immune 
response against a pathogen, though in the case of therapeutic vaccination the pathogen 
already resides in the patient. As chronic HBV infection may arise because of an ineffective 
immune response, or the patient becoming tolerised to HBV, IFN and other cytokines aim to 
boost the inherent immune response against HBV. Studies are underway to investigate 
whether vaccination with either HBV proteins or peptides corresponding to HBV CTL 
epitopes can give rise to protective immunity leading to clearance of HBV (Hourvitz et al., 
1996). Why should vaccination with proteins already present in the patient be successful? It
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is likely that whilst the immune response may not recognise virally produced proteins 
generated endogenously, administration of these proteins with an adjuvant presumably 
enables the host to recognise these antigens. The route of administration could also enhance 
immunogenicity by delivering the antigens more directly to the lymph nodes.
Strains of mice which fail to respond to HBsAg as a result of H-2 type (the murine 
equivalent of HLA type) have been described. These mice can be induced to produce high 
levels of anti-HBs by administration of pre-S 1 and pre-S2 epitopes. These regions should 
therefore possibly be included in a therapeutic vaccine. A recombinant vaccinia virus 
encoding the pre-S and S regions of duck HBsAg (DHBsAg) has been used to immunise 
ducks persistently infected with DHBV. This resulted in a significant, though transient, 
decrease in serum DHBsAg. Preliminary studies have shown infants chronically infected 
with vaccine escape mutants to respond favourably to administration of pre-S2 vaccines 
(Machida et a l., 1994, Noto et a l., 1997).
A peptide therapeutic vaccine based on HLA-A2-restricted HBeAg CTL epitopes has 
been developed. Peptides corresponding to CTL epitopes are poor immunogens, so to aid 
presentation these peptides are covalently attached to a T helper epitope peptide and to a pair 
of lipid moieties (Vitiello et a l., 1995). A peptide mapping to amino acids 18 to 27 of 
HBeAg was linked to a T helper epitope from the tetanus toxoid protein and two molecules 
of palmitic acid. This conjugate was shown to elicit a primary HBV-specific CTL response 
in normal subjects in a dose dependent fashion. Although early indications were promising, 
this approach as since been abandoned because of commercial considerations.
1.8 ENZYME INHIBITORS
Numerous agents have been studied to investigate their ability to inhibit the HBV 
polymerase. These are primarily nucleoside analogues, many of which were developed for 
treating other viral infections, primarily herpesviruses (figure 1.8). These have been used 
alone, in combination or in conjunction with immune modulators.
For a nucleoside analogue to become active, it must first be converted to a 
triphosphate form. The majority of compounds active against herpesviruses are only 
phosphorylated by the viral thymidine kinase, and not by host cell kinases. Therefore these 
cannot be used against HBV, which is not known to possess a nucleoside kinase activity. A 
limited number of nucleoside analogues are phosphorylated by cellular kinases, but these are 
more likely to have increased toxicity, or less specificity for the viral polymerase. In 
particular, mitochondrial DNA polymerase is sensitive to inhibition by some of these agents. 
The efficacy of a number of these agents against hepadnaviruses has been evaluated in 
animal models and clinical trials.
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against HBV. Acyclovir, famciclovir and ganciclovir where originally designed for use  
against herpesviruses. Lamivudine was originally designed as an anti-HIV agent, whilst 
fialuridine was designed specifically for use against HBV.
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Figure 1.8b. Pyrophosphate plus the pyrophosphate analogue foscarnet 
(phosphonoformic acid). Foscarnet is particularly effective when used in combination with 
nucleoside analogues, especially ganciclovir. Foscarnet is administered as sodium 
phosphonoformate.
1.8.1 Acyclovir
Acyclovir (9-(2-Hydroxy ethoxy methyl) guanine), a guanosine analogue which is 
widely used to treat herpes infections, has been tried in chronic HBeAg positive infection 
(Weller et al., 1982, Weller et al., 1983). Preliminary studies showed that intravenous 
administration caused a reduction in DNA polymerase and HBV DNA levels (Trepo et al., 
1986). In vitro studies using the cell line HB611, which continuously replicates HBV DNA 
from a transfected genome, confirmed these findings. Administration of acyclovir to this cell 
line not only reduced HBV replication, it also removed the HBV-induced block on HLA
29
Chapter 1 Introduction
class-1 expression, which has important implications for immune recognition of infected 
cells (Takehara et al., 1992).
However, acyclovir has poor bioavailability when administered orally, and can be 
nephrotoxic when delivered intravenously. In vitro studies using DHBV-infected primary 
hepatocytes showed acyclovir to be ineffectual against cells obtained from carrier ducks, 
though some reduction in DHBV DNA levels was seen if cells were treated immediately after 
infection.
Acyclovir is not considered to be a viable option as a single therapeutic agent. One 
study has looked at its use in conjugation with lymphoblastoid IFN-a, but acyclovir was not 
found to enhance the effects of interferon on serum HBeAg levels. An oral prodrug, 6- 
deoxyacyclovir, is completely absorbed through the gut. Despite 6-deoxyacyclovir’s 
increased bioavailability, the single pilot study performed using it resulted in no 
seroconversions (Weller et al., 1986).
1.8.2 Adenine arabinoside
A potent inhibitor of DNA polymerase activity, the purine analogue adenine 
arabinoside (ARA-A) has limited clinical use because of its low solubility in water (Watanabe 
et al., 1982b). A highly soluble derivative, adenine arabinoside monophosphate (ARA- 
AMP), has been studied in various trials (Trepo et al., 1983). Because of heterogeneity 
between the populations studied seroconversion rates vary widely between 5% and 80% 
(Watanabe et al., 1982a, Perillo 1985, Trepo 1986). A more recent study (Buti 1993) 
showed in patients who seroconverted to anti-HBe following treatment with ARA-AMP that 
all patients who also lost HBsAg also became HBV DNA negative by PCR, whilst 81% of 
those who failed to lose HBsAg also became HBV DNA negative (Buti et al., 1993).
Successful treatment with ARA-AMP does depend on low initial levels of HBV DNA 
(below lOOpg/ml) (Marcellin eta l, 1995). This could be due to the necessity o f limiting the 
duration of treatment to under 28 days because of ARA-AMP’s side effects. Many patients 
develop severe neuropathies and myalgias, which can sometimes lead to long-standing 
disability. This has lead to ARA-AMP being withdrawn from use in single agent treatments 
in chronic HBV infection. However, the development of ARA-AMP-lactosaminated 
albumin conjugates which can be specifically targeted to hepatocytes has enabled lower 
effective doses to be used . Although studies using these conjugates are in an early stage, it 
is hoped that the results will lead to the reintroduction of ARA-AMP as a therapeutic agent
1.8.3 Fialuridine
Although fialuridine (l-p-D-2'-deoxy-2'-fluoro-arabinofuranosyl-5-iodouracil) is a 
potent reverse transcriptase inhibitor, it has been withdrawn from use as an antiviral 
following the deaths of a number of patients in a clinical trial. Animal and cell culture
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experiments have shown that fialuridine has an extremely high mitochondrial toxicity 
(Colacino, 1996).
1.8.4 Ganciclovir and foscarnet
Ganciclovir (9 -(l,3-Dihydroxy-2-propoxymethyl) guanine) is an acyclic guanosine 
analogue which is used to treat CMV infection in immunocompromised patients. It was 
observed that ganciclovir significantly inhibited HBV DNA replication in patients coinfected 
with HIV (Locamini et al., 1989). It has since been shown to inhibit DHBV replication in 
persistently infected hepatocytes in cell culture and in vivo (Luscombe et al., 1996), and to 
inhibit WHV replication in chronic carrier woodchucks.
Despite its efficacy against HBV, ganciclovir does have some drawbacks. It requires 
parenteral administration due to poor oral bioavailability. As ganciclovir is virustatic, rather 
than virucidal, withdrawal of treatment causes rebound of viral replication. This necessitates 
long term treatment, which frequently leads to myelosuppression.
These problems have lead to ganciclovir being used in combination with foscamet 
(sodium phosphonoformate). Foscarnet is a pyrophosphate analogue which inhibits DNA 
polymerase (figure 1.8b). The inhibitory action of foscamet differs from that of the 
nucleoside analogues, as a different part of the reverse transcriptase active site is targeted. A 
combination of ganciclovir and foscamet has been shown to act synergistically against 
human herpesviruses and against DHBV in vivo (Civitico et al., 1996). This combination 
therapy also reduces HBV replication in immunosuppressed patients, suggesting a role post 
liver transplant (Gish et al., 1994).
1.8.5 Famciclovir
Famciclovir (9-(4-acetoxy-3-acetoxymethylbut-l-yl)-2-amino purine) is the oral 
prodrug of penciclovir, and was originally used as an anti-herpes vims agent (Cirelli et al., 
1996). The conversion of famciclovir to penciclovir is mediated by an esterase and xanthine 
oxidase (figure 1.9). Penciclovir is efficiently phosphorylated in infected cells by 
herpesvirus specific thymidine kinase to generate an active triphosphate form with an 
intracellular half life of up to 20 hours. In treatment of varicella zoster vims infection, 
famciclovir has been shown to accelerate healing of cutaneous lesions and reduce the period 
of post-herpetic neuralgia.
HBV is not known to encode a thymidine kinase. Although penciclovir is poorly 
phosphorylated by cellular kinases, it is thought that hepadnaviral reverse transcriptase is 
particularly sensitive to penciclovir triphosphate inhibition (Dannaoui et al., 1997) (Korba & 
Boyd, 1996) (Shaw et al., 1996). The antiviral effect is prolonged by penciclovir 
triphosphate’s long half life.
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Figure 1.9. The conversion of the oral prodrug famciclovir to the active antiviral penciclovir 
by intracellular esterases and xanthine oxidase.
Famciclovir is unique amongst nucleoside analogues as short-term treatment has been 
shown to result in a sustained response, with undetectable HBV DNA and normalised ALT. 
Trepo et al (1997) showed in a phase II trial that patients who had received 500mg 
famciclovir thrice daily for 16 weeks still showed a sustained response 8 months after the 
end of treatment. There was also evidence for an increased rate of seroconversion to anti- 
HBe over the placebo group. In addition to these encouraging results, famciclovir is also 
well tolerated. Famciclovir also shows promise in the treatment of orthotopic liver transplant 
patients, being used either prophylactically pre-transplant (Singh et al., 1997), or post­
transplant to prevent reinfection (Prieto et al., 1996).
1.8.6 Lamivudine
Lamivudine (p-L-2’3’dideoxy-3’thiacytidine), or 3TC, was originally designed for 
use against HIV. It was observed in patients coinfected with both HIV and HBV that 
lamivudine inhibited HBV replication as well as HIV (Benhamou et al., 1995). Further 
studies confirmed this, paving the way for clinical trials in patients with chronic HBV. 
Lamivudine has good oral bioavailability and lacks long term toxicity (Honkoop et al., 
1996). This is a great benefit, as lamivudine treatment may have to be life-long because 
HBV can reappear even from undetectable levels on withdrawal of treatment. An important 
observation was that lamivudine can inhibit HBV replication in Oriental patients who fail to 
respond to interferon treatment (Lai et al., 1994, Lai et al., 1997) (see section 1.7.Id).
Despite lamivudine only having been used for a short period of time, resistant HBV 
mutants are already appearing (Bartholomew e ta l ,  1997). These viruses carry mutations in 
the YMDD motif of the reverse transcriptase active site (Tipples et al., 1996, Schalm, 1997). 
Similar mutations have also been observed in lamivudine resistant strains of HIV. 
Lamivudine escape mutants occur in approximately 30% of patients per year who relapse. 
However, the viral load is often below pre-treatment levels, so the clinical importance of 
such mutants is not yet clear. Combination therapy may offer a solution to this problem.
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Lamivudine and penciclovir have been shown to act synergistically in blocking HBV 
replication when administered together (Colledge et al., 1997). It was also hypothesised that 
treatment with lamivudine to reduce viral replication may assist IFN treatment in patients 
who fail to respond to IFN alone. Unfortunately this was not the case, with no increase in 
IFN induced CTL response in patients treated with lamivudine and IFN compared to those 
patients treated with IFN alone (Kuhns et al., 1995). However, it is generally considered 
that lamivudine is the best of the current enzyme inhibitors available.
1.8.7 Dideoxynucleosides
Dideoxynucleosides are potent inhibitors of HIV reverse transcriptase. Several 
studies in vitro and in ducks have shown that dideoxynucleosides can inhibit hepadnaviral 
reverse transcriptases. However they fail to show any appreciable effect on HBV replication 
in humans.
1.9 FUTURE DIRECTIONS FOR ANTI-HBV THERAPIES
It can be clearly seen that there is a desperate need for an anti-HBV agent which 
produces improved rates of HBe seroconversion and loss of HBV DNA compared to current 
therapies, but without any danger of side effects. Gene therapy is being considered as a 
possible treatment for chronic viral infections, including HBV and HIV. One approach is to 
use dominant negative mutants to interfere with the viral lifecycle (Scaglioni et a l ., 1996). 
Fusion proteins containing the N-terminal region of HBc and the C-terminal region of HBs 
have been shown to inhibit the replication of HBV, DHBV and WHV in cell culture by over 
95% (von Weizsacker et al., 1996). These mutant proteins blocked encapsidation of the 
pgRNA and DNA synthesis, and prevent normal HBc from functioning correctly. RNAs 
corresponding to the tat and rev response elements have been used to block HIV replication 
in vitro. The tat and rev response elements are structured regions of the HIV transcripts 
which bind the tat and rev proteins as a necessary step in the regulation of viral translation. 
The RNAs used in this study titrate out the tat and rev proteins, thus blocking viral protein 
synthesis. It is feasible that similar RNAs corresponding to the HBV £ signal could be used 
to block the encapsidation of HBV pgRNA.
Another new approach which is being widely investigated with regards to the 
treatment of viral infections and cancers is the direct targeting of deleterious genes and their 
transcripts. These protocols utilise nucleic acids (NA) or their chemically modified 
derivatives as agents for silencing genes. Such treatments can take the form of gene therapy, 
in which the therapeutic molecule is an RNA transcribed from a gene which has been 
delivered to the diseased tissue, or more conventionally can involve the administration of 
exogenously synthesised DNA or modified NA. This area can be broadly divided into three 
sections; 1) triplex forming oligonucleotides (TFOs), 2) antisense oligonucleotides and 3)
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ribozymes. Although a few of these agents have entered preliminary clinical trials, most 
work in this area is still at an experimental stage. These three different approaches will now 
be reviewed, and their applications with regards to chronic HBV infection will be discussed.
1.10 TRIPLEX FORMING OLIGONUCLEOTIDES (TFOs)
Since the late 1950s it has been known that some DNA sequences are able to assume 
a triple helix, or triplex, structure (Felsenfeld et al., 1957). This was initially shown to 
occur between duplexes in which one strand consisted entirely of purines (R) and the other 
entirely of pyrimidines (Y), and a third strand consisting of either purines (R, giving a YR*R 
triplex) or pyrimidines (Y, giving a YR*Y triplex). The initial duplex is bound by 
conventional Crick-Watson base pairing, whilst the third strand binds by Hoogsteen base 
pairing into the major groove of the duplex (figure 1.10). The third strand always lies anti­
parallel to its analogous strand in the duplex (i.e. if the third strand is a homopurine, it will 
lie anti-parallel to the homopurine strand of the duplex). A triplex can either be intra- or 
inter-molecular, with the third strand in the latter being either RNA, DNA or a modified NA 
(figure 1.11) (Reviewed in (Frank-Kamenetskii & Mirkin, 1995)). Kinetic studies have 
shown that triplex formation is two to three orders of magnitude slower than duplex 
formation. The rate limiting step is formation of the first three or four base triplets, after 
which the rest of the TFO rapidly zips into place (Plum et al., 1995, Paes & Fox, 1997). 
This phenomenon was largely ignored until the mid-eighties when its potential as a gene 
silencing technique was first mooted.
Two major factors have to be addressed in considering TFOs as therapeutic agents: 
specificity and stringency. As TFOs are limited to targeting homopurine-homopyrimidine 
sequences, there have been extensive studies investigating alternative bases which can be 
incorporated into the TFO to enable recognition of thymines or cytosines in the otherwise 
homopurine duplex strand (Griffin & Dervan, 1989, Macaya et al., 1991, Mergny et al., 
1991, Griffin et al., 1992). Although single mismatches can be tolerated, each successive 
mismatch disfavours triplex formation, with energies of 3 to 6 kcal/mol being lost with each 
mismatch, though this does at least reduce the chances of non-specific binding. Attempts to 
replace bases in the third strand with non-canonical bases (e.g. GC*T rather than TA*T) 
have not been very successful, mainly due to the weaker binding of these pairs. Artificial 
DNA bases may provide the solution. Several studies utilising non-natural bases, including 
2’-deoxynebularine (Stilz & Dervan, 1993) and 2 ’-deoxyformycin A (Rao et al., 1994), 
suggest that these bases form stable triads with cytosine and thymines interrupting the 
homopurine strand, though it is as yet unclear whether they provide the required specificity 
and stringency.
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Figure 1.10b. Base triads of YR*R triplexes. In addition to the canonical triads CG*G (iii) 
and TA*A (v), YR*R triplexes can also accommodate TA*T (iv) and CG*A+ (vi) triads, often 
resulting in greater stability. Crick-Watson duplex base pairs are within brackets. Taken 
from Frank-Kamenetskii and Mirkin, (1995).
Can triplexes be stabilised in vivo without any loss of specificity? Stable triplex 
formation in vitro requires non-physiological conditions, with YR*Y triplexes requiring a 
pH below 4 (as cytosine residues must be protonated) and YR*R triplexes requiring
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millimolar quantities of bivalent cations. YR*Y triplexes can be stabilised by poly amines, 
which are found at millimolar quantities in the nucleus (Hampel et al., 1991, Barawkar et al.,
1996), and by basic oligopeptides (Potaman & Sinden, 1995). The requirement for cytosine 
protonation can be overcome slightly by substituting it with 5-methylcytosine in the TFO 
(Barawkar et al., 1994, Rajeev et al., 1997). A range of artificial bases are also being 
investigated for this role, with extended aromatic bases to allow intercalation into the target 
duplex (Lehmann et al., 1997).
Figure 1.11. Formation of triplex DNA. Triplex can arise either from one strand of a region 
of duplex DNA doubling-back on itself (A), or from the binding of an oligonucleotide into the 
major groove of duplex DNA (B).
Addition of an intercalator can also stabilise TFO binding. Moieties such as acridine 
(Miller et al., 1991) and psoralen (Bates et al., 1995) slot between the two strands of the 
target duplex, anchoring the TFO into its binding site. UV-irradiation can irreversibly cross­
link psoralen TFOs with DNA, allowing permanent gene suppression. This is more 
effective if the intercalator is bound to the 5 ’ end of the TFO, though it is not known why. 
Agents which preferentially intercalate into triplex DNA, such as benzo[e]pyridoindole 
(Escude et al., 1995) and coralyne (Lee et al., 1993), have also been shown to stabilise TFO 
binding. TFOs can also be modified to mediate cleavage of the target DNA duplex by 
conjugation with organometallic complexes (Joshi & Ganesh, 1994, Kane et al., 1994), or 
inclusion of a radioactive atom (McShan & Kinsey, 1993).
A new class of agent which could be used as a TFO is peptide nucleic acid (PNA). 
This forms strong triplex complexes with duplex DNA by forming a P-loop structure (figure 
1.12). The strength of interaction is thought to be due to PN A ’s protein-like uncharged 
backbone (Knudsen & Nielsen, 1996). However, P-loop formation is kinetically 
unfavourable, as it depends on duplex DNA ‘breathing’ and opening up homopurine- 
homopyrimidine tracts, and is also sensitive to ionic conditions. Despite this, PNA activity
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has been shown in transient transfections in cell culture (Vickers et al., 1995). PNA has 
been used to inhibit HIV-1, though this may be by a non-triplex mechanism, as PNA has 
been shown to stimulate IFN-y production (Hirschman & Chen, 1996).
The use of TFOs in vivo  could be limited by competition for binding sites from 
DNA-binding proteins (Espinas et al., 1996). The promoters of many genes contain 
homopurine-homopyrimidine regions which could be targeted by TFOs. However, these 
regions are usually binding sites for transcription factors. Therefore TFOs must bind with 
greater affinity than these proteins in order to silence genes. It is perhaps more important to 
consider inhibition by histones (Giovannangeli et al., .1997). These are basic proteins which 
form the nucleosomes which package DNA into chromatin. In vitro studies have shown that 
nucleosomes can block TFO binding and vice versa (this would appear to be down to 
whether the nucleosome or the TFO binds to the DNA first). Fortunately, active genes are 
located in areas of decondensed chromatin and therefore should be accessible to TFOs. 
TFOs have been shown to alter the patterning of nucleosome binding in the mouse mammary 
tumour virus long terminal repeat (MMTV LTR) (Westin et al., 1995). The organization of 
nucleosomes in the MMTV LTR is very important for viral gene expression. This work has 
implications for using TFOs not only to silence genes, but also to lock genes into a state of 
permanent expression by manipulating chromatin structure and recruiting transcription 
factors (Svinarchuk eta l., 1997).
Figure 1.12. (A) The chemical structures of peptide nucleic acid (PNA) and DNA. (B) P- 
loop formation. A PNA oligo (dashed line) displaces one of the strands of the DNA duplex 
(bold lines). Binding of the PNA to the DNA is stabilized by a second PNA oligo slotting 
into the major groove of the PNA-DNA hybrid duplex. Taken from Frank-Kamenetskii and 
Mirkin, (1995).
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1.9.1 Therapeutic applications for TFOs
Following the successful demonstration of TFOs selectively binding their targets and 
inhibiting transcription in vitro and in transient transfections, the next stage was to 
investigate whether TFOs could specifically inhibit expression of clinically relevant 
endogenous genes. Two major areas of research have looked at the c-myc oncogene and the 
HIV-1 provirus.
Mutations in the c-myc proto-oncogene are implicated as playing a key role in the 
development of many malignancies. Two studies have demonstrated a downregulation of c- 
m yc  mRNA following treatment with TFOs. The first study used a 27-base TFO targeted 
against the PI promoter of c-myc in HeLa cells. The TFO was shown to protect the PI 
region from DNase I digestion, and to reduce c-myc mRNA relative to total cellular RNA, 
p-actin mRNA and c-myc mRNA produced from the c-myc P2 promoter (Postel et al.,
1991). More recently a 37-base TFO, again targeted against the c-myc promoter, was 
shown not to bind to, or inhibit transcription from, the c-myc promoter in MCF-7 breast 
carcinoma cells (Thomas et al., 1995). However, addition of the synthetic polyamine, 1,3- 
diaminopropane (DAP), in conjunction with lOpM TFO, led to a 65% reduction in c-myc 
mRNA. This was not observed with DAP alone. Addition of synthetic polyamines can 
sometimes disrupt the tightly controlled balance of endogenous poly amines, such as 
spermine and spermidine, in the nucleus. The endogenous polyamines are important in 
regulating cell proliferation and differentiation. Fortunately in this study, addition of DAP to 
concentrations of 2mM caused no disruption.
Studies investigating TFO inhibition of the H IV-i provirus have used the U937 cell- 
line, which contains two stably integrated copies of the viral DNA (Giovannangeli et al., 
1996, Giovannangeli et al., 1997). Targeting of the polypurine tracts in the transcription 
initiation site and the SP-1 binding site have been shown to reduce p24 antigen production, 
viral titre and levels of intact 9.2kb viral mRNA. Circular dichroism indicated the presence 
of triplex DNA, though the specificity was not unambiguously proven. The accessibility of 
these sequences by TFOs has since been demonstrated using TFO-psoralen conjugates 
crosslinked to the target site by UV-irradiation. These were shown to specifically block a 
Dral cleavage site in the target from restriction digestion. Efficiency can be increased using 
the polyaromatic antibiotic chromomycin (Bianchi et al., 1997).
Targeting the cccDNA of HBV in chronic carriers is a particularly attractive 
proposition. It is the repository of cccDNA in infected hepatocytes which allows the virus to 
rebound on the removal of antiviral therapy. A TFO targeted against a 21 base-pair purine 
rich region of the core promoter has been shown to function in HuH7 cells. A luciferase 
reporter gene was cloned downstream of the core promoter. 24 hour treatment with ImM 
TFO reduced luciferase activity by 60% (Ito et al., 1997). No work has yet been done 
targeting TFOs against wild-type HBV.
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1.11 ANTISENSE OLIGONUCLEOTIDES
Whilst TFOs target the gene of interest itself, antisense oligonucleotides are targeted 
against RNA (Wagner & Flanagan, 1997). A number of targets are available: the small 
nuclear RNAs, which are involved in splicing; the pre-mRNA, where antisense can interfere 
with splicing and polyadenylation; and tRNA, which is involved in translation. Probably the 
most important target is the mRNA, which is the template for translation. The sequence- 
specific mechanism of inhibition depends on the type of oligonucleotide used. Indeed, there 
has also been controversy in recent years as to whether the antisense effect in vivo  is real, or 
whether it is a result of non-sequence specific effects (see section 1.10.4). However, 
antisense inhibition has been observed in natural systems such as the nematode, 
Dictyostelium  and in prokaryotes (Thomas, 1992). It has also recently been proposed that 
the highly conserved 5' and 3' UTR (untranslated regions) of many eukaryotic genes are 
targets for endogenous antisense binding, as part of a control mechanism for regulating 
mRNA stability.
Therapeutic antisense oligonucleotides can be divided into two groups: RNA 
antisense (which is expressed endogenously and can therefore be considered as a form of 
gene therapy); and DNA antisense and its chemically modified derivatives. Both of the latter 
forms of antisense must be synthesised outside the body and delivered to their targets like 
conventional drugs.
1.11.1 Antisense RNA
The principle of antisense RNA is simply to introduce RNA into the cell which is 
complementary to the mRNA of interest (reviewed in (Takayama & Inouye, 1990)). This 
leads to the formation of dsRNA which either blocks the passage of the ribosome down the 
mRNA during translation, or triggers host cell responses to dsRNA (see section 1.7.1b). As 
these responses are in part mediated by IFN, there is a strong case for using antisense RNA 
and IFN in combination therapy. In cell culture, antisense RNA can be easily delivered to 
target cells by standard transfection techniques or by microinjection. These are not practical 
in a therapeutic situation, so genes encoding the antisense RNA must be delivered to the 
target cells within the organism. However, this requires the development of a safe, efficient 
vector, which is a problem facing all gene therapy strategies. Vectors under development 
include cationic liposomes, which can be conjugated with membrane proteins in order to 
improve targeting efficiency, and a range of viral vectors, including retroviruses, 
adenoviruses, herpesviruses and adeno-associated virus. Although many groups are 
working on designing such vectors, with some entering clinical trials, none are yet licensed 
for use in vivo in humans. Problems include an immune response against the vector, 
recombination with wild-type (or in the case of retroviruses, endogenous) virus, or the 
development of disease. In light of these problems all antisense strategies currently in the
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final stages of clinical trials are oligodeoxyribonucleotide derivatives, which are synthesised 
ex vivo and delivered as conventional drugs.
1.11.2 Antisense DNA
Antisense oligodeoxyribonucleotides are short, single-stranded DNA fragments 
synthesised in vitro. Their mechanism of action has been the subject of some debate (see 
section 1.10.3), though it is considered that sequence-specific antisense effects are mediated 
either by the DNA-RNA complex blocking progress of the ribosome during translation or by 
cleavage of the RNA strand of the hybrid duplex by RNase H (reviewed in (Toulme & 
Helene, 1988)).
Antisense DNA has been studied since the 1970s (Stephenson & Zamecnik, 1978) 
but it soon became apparent that unmodified DNA would be unsuitable for therapeutic 
applications. There are three problems. The first is that DNA is a strongly charged 
polyanion and is therefore unable to cross through the lipid cell membrane. In addition, this 
strong charge can cause the oligonucleotides to bind to cationic proteins and be repelled away 
from other nucleic acids. This problem can be reduced to an extent by using shorter 
oligonucleotides. However, there is a limit to how short an antisense molecule can be. It 
has been calculated, taking into account the non-random distribution of nucleotides in human 
genomic DNA (which is 40% GC), that an antisense oligonucleotide must be at least 11 to 
15 bases long to ensure that its target site is unique. Another disadvantage of longer 
oligonucleotides is that their specificity is reduced, as mismatches are tolerated better the 
longer the oligonucleotide is.
Perhaps more importantly, single-stranded DNA is very susceptible to nuclease 
degradation, especially in serum. Degradation is not quite as severe for the small fraction of 
oligonucleotides which enter cells, and which manage to avoid destruction in the endosome. 
Degradation can be partially blocked by incorporating hairpins at the ends of the antisense 
oligonucleotide, thus preventing cleavage from the ends by exonucleases, though the central 
portion of the oligonucleotide is still exposed to endonucleases (Zhang et al., 1995). 
Another problem is that the affinity of the antisense DNA for its target site may be low. This 
can be influenced by the mRNA secondary structure and competition with RNA binding 
proteins. These problems mean that an effective therapeutic dose may be unfeasibly high, 
and has led to the development of chemically modified oligonucleotides.
1.11.3 Chemically modified oligonucleotides
As described in the previous section, chemical modifications need to deal with a 
number of problems: nuclease degradation, cellular uptake and binding affinity. Any 
modifications made must still allow RNase H degradation of the mRNA strand of an 
antisense:mRNA complex, as well as not make the oligonucleotide toxic (Miller, 1996).
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Nucleases function by cleaving the phosphodiester bonds between adjacent 
nucleotides in a stretch of nucleic acid. The phosphodiester bond has been the subject of a 
number of modifications, some of the most common of which are shown in figure 1.13.
HO----
Backbone Modification
NH
Phosphodiester
(normal)
Phosphorothioate s
NHMethylphosphonate c h 3
Phosphorodithioate
o -
oh
Figure 1.13. The structure of single-stranded DNA, showing the naturally occurring 
phosphodiester bond, plus three modifications commonly used in the construction of 
antisense oligonucleotides; phosphorothioate, methylphosphonate and phosphorodi­
thioate. Taken from Arnold (1996).
The most widely used modification is the phosphorothioate (Crooke et al., 1995), 
which has been characterised in detail, can be produced on an industrial scale, and which is 
now entering clinical trials. Initial trials have focused on haematological malignancies 
(Bayever & Iversen, 1994, Bishop et al., 1996), where mutant forms of the tumour
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suppressor gene p53 have been targeted. Initial results have reported no side effects, and no 
degradation of the oligonucleotide, with intact molecules being recovered in patients’ urine.
Despite the substitution of a sulphur for an oxygen, phosphorothioate 
oligonucleotides can still direct RNase H cleavage of mRNA, though some oligonucleotide 
sequences do appear to inhibit RNase H activity (Gao et al., 1992). However, 
phosphorothioates are still charged, and can have some non-sequence specific effects (see 
section 1.11.4). Concerns have also been raised regarding possible toxicity, though this is 
dependent on dose, length of the oligonucleotide and the method of delivery. Side effects 
include prolongation of blood coagulation (Nicklin et al., 1997), activation of complement 
(Shaw et al., 1997) and B-cell stimulation (Monteith et al., 1997).
Methylphosphonates do not carry a charge, and are therefore less likely to interact 
non-specifically and to have increased lipid solubility, thus aiding passage across the cell 
membrane (Miller, 1991). However, they do have a centre of chirality at the phosphorus 
atom, and one of the enantiomers is sterically hindered in binding its target by the 3'-H sugar 
proton (figure 1.14). Removal of this enantiomer gives an oligonucleotide preparation that 
has a much tighter binding affinity than the racemic mixture. Methylphosphonates also have 
increased stability (table 1.2). The chirality of the phosphorothioate modification has also 
been investigated. The chiral centre can be lost if a second sulphur-for-oxygen substitution 
is made to give a phosphorodithioate (Ghosh et al., 1993). This extra modification did not 
increase antisense activity compared to the phosphorothioate.
CH
Figure 1.14. The Rp and Sp enantiomers of the methylphosphonate linkage. In the Sp  
enantiomer the methyl group sterically interacts with the 3' proton on the sugar. This 
interaction weakens the oligonucleotide's binding affinity for its target. In the Rp enantiomer 
the methyl group points out from the major groove and has no interactions with the sugar. 
Taken from Arnold (1996).
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Further modifications can be made to the sugar component of the backbone. 
Alkylation of the 2' position, particularly addition of an O-methyl group, has been shown to 
increase binding affinity and protect against nucleases (Fisher et a l., 1993) (figure 1.15). 
Addition of the O-methyl group induces the oligonucleotide to assume A-form helical 
geometry. This is the same form assumed by RNA, which presumably favours the binding 
of the modified oligonucleotide to mRNA. The benefits of this modification are 
synergistically increased by including it in methylphosphonate oligonucleotides (table 1.2).
Figure 1.15. Oligonucleotide phosphate-sugar backbone with both the Rp 
methylphosphonate and 2'-0-methyl modifications. Incorporation of both modifications 
greatly enhances stability and binding affinity. Taken from Arnold (1996).
As well as changing or adding chemical groups, modifications can take the form of 
changes in the backbone linkages. Normal DNA and RNA is formed of nucleotides 
polymerized via 3'-5' phosphodiester bonds. In some situations, such as IFN stimulation 
(see section 1.7.1b) and during intron splicing, 2'-5' phosphodiester bonds can form. 
These cannot be cleaved by the majority of cellular nucleases. 2'-5' phosphorothioate 
oligonucleotides show preferential binding to RNA compared to DNA, and in vitro studies 
suggest they also have less side effects (Kandimalla et al., 1997). One drawback is that 2 '-  
5' oligonucleotides cannot recruit RNase H to the antisense:mRNA complex. It is therefore 
necessary to produce mixed backbone oligonucleotides, composed of 2'-5' linkages at the 
ends, and a central portion with 3'-5' linkages.
B
\
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HALF-LIFE OF BACKBONE ANALOGUE
ENZYMATIC
CONDITION
Normal
phospho­
d ie s te r
2 '-0-M ethyl
RNA
Rp-MP/DE 2'-0-M ethyl
Rp-MP/DE
10% Foetal calf serum, 
pH 8.0
12 minutes 40 minutes 5 hours >300 hours
Green monkey kidney 
cell lysate, pH 6.0
< 10  minutes ~ 5 hours ~ 25 hours Stable*
Green monkey kidney 
cell lysate, pH 7.4
< 5 minutes ~ 5 hours ~ 20 hours Stable*
E.coli lysate 1 -3 minutes 1.2 hours ~ 65 hours Stable*
S.aureus lysate 13 minutes ~ 20 hours ~ 75 hours Stable*
Snake venom 
phosphodiesterase
15 minutes 2.5 minutes 167 minutes Stable*
Table 1.2. Half-lives of normal DNA oligonucleotides and three modified DNA analogues in 
a range of conditions. The modifications include the 2'-0-methyl addition to the ribose 
group, the methylphosphonate diester backbone (Rp-MP/DE) and a combination of the 
two modifications (see figure 1.15). Although both single modifications give some degree of 
nuclease protection, incorporation of both modifications yields stable oligonucleotides. (*, 
no detectable degradation after 24 hours incubation.) Taken from Arnold (1996).
1.10.4 2’-5’A-antisense
In section 1.7.1b it was described how IFN stimulates the production of 
oligoadenylate with the generalised structure ppp(A2’p)nA, known as 2 ’-5’A. This 
stimulates RNase L activity, which cleaves double-stranded RNA. This can be taken 
advantage of by conjugating 2 ’-5’A to antisense RNA. If unconjugated 2 ’-5’A is applied to 
cells there is a general degradation of mRNA and rRNA. However, if 2’-5’A is conjugated 
to the 3’ end of a specific antisense molecule, then only the RNA to which the antisense is 
complementary is degraded, with cleavage occurring at the 3’ end of the chimaera. 
Recruitment of RNase L is dependent on the terminal 2 ’ phosphate. Removal of this 
phosphate from the 2 ’ -5’ A-antisense chimaera prevents degradation of the target RNA. This 
approach has been used successfully to suppress replication of respiratory syncitial virus in 
human tracheal epithelium cells. Unconjugated 2’-5’A and antisense alone showed minimal 
inhibitory effects.
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1.10.5 Is the antisense effect real?
As already described, the most commonly used antisense molecule at present is the 
phosphorothioate. Despite the successful use of this class of antisense in cell culture and in 
vivo, it has been questioned whether or not the inhibitory effects observed are really due to 
sequence-specific binding to mRNA.
Phosphorothioates are polyanionic, and therefore bind strongly to proteins (Bock et 
al., 1992, Gao et al., 1992, Yakubov et al., 1993). As the oligonucleotide's positive charge 
resides in the backbone of the molecule, this binding is not sequence dependent, and 
increases in affinity with the length of the oligonucleotide. It has been shown that 
phosphorothioate oligonucleotides can bind to soluble CD4 near the HIV-1 binding site, and 
also to the V3 loop of the HIV-1 envelope glycoprotein gpl20. In cell culture these 
oligonucleotides can inhibit HIV-1 infection (Lederman eta l., 1996, Lederman et al., 1997).
This non-sequence dependent effect quite clearly could have a therapeutic benefit. 
Unfortunately this probably will not be the case in vivo. Phosphorothioate oligonucleotides 
can bind to a wide range of proteins. This affinity for binding proteins can be increased by 
the presence of a guanosine tetrad, or G4, motif (Agrawal et al., 1997). This tertiary 
structure is formed by non-Crick-Watson base pairing, and the mechanism by which it 
enhances oligonucleotide-protein binding is unclear. This observation is particularly of 
concern for studies where the G4 motif has been included in specific antisense 
oligonucleotides to protect against nuclease degradation.
Misinterpretation of results caused by the presence of the G4 motif can best be seen 
in the study of the rat carotid model of restenosis after balloon angioplasty (Simons et al., 
1992, Morishita eta l., 1993, Abe et al., 1994, Bennett et al., 1994, Morishita et al., 1994, 
Simons et al., 1994). Much work has been done to try and inhibit restenosis by using c-myc 
and c-myh antisense with apparent success. The inhibition was believed to be sequence 
specific as a random sequence control oligonucleotide did not block restenosis. However, 
the phosphorothioate oligonucleotides used in this study all contained the G4 motif, except 
for the control oligonucleotide. Such oligonucleotides have been shown to block the binding 
of a variety of vascular growth factors to their receptors, including fibroblast growth factor, 
platelet-derived growth factor and vascular epithelium growth factor. It is thought that 
inhibition of these growth factors was the mechanism by which the oligonucleotides 
mediated their anti-restenosis effect. This later study also failed to find any antisense 
oligonucleotides outside the endosome, suggesting that the oligonucleotides failed to cross 
the cell membrane and reach the mRNA targets anyway. Many other studies have also 
utilised oligonucleotides containing G4 motifs, all of which will have to be re-evaluated. It 
is not enough to simply include a random sequence control oligonucleotide containing a G4 
motif, as the activity of the G4 motif is dependent on both the surrounding sequence and the 
length of the oligonucleotide.
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Is it sufficient to simply exclude G4 motifs from antisense oligonucleotides in order 
to ensure a sequence-specific antisense effect? Unfortunately not, as oligonucleotides 
containing unmethylated CpG motifs can be strongly immunogenic (Krieg et al., 1996). 
Vertebrate DNA is methylated at virtually all CpG motifs as part of the controls of gene 
expression. Bacterial and viral DNA is not, and therefore appears to be recognised as being 
foreign by the immune system. CpG containing DNA has been shown to elicit strong' B and 
T-cell responses, and has been suggested as a possible adjuvant for vaccines. However, 
these observations call into question the results of studies in mouse tumour models where 
antisense oligonucleotides have been implicated in causing tumour regression.
What can be done to ensure that any changes following treatment with 
oligonucleotides is due to an antisense effect, other than eliminating G4 and CpG motifs 
unless really necessary? In future it will be important to monitor the levels of target protein 
and target mRNA relative to a constant marker such as a housekeeping gene. This need for 
confirming specificity will become more important as the first generation of antisense drugs 
starts to enter the clinic.
1.10.6 Oligonucleotide aptamers
Although the interaction between oligonucleotides and proteins can be a problem with 
antisense strategies, oligonucleotides are being specifically designed to bind to protein 
targets. Single-stranded nucleic acids can form an immense variety of structures depending 
on sequence. By using selection techniques and 'in vitro evolution' it is possible to screen 
libraries of randomly generated nucleic acids for enzyme- or receptor binding inhibitors 
(figure 1.16). These oligonucleotide ligands are known as aptamers (Chapman & Szostak, 
1994).
Although this technology has yet to be applied to HBV, a number of studies have 
looked at aptamer applications for anti-HIV agents. Most notable among these are the tat and 
rev response element decoys (see section 1.8.8), though these were based on the native 
sequence rather than being derived from in vitro selection. However, in vitro selection has 
been used to identify an RNA aptamer capable of inhibiting the NS3 protease of hepatitis C 
virus (Kumar et al., 1997, Urvil et al., 1997).
1.10.7 Antisense inhibition of HBV
As HBV replicates via an RNA genomic intermediate, the pgRNA, it is an ideal target 
for an antiviral strategy, such as antisense inhibition, which targets RNA. Initial studies 
looked at hepatoma cell lines either transiently or stably transfected with HBV genomes. 
Blum e ta l, (1991) showed that a40-m er oligodeoxyribonucleotide antisense molecule could 
inhibit HBsAg and HBeAg production when applied to HuH7 cells transiently transfected 
with HBV genomes. Inhibition was not observed with the corresponding sense
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Figure 1.16. In vitro selection of oligonucleotide ligands, or aptamers. A pool of 
oligonucleotides with the structure show in panel A are produced, with 5' and 3' regions with 
constant sequence flanking a region with random sequence. Depending on the length of 
this region, up to 1010 to 1012 different oligonucleotides can be generated. These  
oligonucleotides can either be used directly (as DNA aptamers) or be made double 
stranded and cloned into plasmids for use as in vitro transcription templates for generating 
RNA aptamers.
The selection procedure is shown in panel B. A column is coated with the protein of 
interest. The pool of random aptamers is passed through the column, allowing any  
possible binding interactions to occur. After washing away any unbound aptamers, those 
aptamers which have bound to the column are eluted off. This enriched pool is then 
amplified by PCR (or RT-PCR if the aptamers are RNA) using primers complementary to 
the 5' and 3‘ constant regions. The amplified products are then used to repeat the process, 
enriching the pool even further. The selection pressure can be increased in further rounds 
of screening by increasing the stringency of the binding and washing steps. Use of a DNA 
polymerase lacking proof-reading capabilities in the PCR step can introduce mutations in 
the enriched pool, which are then selected in subsequent rounds of screening by a process 
of in vitro evolution.
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oligonucleotide. Goodarzi et al., (1990) targeted antisense 15-mers to the cap site and 
translation initiation site of SP-II mRNA in stably transfected PLC/PRF/5 cells, which 
secrete HBsAg. The antisense oligonucleotides achieved 90% inhibition of HBsAg 
production when administered at 17.4pM. Phosphorothioate derivatives of these 
oligonucleotides also produced 90% inhibition, but at a lower concentration (5.8|iM ). 15- 
mer phosphorothioate oligodeoxynucleotides have been shown to have no toxicity towards 
cultured hepatoma cell-lines at concentrations up to 20mM (Yao et al., 1996b). In this 
study, phosphorothioate antisense oligonucleotides were shown to inhibit HBsAg 
production in transfected HepG2 cells in a dose dependent fashion. Maximum inhibition 
occurred between 3 and 5 days after treatment, but inhibition was completely lost after 15 
days. This work has been successfully followed up with delivery of phosphorothioate 
oligonucleotides to human hepatoma cells implanted in athymic nude mice (Yao et al., 
1996a).
In all these studies the 5’ ends of mRNAs were targeted, due to the belief that these 
regions are not locked in secondary structure which could not only block antisense binding, 
but also impair capping and translation initiation. Korba and Gerin (1995) showed that for 
antisense to be most effective, it should be targeted at functionally important regions of 
mRNA (Korba, 1996). They screened over 50 antisense oligonucleotides between 14 and 
23 bases long targeted against various regions of the HBV genome in the 2.2.15 cell line. 
Antisense oligonucleotides targeted directly to key regions such as capping, translation 
initiation and polyadenylation signals all were far more efficient at inhibiting protein 
synthesis and viral DNA levels. Interestingly levels of viral transcripts did not fluctuate 
significantly from the controls, suggesting that RNase H mediated destruction of transcripts 
was not occurring. HBV replication was most inhibited by antisense targeted against the 
encapsidation signal. This is surprising, as the encapsidation signal is highly structured 
(figure 1.4) with very little single-stranded RNA to which antisense oligonucleotides could 
feasibly bind. There is some controversy over how significant a factor substrate secondary 
structure is in choosing target sites for antisense and ribozymes (see section 1.15.4), though 
this is probably due in part to an incomplete understanding of RNA tertiary structure.
How can antisense be efficiently delivered into HBV infected cells? A number of 
methods have been studied in vitro. Nucleic acids can be targeted to liver cells using poly-L- 
lysine-asialoglycoprotein conjugates. Poly-L-lysine is a strong polycation, which enables 
nucleic acids to bind strongly, but non-covalently. Asialoglycoprotein is a serum protein 
which binds specifically to receptors on hepatocytes. Wu and Wu (1991) showed that a 21- 
mer antisense oligonucleotide complexed with the poly-L-lysine-asialoglycoprotein carrier 
targeted to the HBV polyadenylation signal could be specifically delivered to cultured 2.2.15 
cells and result in an 80% reduction in viral DNA and HBsAg in the culture medium after 24 
hours exposure. This inhibition was maintained for 6 days. No significant inhibition could
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be seen with uncomplexed antisense or with complexed random control oligonucleotides. 
The inhibition could be competitively blocked with free asialoglycoprotein.
Although this approach clearly works, the use of oligodeoxyribonucleotides and their 
derivatives requires frequent administration in order to maintain inhibition. Delivery of 
genes encoding antisense RNA would provide prolonged inhibition with only a single 
administration of therapy. Vectors based on the Moloney murine leukaemia retrovirus have 
been used to deliver antisense in vitro (Ji & Si, 1997). A 2.3kb antisense RNA to preS/S 
and a 1.5kb antisense RNA to preC/C were delivered to 2.2.15 cells. The 2.3kb antisense 
produced a 71% inhibition of HBsAg and a 23% inhibition of HBeAg, whilst the 1.5kb 
antisense produced a 23% inhibition of HBsAg and a 59% inhibition of HBeAg. Inhibition 
started 3 days after transduction with the retroviruses and was still maintained 11 days later. 
It is possible that inhibition was not complete because the antisense RNAs were so long that 
they adopted secondary structures which prevented them from hybridising with their targets. 
It is unlikely that antisense constructs this long would be used as therapeutic agents because 
of the potential decrease in specificity. There are also problems in using retroviral vectors. 
Retroviruses can only infect cells in mitosis and only a small proportion of hepatocytes will 
be dividing at a given time. Although murine viruses, such as the one used in this study, are 
used in experimental human gene therapy protocols to avoid the risk of recombination with 
endogenous human retroviruses, they do elicit a strong immune response. This results from 
complement activation by the lipids in the retroviral envelope, which are derived from murine 
cells. Vectors derived from human lentiviruses such as HIV may provide the answer to 
these problems, as they are capable of infecting non-dividing cells and do not contain 
immunogenic lipids.
A more successful technique has utilised episomal vectors, which form stable, 
replicating units in the nucleus (Wu & Gerber, 1997). Three constructs, encoding 1.4kb, 
l.Okb and 0.58kb antisense RNA to the 5’ end of SPII mRNA were transfected into Hep3B 
cells, a cell line which secretes HBsAg. All three constructs caused a total block of HBsAg 
production which was maintained for 10 months.
Initial in vivo  studies have focused on phosphorothioate oligonucleotides targeted 
against the pre-S region of DHBV . Following initial in vitro studies, a 15-mer targeted 
against the pre-S region of DHBV was administered to chronically infected ducks at a dose 
rate of 20pg/g body weight daily. After 10 days treatment, DHBsAg had been lost from 
serum and DHBcAg had been lost from the liver, with no detectable side effects. This 
closely matched the in vitro results, suggesting that the inhibition was due to an antisense 
effect. An identical regime was used in athymic nude mice into which 2.2.15 cells had been 
injected in order to establish tumours which secrete HBsAg and HBeAg. Administration of 
phosphorothioate oligonucleotides targeted to the translation initiation point on the SP-II 
RNA led to an 81% reduction in HBsAg and a 60% reduction in HBeAg. Delivery of anti-
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DHBV antisense can be enhanced by trapping the oligonucleotides in liposomes (Soni et al., 
1995, Soni e ta l., 1996, Soni eta l., 1997).
The poly-L-lysine-asialoglycoprotein carrier has been used in woodchucks to deliver 
antisense oligonucleotides targeted against the polyadenylation signal of WHV in neonately 
infected animals (Bartholomew et al., 1995). The antisense-carrier complex was 
administered at 0.1 mg/kg body weight per day for 5 days. Although there was no 
significant decrease in WHBsAg, there was a five to ten fold decrease in viraemia, as 
measured by serum viral DNA levels, 25 days post treatment. The decline in viraemia lasted 
for two weeks, after which viral DNA levels in serum began to rise. This decrease in 
vireamia was not seen when antisense DNA alone, or carrier complexed with a random 
oligonucleotide, were used.
Although antisense technology does appear to offer a promising alternative to current 
anti-HBV therapies, there are still a number of problems that need to be addressed. Most 
important is the need to decide whether antisense RNA or DNA should be used, and how 
these constructs could be delivered safely. As the cccDNA is not targeted by antisense 
therapy, it will be necessary to maintain treatment for a long time, which raises concerns 
about possible side effects. Although current studies have only looked at antisense in 
isolation, it will eventually become necessary to see how antisense performs in combination 
with immune modulators and enzyme inhibitors.
1.12 RIBOZYMES
In 1982 Thomas Cech and co-workers made the surprising discovery that some RNA 
molecules possessed the ability to undergo chemical reactions without the aid of any protein 
enzymes (Kruger et al., 1982). These initial studies focused on the group I self-splicing 
introns from the protozoan Tetrahymena, which are not truly catalytic as the mechanism is 
intramolecular, with only a single turnover in which the molecule is changed. A true catalyst 
can process multiple substrates without becoming chemically altered itself. The term 
‘ribozyme’ was coined for these pseudo-catalytic RNAs. The group of ribozymes known 
has since expanded to include the group II self-splicing introns, the RNA moiety from 
RNase P and a variety of motifs from RNA viroids and satellite DNA transcripts. The term 
‘ribozyme’ is generally restricted to these motifs, all of which possess a sequence-specific 
endoribonuclease, and in some cases RNA ligase, activity. In vitro evolution experiments, 
similar to those described in section 1.11.5, have produced catalytic RNAs with a variety of 
other functions, such as kinase (Lorsch & Szostak, 1995), amino-acyl transferase (Lohse & 
Szostak, 1996) and C-C bond formation activities (Hager & Szostak, 1997). These 
experiments have important implications for the ‘RNA world’ hypothesis of the origins of 
life. This theory states that the earliest self-replicating organic molecules were likely to have 
been ribozymes, as RNA possesses both an informational storage capacity (in the genetic
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code) and catalytic activity. DNA could also have had an early role, as recent experiments 
have also discovered catalytic DNA.
This thesis is concerned solely with the classical phosphodiesterase ribozymes. 
These all produce fragments containing a 5’-hydroxyl and 2 ’,3’-cyclic phosphate and have a 
requirement for divalent cations, usually M g2+. Ribozymes are potentially more powerful 
gene silencing tools than antisense oligonucleotides (Altman, 1993). The catalytic domain of 
ribozymes can cleave a targeted mRNA, thus irreversibly blocking translation, whereas 
antisense oligonucleotides can fall off or be displaced from their targets.
1.12.1 SELF-SPLICING INTRONS
This group includes the first catalytic RNA discovered, the group I self-splicing 
intron from the nuclear pre-rRNA of the protozoan Tetrahymena thermophila (Zaug et al., 
1986). It has since expanded to include group II introns. Examples have been found in the 
nuclei of protists and fungi, fungal mitochondria, the chloroplasts of algae and higher plants 
and in bacteriophages (Durrenberger & Rochaix, 1991, Ferat & Michel, 1993). Group I and 
group II introns differ in their mechanisms (figure 1.17). Although both can function in vitro 
on their own, there is evidence that proteins are required for successful splicing in vivo.
Group I 
self-splicing
Group II 
self-splicing
Figure 1.17. Simplified view of the cleavage mechanisms of group I and II self-splicing 
introns. The attacking group in group I introns is the ribose 2’-hydroxyl of a guanosine 
cofactor. In group II introns the attacking group is the ribose 2’-hydroxyl of an adenosine 
residue within the intron sequence itself.
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Computer modelling has suggested that although the tertiary structure of the intron is 
important to self-splicing (Inoue, 1990), the actual sequence of folding which the intron 
passes through as it assumes its active structure is also important (Emerick & W oodson, 
1993, Jaeger et al., 1993, Franzen et al., 1994,). This is thought to allow the recruitment of 
co-factors to the correct places within the structure (Bass & Cech, 1984). It is believed that 
divalent cations play a direct role in the cleavage reaction (Christian & Yarns, 1993). 
Substitution of the bridging 3’-oxygen at the cleavage point with a sulphur reduces cleavage 
by a thousand-fold when Mg2+ is used as the cation (Suh & Waring, 1992). However, 
when Mn2+ or Zn2+ are used, there was little inhibition of cleavage. This is because the two 
transition metal ions co-ordinate sulphur more strongly than M g2+ does, implying that the 
metal ion plays a direct role in catalysis by co-ordination to the 3’-oxygen in the transition 
state (Suh & Waring, 1992).
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Figure 1.18. C/'s- and trans-splicing of lacZ transcripts, (a) The lacZ mRNA containing a 
group I self-splicing intron. The intron excises itself from the pre-mRNA, and ligates the two 
exons together. The specificity of the splicing reaction comes from the hybridization of the 
CCCUCU sequence at the 3’ end of the 5’ exon with its complementary sequence within 
the intron. (b) A truncated lacZ mRNA, with the group I self-splicing intron recognition 
sequence, CCCUCU, at the 3’ end. A free group I intron, carrying the 3’ end of the lacZ 
gene, hybridizes with the recognition sequence at the 3’ end of the 5’-truncated portion of 
the lacZ mRNA. Despite operating in trans the group I intron can splice together the ends of 
the 5’ and 3’ portions of the lacZ mRNA. Taken from Sullenger & Cech, (1994b).
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Group I self-splicing introns catalyse both a phosphodiesterase activity (in excising 
themselves from the pre-mRNA) as well as an RNA ligase activity which joins together the 
exons on either side of the excised intron (Zaug & Cech, 1986). The reaction’s specificity 
arises from internal guide sequences which direct cleavage and religation to specific splice 
sites. This specificity has been used to direct self-splicing introns to cut mRNA and replace 
the 3’ end of the RNA with RNA from the 3’ end of the intron itself (figure 1.18) (Been et 
a l ,  1987). This could have potential applications in gene therapy for inherited disorders, 
enabling the mRNA of a defective gene to be repaired without having to replace the faulty 
gene at the DNA level. Modified trans-splicing introns have been used in E. coli to 
regenerate the coding capacity of truncated lacZ transcripts, allowing protein synthesis 
(Sullenger & Cech, 1994b).
1.12.2 RNASE P
RNase P is a ubiquitous enzyme which processes the 5 ’ ends of tRNA precursors 
(Altman et al., 1981). RNase P is a ribonucleoprotein,'the best characterised of which is 
from E. coli. The E. coli enzyme consists o f  a 113.8kD basic protein and a 377 nucleotide 
RNA known as M l (Altman & Guerrier-Takada,11986). The sequence of the RNA is poorly 
conserved between bacterial species, though all share remarkably similar secondary 
structures. The protein and M l RNA segments from different bacterial RNase P 
holoenzymes can be reconstituted to form functional hybrid enzymes (Altman et al., 1987). 
Under certain conditions in vitro, the M l RNA can function catalytically in the absence of the 
protein subunit, though this has only been shown for bacterial RNase P (Guerrier-Takada et 
al., 1983, Altman et al., 1989). These isolated RNAs have similar catalytic efficiencies to 
the native holoenzyme. Unlike the self-splicing introns and the small catalytic RNAs, the 
RNase P ribozyme is a true catalyst, as it cleaves other RNA molecules rather than itself, and 
processes multiple substrates.
How does one enzyme manage to recognise and process the several dozen pre- 
tRNAs which are produced in all cells? All tRNAs have a CCA triplet at their 3’ end, in the 
acceptor arm which binds amino acids. The M l RNA contains a conserved GGU triplet 
which forms Watson-Crick base-pairs with the CC doublet in the CCA motif, whilst the U 
residue interacts with the so called ‘discriminator’'base (figure 1.19). This discriminator 
base can either be an A residue, allowing a third, tight Watson-Crick base-pair, or a 
‘wobble’ residue which produces a weaker interaction, and slows down cleavage (Guerrier- 
Takada et al., 1989). In addition to this tight binding, a number of weaker non-Watson- 
Crick interactions have also been found by crossdinking experiments. Once the pre-tRNA is 
bound by the M l RNA, the 5’ end of the pre-tRNA is cleaved.
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M1 RNA
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Figure 1.19. Binding of RNase P M1 RNA to the 3' acceptor arm of pre-tRNA. The 
discriminator base (D) is highlighted, with the cleavage point indicated by an arrow. The 
key recognition step is the hybridization of the CC residues in the pre-tRNA acceptor arm 
with residues 292 and 293 of the M1 RNA. Cleavage is particularly favoured if the 
discriminator base is an A, though non-Crick-Watson recognitions are made between the 
two RNAs (not shown). Taken from Tallsjo (1996).
1.12.2a External Guide Sequences (EGS)
Cleavage of the 5 ’ end of pre-tRNA by RNase P is directed by the M l RNA 
recognising the CCA motif in the 3 ’ acceptor arm of the pre-tRNA. As this recognition 
domain is not within the substrate (the 5 ’ end of the pre-tRNA) itself, this has become 
termed the external guide sequence (EGS). Forster and Altman proposed that short RNAs 
containing the CCA motif could be targeted to any RNA and direct the cleavage of that RNA 
by RNase P (figure 1.20) (Forster & Altman, 1990). This has been successfully 
demonstrated using the E. coli enzyme in vitro and in vivo  to reverse an antibiotic resistance 
phenotype (Yuan & Altman, 1994).
EGSs are being extensively studied as potential agents for use against HBV 
(Bockman et al., 1993). Activity has been demonstrated in HeLa cell extracts against an 837 
nt RNA fragment corresponding to parts of pre-S2 and S (George et al., 1993). It was 
shown that phosphorothioate RNA EGSs had increased stability in cell extracts compared to 
their RNA counterparts, and could still mediate cleavage by M l RNA and RNase P (Narayan 
et al., 1993). EGSs made from DNA could not mediate cleavage (Kahle et al., 1993). This 
work is rapidly moving towards initial clinical trials.
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‘ 5’
Figure 1.20. An RNase P substrate bound to an EGS. The discriminator base (D) and the 
CCA triplet are shown within the EGS, with the cleavage site indicated by an arrow. 
Cleavage is not dependent on the substrate sequence, allowing EGSs to be used to target 
any RNA.
1.12.3 SMALL CATALYTIC RNAS
This group of ribozymes consists of several motifs found in a number of viroids, as 
well as in the RNA transcripts of Neurospora mitochondrial DNA and a newt satellite DNA. 
All these motifs participate in single turnover, intramolecular reactions and are therefore 
pseudo-catalytic. However, these ribozymes can be manipulated to function in trans, thus 
offering potential as extensions of antisense RNA for gene silencing.
1.12.3a Plant viroid ribozymes
Viroids are infectious agents which require coinfection with a virus which provides 
helper functions to assist with the viroid’s replication (Symons et al., 1987). A number of 
RNA viroids have been characterised in plants which replicate by a rolling circle mechanism 
(figure 1.21). This generates a string of viroid genomes joined head-to-tail which must be 
separated to allow viroid maturation. This is achieved by small regions of secondary 
structure at the junction of adjacent genomes. Two such motifs have been described. The
A B
Minus
Figure 1.21. Two alternative forms of rolling circle replication employed by viroid RNAs. A 
Both plus and minus strands are self-cleaved. B Only the plus strand self-cleaves. Sites 
of self cleavage are indicated by arrows. Taken from Forster & Symons, (1987).
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first to be discovered was the hammerhead motif, which is discussed in detail in section 
1.12.4. The second motif is the hairpin ribozyme (figure 1.22).
The hairpin was originally found in the 359 nt linear satellite RNA of tobacco 
ringspot virus (Haseloff & Gerlach, 1989). The (+) strand RNA is cleaved by a 
hammerhead domain, whilst the (-) is cleaved by the hairpin. The hairpin differs from the 
hammerhead by catalysing the reverse, re-ligation, reaction as well as the phosphodiesterase 
cleavage. Essential residues have been investigated by in vitro selection of a pool of variants 
containing point mutations at all sites in a 50 nt hairpin catalytic RNA (Joseph & Burke, 
1993). This allowed the precise base-pairing requirements of helices III and IV to be 
shown, and to identify eight essential nucleotides (G8, A9, A10, G21, A22, A23, A24, and 
C25). The importance of the ribose 2 ’-hydroxyl groups was determined by making single 
substitutions with deoxyribonucleotides. This identified residues A 10, G i l ,  A24 and C25 
as providing hydroxyl residues vital for ribozyme function (Chowrira et al., 1993). These 
results are supported by data showing that 2 ’-0-methyl substitutions at G i l  and A24 also 
inhibit ribozyme activity. The hydroxyl moieties are thought to provide either important 
tertiary structure contacts or co-ordination sites for Mg2+ (Berzalherranz et al., 1993). 
Although Mg2+ is required for hairpin activity it is unclear whether it provides a structural or 
catalytic function (Hampel & Cowan, 1997). The helix IV stem has been extended to allow 
RNA binding proteins to associate, such as rev from HIV. This does not seem to affect 
ribozyme activity, and offers intriguing possibilities for modulating ribozyme expression and 
intracellular localisation.
The hairpin ribozyme can be manipulated to function in trans. Modified hairpins 
have been used to cleave HBV substrates in vitro (Welch et al., 1997). However, most 
progress in the therapeutic application of hairpin ribozymes has come in the targeting of 
HIV, where studies have progressed to human clinical trials.
1.12.3b Therapeutic uses of the hairpin ribozyme
W ork leading to the first human clinical trials of a ribozyme has been performed by 
W ong-Staal’s group. Initially they designed a hairpin ribozyme under the control of a p- 
actin promoter, which was shown in vitro to cleave HIV-1 RNA in the U5 leader region, 
leading to a reduction in tat activity and p24 production (Rappaport et al., 1993). For this 
work to be extended to a cell culture system it was deemed necessary to increase the 
expression of the ribozyme. This was done by cloning the ribozyme into a murine retroviral 
vector under the control of a polymerase III promoter. Retroviral vectors insert into the 
transduced cell’s DNA, giving long-term stable expression of any cloned genes. Genes with 
polymerase III promoters (in this case from human tRNAVal and adenovirus V A l genes) are
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Figure 1.22. Secondary structure model of the hairpin ribozyme from the negative strand of 
the tobacco ringspot virus satellite RNA. The ribozyme sequence is numbered from 1 to 
50, with essential residues marked in bold and boxed. The cleavage site on the substrate 
strand is to the 5’ side of an essential G residue, and is indicated by an arrow. Taken from 
Berzalherranz etai., (1993).
expressed in all cell types at a much higher level than those with polymerase II promoters, 
which drive protein-encoding genes. In transient transfections of HeLa cells, these 
constructs were shown to reduce p24 expression by 95%. An inactive ribozyme mutant was 
shown to inhibit p24 production by only 10%, thus showing the bulk of the inhibitory 
activity is due to ribozyme, rather than antisense, activity (Ojwang et al., 1992).
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The long-term goal of this work is to create a population of lymphoid cells which are 
resistant to HIV infection. The human lymphoid cell line CEM/174 was transduced with a 
retroviral vector encoding a hairpin, under the control of a polymerase III promoter, targeted 
to the 3’ LTR of SIV (Heusch et al., 1996). This treatment provided long-term resistance to 
infection by SIV, reducing the burden of proviral DNA. This was achieved by presumably 
cleaving viral RNA as it entered the cells. This has paved the way to human stem cell 
therapy.
Human haematopoeitic stem cells can be identified by the CD34 marker. This has 
enabled stem cells to be enriched from the umbilical cord blood of healthy and HIV-positive 
donors. Transduction of these cells with retroviral vectors encoding the U5 ribozyme 
yielded stable ribozyme expression with no changes; in phenotype or proliferation. The 
macrophage progeny of these cells were resistant to HIV infection (Yamada et al., 1994a, 
Yamada eta l., 1994b). However, to reduce the risk o f escape mutants appearing, cells will 
be transduced with a second ribozyme targeted to the pol region. The importance of this was 
demonstrated by targeting a hairpin to the rev/env region at a point where the infectious clone 
SF2 has a single nucleotide substitution compared to the HXB2 prototype virus (N*GUC 
mutated to N*UUC). The ribozyme could/inhibit HXB2 replication in Molt 4 cells, but 
could not block SF2 replication (Yu et al., 1993). A phase I clinical trial has been 
undertaken using these vectors to transduce peripheral blood lymphocytes ex vivo, which 
will then be used for autologous reinfusion. The possibility of using modified CD34 cells 
from cord blood for autologous reinfusion of neonates born to HTV-positive mothers is also 
being investigated (Ho et al., 1994, Rosenzweig et al., 1997).
1.12.3c Hepatitis delta ribozyme
Hepatitis delta virus (HDV) is similar to the plant viroids. It has a circular RNA 
genome of 1.7kb, and is only able infect persons already infected with HB V, or to coinfect 
along with HBV (Rizzetto, 1990). HDV encodes a single nucleocapsid protein, the delta 
antigen. The HDV particle also includes HBsAg provided by HBV. HDV replicates via a 
rolling circle mechanism, and processes its genomes using a unique ribozyme motif (Perrotta 
& B een, 1990). The HDV ribozyme structure consists of four helices (figure 1.23a) and is 
thought to contain a pseudoknot four base-pair sequence, which corresponds to helix III. 
Mutational data from different laboratories do differ, leading some to suggest that the 
ribozyme has an axehead, rather than a pseudoknot, structure (figure 1.23b) (Kumar et al., 
1992, W u et al., 1992). The pseudoknot structure is supported by the observation that most 
of the sequence which forms helix IV in this model can be deleted without a loss of activity. 
The hepatitis delta ribozyme does have a requirement for M g2+ ions, though they appear to 
play a structural rather than a catalytic role.
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Figure 1.23. Two alternative structures for the hepatitis delta ribozyme. (a) pseudoknot 
structure formed by helices II and III. (Perrotta & Been, 1990). (b) ‘axehead’ structure. 
(Branch & Robertson, 1991). The cleavage point is indicated by an arrow. Base positions 
within the HDV genome are also shown.
The hepatitis delta ribozyme has been used to generate precise 3’ ends of in vitro 
transcribed RNAs for use in in vitro assembly of negative-stranded RNA viruses (Bridgen & 
Elliott, 1996). This was acheived by blunt-end cloning the ribozyme domain onto the 3’-end 
of the gene of interest. The ribozyme can also be modified to function in trans by allowing 
the formation of helix I between two separate RNA molecules, one of which carries the 
ribozyme catalytic domain (Perrotta & Been, 1992, Shih et al., 1993, Fauzi et al., 1997). 
This offers the possibility of infecting chronic HBV carriers with a modified HDV which 
carries a ribozyme which not only allows HDV to replicate, but which also cleaves HBV
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RNA. However, coinfection with wild-type HDV can lead to more severe disease, which 
may prevent the use of modified HDV as a therapeutic agent.
1.12.3d Other motifs
The genomes of the newts Notophthalamus and Triturus contain a highly repetitive 
family of satellite DNAs which are distributed in clusters throughout the genome and which 
are transcribed to produce stable, strand-specific RNAs (Luzi et a l., 1995). This differs 
from other satellite DNAs which are usually transcriptionally inert and restricted to the 
heterochromatin. The RNAs exist as monomers or multimers of the 330 base repeat of the 
satellite sequences, and contain a motif similar to the hammerhead ribozyme (see section 
1.15). Although these ribozymes do cleave at a specific site in the same fashion as the plant 
viroid hammerheads, cleavage has also been observed about 50 nt upstream of the expected 
cleavage site, suggesting some other mechanism. It has been shown that for the newt 
ribozyme to function in vivo it must be associated in a ribonucleoprotein complex of 
approximate size 12S (Luzi e ta l ., 1997).
The 881 nt transcript of the circular Neurospora VS mitochondrial DNA plasmid 
contains a ribozyme motif which is thought to be similar to the hairpin motif (Saville & 
Collins, 1991). This is purely on the basis of computer modelling, as there is too little 
variation between VS RNA isolates to allow the identification of essential residues. The 
cleavage activity has been localised to a 154 nt region, with only one residue required 5 ’ to 
the cleavage site (Rastogi eta l., 1996). The functions of both the newt and the Neurospora 
motifs are unknown (Crisell et al., 1993).
1.12.4 HAMMERHEAD RIBOZYMES
The hammerhead motif was the first of the small catalytic RNAs to be discovered 
(Tritz & Hampel, 1988). It has since been found in a number of plant viroids, either in both 
the positive and negative strands (e.g. avocado sunblotch viroid, ASBV (Daros et al., 1994)) 
or just in the positive strand (e.g. tobacco ringspot encapsidated linear satellite RNA 
(Feldstein & Bruening, 1993)). The hammerhead is the best characterised of all the catalytic 
RNAs, with detailed studies of its structure and mechanism being facilitated by its small size. 
There have also been many studies focused on trying to manipulate the hammerhead 
ribozyme for use as a gene silencing and therapeutic agent.
1.12.4a Key elements
The hammerhead ribozyme consists of three helices surrounding a central region 
containing 13 conserved residues (figure 1.24) (Haseloff & Gerlach, 1989). Cleavage 
occurs on the 3 ’ side of a triplet with the consensus sequence NUX, where N can be any 
base and X can be any base other than guanosine. In wild-type hammerheads this triplet is 
always GUC, with the exception of the Lucerne transient streak viroid in which the triplet is
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CUC. Despite the flexibility of the NUX triplet sequence, the rate of cleavage at different 
triplets is variable (Zoumadakis & Tabler, 1995). The greatest rates are seen at GUC and 
CUC triplets. The sequences of the three helices are not important provided that base-pairing 
is maintained. The lengths of these helices can effect ribozyme activity (see section 
1 .12.4d).
3’
(47) A
helix III
5’
c
G -C
G -C
A -U
C -G
(353)
helix
G
U
XJGGCCUc
u [a g helix I
U g u
G
C
Figure 1.24. The hammerhead domain from the positive strand of the tobacco ringspot 
virus satellite RNA. Conserved bases are boxed and in bold type. The NUX triplet (in this 
case GUC) is in italics. The cleavage point is indicated by the arrow, and helices I, II and 
III are marked. The numbers in brackets refer to the base positions in the satellite RNA’s 
genome, with the first base immediately following the cleavage point (Haseloff & Gerlach, 
1989).
There is evidence in ASBV for a double-hammerhead structure consisting of the plus 
strand motif and the complement of the negative strand motif (Daros et al., 1994). This has 
been shown to have greater cleavage efficiency than just the positive strand motif alone. 
This is probably due to the increased stability gained by having both structures next to each 
other. The ASBV hammerhead is particularly likely to benefit from increased stability as 
helix II only has two or three base-pairs.
1.12.4b Cis- and trans-cleaving hammerheads
Wild-type hammerhead ribozymes all operate in a cis conformation, with the whole 
structure being formed by RNA from the same small segment of the molecule. However, 
helices I and III of the ASBV positive and negative strand hammerheads are formed between 
sequences from opposite sides of the genome (figure 1.25a). This suggested that
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hammerheads had the potential for rrarcs-cleavage. Uhlenbeck demonstrated this using a 24- 
mer generated by in vitro transcription which contained helix III, the cleavage site and 
sequences which would allow it to hybridise with a 19-mer to form helices I and II (figure 
1.25b) (Uhlenbeck, 1987). The sequences of these constructs matched that of the ASBV 
hammerhead. The 24-mer substrate was cleaved and, as the 19-mer was not consumed in 
the reaction, the 19-mer was able to dissociate from the products and mediate subsequent 
reactions.
Could the specificity of a trans-cleaving hammerhead be altered? This was shown by 
Haseloff and Gerlach who designed a hammerhead to cleave the mRNA of the 
chloramphenicol acetyl transferase gene (Haseloff & Gerlach, 1988). This ribozyme 
differed from Uhlenbeck’s in that the ribozyme strand contained helix II and the central loop, 
and hybridised with the substrate strand to form helices I and III. This lead to a generalised 
model for the design of hammerhead: ribozymes (figure 1.25c). This model does not 
demand any structural constraints in the choice of substrate, merely that an NUX triplet is 
present.
1.12.4c Structure and mechanism
The determination of RNA tertiary structures by X-ray diffraction crystallography 
has lagged considerably behind that of proteins. This is mainly due to the difficulty in 
obtaining crystals of sufficient quality for analysis. The first RNA structure to be determined 
was that of yeast tRNAPhe (Brown et al., 1983, Brown et al., 1985). The RNA was treated 
with Pb(II) prior to crystallisation, with the unexpected result that the tRNA was specifically 
cleaved between residues 17 and 18. This cleavage was at its most efficient at neutral pH , 
producing a 5 ’ hydroxyl and 2’3’-cyclic phosphate, products which are also produced by 
ribozymes. By altering the pH and freeze-trapping, it was possible to obtain a structure of 
the tRNAPhe-Pb(II) complex. The Pb2+ ion was shown to be bound covalently in the T\|fC 
loop next to the cleaved bond. It was proposed that the Pb2+ ion acts as a source of metal- 
bound hydroxyl ions (which would only be present at neutral pH) which could abstract a 
proton from the ribose 2 ’-hydroxyl group of residue 17, thus cleaving the phosphodiester 
bond. This gives clues as to the hammerhead mechanism, as the hammerhead also requires 
divalent cations and a neutral pH for cleavage.
The first hammerhead structure was obtained by Pley et al, (1994, 1995). To 
prevent the substrate being cleaved, an all-RNA ribozyme/ all-DNA substrate complex was 
crystallised (Pley eta l., 1993). Intermolecular contact was made within helices I and III, as 
in Haseloff and Gerlach’s model. It was believed that the structure would not be radically 
different from that formed with an all-RNA substrate, as the ribozyme was shown to cleave a 
substrate which was entirely DNA apart from the residue to the 5 ’ side of the cleavage site. 
The high salt concentration (1.6M LiCl) in which the crystals were grown was also cause for
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Figure 1.26a. Crystal structure of hammerhead ribozyme (red) bound to an all-DNA 
substrate (yellow). B ases in domain I (the uridine loop) are shown as blue dot-surfaces. 
Domain II (the non-Watson-Crick base-pairing) is shown as gold dot-surfacing. 
Intermolecular contacts are made within helices I and III. Helix I is at the top right, helix II at 
the top left and helix III at the bottom. Taken from Pley etal., (1994).
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Figure 1.26b. The original proposed secondary structure of the hammerhead ribozyme 
(left) and the secondary structure suggested by the three-dimensional structure determined 
by Pley et al. The substrate strand is shown in italics, Watson-Crick base-pairs as thin 
black lines, and novel base-pairs as thick grey lines. The cleavage site is indicated by an 
arrow.
concern. However, the ribozyme was shown to cleave an RNA substrate in these 
conditions. The final structure (figure 1.26) was very different from the predicted secondary 
structure, which was based purely on Watson-Crick base-pairing (figure 1.24). The three 
helices all showed an A-form structure typical of double-stranded RNA. The core was 
shown to have two domains. The first, following helix I with the sequence 5 ’CUGA, forms 
a sharp turn identical to the uridine turn of the anticodon loop from tRNA (Schweisguth & 
Moore, 1997). This is followed by the second domain, a 3 base-pair duplex of non-Watson- 
Crick base-pairing stabilised by base-stacking which has the potential to bind divalent 
cations. The structure suggested that the ribozyme twists the substrate in such a way as to 
bring the ribose 2 ’-hydroxyl group on the cytosine to the 5 ’ side of the cleavage site into 
position to attack the phosphate in the scissile bond. There was no indication as to whether a 
divalent cation is situated at the cleavage site, though some evidence suggesting this is the 
case has been gleaned from the use of modified substrates (Kuimelis & McLaughlin, 1997). 
If the Rp oxygen of the scissile bond phosphate is replaced with sulphur, cleavage in the 
presence of M g2+ is substantially reduced, though cleavage with Mn2+ is unaffected (see 
section 1.12) (Herschlag et al., 1991). This is not observed if the Sp oxygen is substituted, 
suggesting a direct interaction between the Rp oxygen and a divalent cation. However, a 
conformational change would be required in the RNA-DNA crystal structure for a divalent 
cation at this position to be brought into the correct position for cleavage to occur.
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Figure 1.27. Structure of a hammerhead ribozyme (red) bound to an all-RNA substrate 
(yellow). The key cytosine residue, w hose ribose 2 ’-hydroxyl group is involved in the 
cleavage reaction, is shown in green. Five of the six potential Mg2+ binding sites are 
shown in blue (site 5, though it binds Mn2+, does not bind Mg2+ as tightly as the other 
sites). This intermediate w as captured by freeze-trapping. The Mg2+ at site 6 is deemed to 
be important in the base-catalysed step of the cleavage reaction. Taken from Scott et al., 
(1996).
66
Chapter 1 Introduction
Scott et al (1995) produced the structure of a hammerhead attached to an all RNA 
substrate. Cleavage was blocked by substituting the ribose 2’-hydroxyl on the 5 ’ side of the 
scissile bond with a 2 ’-0-methyl group. The backbone connectivity differed from that of 
Pley et a /’s (1994) ribozyme, with the intermolecular contacts being made within helices I 
and II, as in Uhlenbeck’s ribozyme (Uhlenbeck, 1987). The crystals of the ribozyme-RNA 
substrate were grown in a much lower salt concentration, and were packed differently from 
the ribozyme-DNA substrate complex, with two complexes per unit cell rather than three. 
Despite these differences, the two structures are both very similar, the only difference being 
a few extra stabilising hydrogen bonds in the all-RNA structure. Five potential binding sites 
for divalent cations were also located, including one near the catalytic pocket (figure 1.27) 
which had the potential to approach the cleavage site through conformational change. 
Subsequent work using an unmodified RNA substrate has produced crystals in which 
substrate cleavage can occur when the crystals are soaked in a solution of divalent cations. 
Modulating conditions by varying pH and freeze-trapping has enabled two intermediates to 
be trapped (Scott e ta l., 1996). The first shows metal binding prior to cleavage, and has 
revealed a sixth divalent cation binding site on the Rp oxygen of the phosphate in the scissile 
bond, as previously predicted. This binding site is only occupied at neutral to alkaline pH. 
This, rather than the binding site revealed in the previous structure, is likely to be the critical 
point in the cleavage mechanism. Binding of Mg2+ at this point is believed to induce the 
conformational change needed for in-line attack at the cleavage site ribose 2 ’-hydroxyl, as
RO.
Cytosine
H-
Figure 1.28. The metal hydroxide transitional state, with arrows indicating electron 
movements. A lone-pair of electrons on the oxygen of the metal hydroxide attacks the 
proton of the ribose 2’-hydroxyl (nucleophilic attack). This results in the proton being 
removed to produce H20  and a free Mg2+. This then makes it thermodynamically favourable 
for the lone-pair of electrons on the ribose 2’-oxygen (formed by the removal of the proton) 
to attack the phosphorus to form a 2’3’-cyclic phosphate.
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well as providing a metal hydroxide to initiate the base-catalysed step of the cleavage reaction 
(figure 1.28). The second intermediate accumulates just before cleavage occurs. The 
restrictions of the crystal lattice are believed to trap this intermediate. This shows an increase 
in hydrogen bonding within the core produced by base stacking interactions, thus stabilising 
the transition-state.
Although the hammerhead mechanism is becoming clearer, more work needs to be 
done. Generation of ‘kinetic bottleneck’ mutants will enable the cleavage reaction to be 
stalled at different points, extending the lifespans of intermediates enabling structural 
analysis. This approach has proved fruitful with protein enzymes.
1.12.4d Factors affecting activity
Although it has been demonstrated that the hammerhead ribozyme can be manipulated 
to target any RNA, there are a number of factors which must be considered. The lengths of 
the flanking sequences on either side of the conserved catalytic core, which hybridise with 
the substrate to form helices I and El, are very important. Like antisense oligonucleotides, it 
is important that the flanking sequences are sufficiently long (at least 11 to 15 bases) to give 
the required degree of specificity. However, there is a limit to how long the flanks can be. 
If they are too long, then the cleavage products will fail to dissociate from the ribozyme, 
preventing multiple turnover. Goodchild and Kohli (1991) demonstrated that by reducing 
the total flanking sequences of a hammerhead targeted against HIV mRNA from 20 to 12 
bases increased the rate of cleavage 10-fold. In addition, only the shorter ribozymes showed 
multiple turnover. The sequence of the target can also affect the optimum flanking sequence 
length. If helices I and HI are GC-rich, then they will be more stable than AU-rich helices of 
the same length. Not only does this slow down the rate of product dissociation, but it also 
makes the ribozyme more tolerant of mismatches in the target site (Werner & Uhlenbeck, 
1995). U-rich flanking sequences are to be avoided if possible, as G-U wobble base-pairs 
can form, further reducing target specificity (Herschlag, 1991).
Whether ribozymes are generated by in vitro transcription or intracellularly, they 
always carry exogenous sequence outside of the catalytic core and complementary flanking 
sequences. This sequence is derived from the promoter and the transcription termination 
signal. This excess sequence can sometimes assume secondary structures with the ribozyme 
sequences which prevent the ribozyme from binding its target. An example of this can be 
found in the barley yellow dwarf viroid where, under certain conditions, a sequence adjacent 
to the ribozyme can interact with the bulge of helix II and form a pseudoknot structure 
(Miller & Silver, 1991). This is believed to operate as a form of control over viroid 
replication. The incorporation of ds-cleaving hammerheads into transcripts which can excise 
the tams-cleaving hammerhead from the surrounding sequence has been successfully 
demonstrated. Such constructs have allowed hammerheads which were otherwise inactive to 
bind to and cleave their substrates.
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Excess sequences have been specifically chosen to exert allosteric control over 
ribozyme activity. Allostery is a well-characterised phenomenon of protein enzymes, where 
the binding of a factor to an enzyme somewhere other than the active site varies the enzyme’s 
activity. Addition of an ATP-binding RNA aptamer (selected by in vitro screening) to a 
hammerhead ribozyme transcript blocked ribozyme activity when ATP was present (Tang & 
Breaker, 1997). This offers the potential of tightly controlling ribozyme activity with small 
ligands, which could be used to restrict activity to particular cell types.
Substrate secondary structure can also prevent ribozyme binding. mRNAs are 
dynamic structures which constantly switch between a number of different conformations all 
of similar free energy. If any of these structures include regions of duplex within the 
ribozyme target site, then ribozyme-substrate binding may be blocked. Fedor and 
Uhlenbeck (1990) designed four hammerheads of 34 bases each targeted against four 
different 13 base substrates. These showed a 70-fold variation in cleavage rates. However, 
kcat remained virtually the same, whilst varied, indicating the variation arose from 
ribozyme-substrate binding, though this had no effect on the cleavage reaction itself. The 
four substrates each migrated differently when run on a non-denaturing electrophoresis gel, 
indicating they all assumed different secondary structures. In all cases approximately 10% 
of the substrate was resistant to further cleavage, suggesting that some of the substrate had 
become trapped in a stable, but ribozyme-insensitive, structure. As substrates become larger 
(many mRNAs have lengths in the range of kilobases) this problem becomes more 
significant. The presence of single-stranded bulges has been shown to favour the 
hybridisation of sense-antisense RNA (Homann et a l., 1993), whilst the elimination of any 
single-stranded RNA from the target site can completely block ribozyme cleavage (Xing et 
al., 1992). If such regions are unavailable in the desired target, lengthening the flanking 
sequences can allow hybridisation to occur. This was demonstrated by Beck and Nassal, 
who showed that a hammerhead with total flanking sequences of 10 bases could not cleave 
the highly structured HBV encapsidation signal, whereas a hammerhead with flanks of 38 
bases could (Beck & Nassal, 1995). In general it has been found that longer flanking 
sequences are needed for hybridisation to full-length mRNA substrates, presumably because 
of the problems of secondary structure. Although, as discussed, this could reduce the rate of 
product dissociation, this problem can be partially bypassed by designing ribozymes with 
asymmetric flanks. Such ribozymes have one long flank, which binds tightly to the 
substrate, and one short flank, which can be as short as three bases, from which the product 
can rapidly dissociate.
One fact that has become clear from all this work is that there is no set of general 
rules which can be applied to the design of all hammerhead ribozymes. At present, the only 
route to the optimum structure of a ribozyme targeted against a particular point is by trial and 
error. The design of any hammerhead ribozyme for in vivo use will have to be based on a 
compromise of all these factors.
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1.12.4e How can activity be increased?
Although hammerhead ribozymes are promising therapeutic agents, is there any way 
in which their activity can be increased, perhaps circumventing some of the limitations 
described in the previous section?
It has been demonstrated that up to nine hammerhead motifs targeted against different 
sites can be included in a single transcript, resulting in greater cleavage activity than any one 
of the single ribozymes alone (Chen et a l ,  1992). This construct was targeted against the 
env region of HIV, with sequence comparisons indicating potential activity against all 
sequenced HIV isolates then known. Although this approach is important for dealing with 
escape mutants, this construct did not exhibit a nine-fold increase in activity compared to the 
single ribozymes, suggesting that the hammerhead motifs were not functioning at maximal 
catalytic efficiency. Incorporation of cis-cleaving ribozymes between multiple trans-cleaving 
ribozymes targeted against different sites has been shown to result in greater cleavage 
efficiency than if the rra/w-cleaving ribozymes remained joined in the same transcript (figure 
1.29) (Ohkawa et a l ,  1993, Ventura et a l ,  1993, Xing et a l ,  1995). This is known as the 
‘shotgun’ approach. Increasing the number of tandemly linked ribozymes in a single 
transcript did increase cleavage efficiency until n=3, when activity reached a plateau. 
However, when a cw-cleaving ribozyme was included to release the trans cleaving 
ribozymes, activity continued to increase as the number of units grew.
1RNAtRNAtRNA
7>a/u-«cling ribozyme 2 rniUHKting ribozyme J 8-27>aiu-aclinf ribozyme 1
Cleavage ail*
— | P ro m o te r
ana 'IRNAltR N A l
7miu-actlng ribozymerniu-edlnt ribozyme 2Tiwu-acting ribozyme 1
Figure 1.29. Simple tandem-repeat ribozyme expression vector (top), with ribozymes 
exposed in the tRNA anticodon loop. Exogenous sequence is trimmed by cis-acting 
ribozymes at each end. ‘Shotgun’ expression vector (bottom). Each individual ribozyme- 
tRNA unit is liberated from the whole transcript by cis-acting ribozymes. Taken from 
Ohkawa etal., (1993).
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Optimising flanking sequence length is a problem when full-length mRNAs are the 
target. Although ribozymes with longer flanking sequences have been shown to hybridise 
more effectively to long substrates than their counterparts with shorter sequences, they do 
not operate at maximum efficiency, with the ribozyme having to be many hundreds-fold in 
excess of the substrate. This probably arises from the failure of products to dissociate. One 
answer to this problem is the utilisation of ‘facilitator’ oligonucleotides (Jankowsky & 
Schwenzer, 1996a). These are antisense molecules which bind to the substrate immediately 
next to the ends of the ribozyme flanking sequences (figure 1.30). Facilitators can increase 
the stability of ribozyme-substrate binding. It is assumed that this is acheived by base- 
stacking interactions between the terminal residues of the facilitator and the ribozyme. These 
interactions have the energetic equivalent of an extra base-pair in the ribozyme-substrate 
helix, which means that facilitators have greatest benefit when used with ribozymes with 
short flanking sequences (Nesbitt & Goodchild, 1994). However, the greatest benefit may 
come from facilitators opening up any inhibitory secondary structure in the ribozyme target 
by binding to nearby regions of the substrate (Denman, 1996).
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Figure 1.30. Schematic representation of the binding of facilitator oligonucleotides. The 
facilitators (F) bind to the substrate (S) immediately next to the 5’ and 3’ ends of the 
ribozyme (R).
The use of facilitators will probably be dictated by the system under development. 
Facilitators have been shown to reduce kcat, though not in all cases. Facilitators can also 
stabilise the ribozyme-product complex, blocking ribozyme cycling. Janowsky and 
coworkers showed that a facilitator binding at the 3’ end of their ribozyme enhanced 
ribozyme activity, whilst a facilitator binding at the 5’ end reduced activity (Jankowsky & 
Schwenzer, 1996b). The binding energy of the 5 ’ flank of the ribozyme was higher than 
that of the 3 ’ flank, leading to the assumption that the 5 ’ flank was stabilised to such a degree 
by the facilitator that it could not dissociate from the product. The optimum length of the 
facilitators, and whether they are made of RNA or DNA is again dependent on the system, in 
particular the substrate sequence and the concentrations of the ribozyme and substrate.
If hammerhead ribozymes are to be used in vivo they will have to be able to function 
in an environment which contains a number of proteins which can bind non-specifically to
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RNA. Some of these proteins have been shown to enhance hammerhead ribozyme activity 
(Tsuchihashi eta l., 1993, Herschlag eta l., 1994). The HIV nucleocapsid protein NCp7 has 
been shown to enhance the in vitro activity of a hammerhead with total flanks of 14 bases 
against a long substrate, though the activity of hammerheads with longer and shorter flanks 
was inhibited (Bertrand & Rossi, 1994). Further work has shown that kcat is not varied by 
addition of NCp7; enhancement comes from increasing the rate of ribozyme-substrate 
hybridisation and dissociation of products. A peptide from the C-terminal of NCp7 can also 
enhance hammerhead activity in this way. It is believed that NCp7 promotes the 
destabilisation of intramolecular helices, such as inhibitory substrate secondary structure, 
allowing the formation of intermolecular helices between ribozyme and substrate. This 
chaperone property also enables NCp7 to restore a misfolded ribozyme-substrate complex to 
an active conformation. Without addition of NCp7 approximately 20 to 30% of substrate 
was resistant to cleavage, but addition of NCp7 allowed this remainder to be cleaved. As 
this is an HIV nucleocapsid protein which has this ability, it raises possibilities of using 
hammerhead ribozymes as anti-HTV agents. In vitro studies have shown that the tumour 
suppressor protein p53 can enhance the formation of RNA duplexes, which could enable 
p53 to enhance ribozyme-substrate hybridisation (Nedbal et al., 1997). Although this 
activity has been shown to be independent of sequence, the mechanism is unknown, and is 
inhibited by Mg2+.
1.12.4f Cell culture and in vivo applications
The intracellular environment is very different from that found in the in vitro assays 
used to assess hammerhead activity. Ribozymes will have to be able to find their target 
amidst an excess of other cellular RNAs and proteins. In vitro studies have shown that 
addition of total cellular RNA can reduce hammerhead activity (Denman et al., 1992), though 
it is unclear whether this observation can be extended to all ribozymes. A major problem is 
the susceptibility of ribozymes to nuclease degradation. The lifespan of cellular mRNAs is 
regulated by the 5’ and 3’ untranslated regions and by polyadenylation. Though addition of 
such sequences may stabilise ribozymes expressed intracellularly, care must be taken to 
ensure that they will not include inhibitory secondary structures. Addition of palindromic 
sequences at the 3 ’ end of an anti-tumour necrosis factor-a hammerhead resulting in the 
formation of a hairpin has been shown to increase stability by protecting against 3 ’- 
exonuclease degradation. However, inclusion of double-stranded regions may produce sites 
for RNA-binding proteins which could possibly inhibit cleavage (Sioud, 1994).
Investigations of intracellular hammerhead activity have usually been based on 
ribozymes proven to have worked in vitro. Such ribozymes do not always work in cells, 
though there are cases of a ribozyme not working in vitro which did work once expressed in 
cells, suggesting the presence of a protein cofactor (see section 1.12.4e) (Crisell et al.,
1993). Initial studies claimed to have detected specific ribozyme-mediated inhibition of gene
72
Chapter 1 Introduction
expression or RNA degradation in cells (Cotten & Birnstiel, 1989, Cameron & Jennings,
1994). Although controls were unaffected by the presence of the ribozyme, cleavage 
products were not detected. Intracellular cleavage was first demonstrated by Saxena and 
Ackermann, who microinjected ribozymes targeted against the a-sarcin sensitive site of 28S 
rRNA into Xenopus oocytes. Not only were cleavage products detected, but cleavage of the 
28S rRNA lead to a total block of oocyte protein synthesis.
One problem with trying to detect cleavage products is that the target RNA may be at 
such low abundance that it, and any ribozyme cleavage products, may be undetectable by 
Northern blotting or RNase protection assays. Therefore it is important to use an inactive 
ribozyme mutant as a control. Such a mutant behaves as an antisense oligonucleotide, 
binding to the target sequence, but not mediating cleavage. This enables the relative 
contributions of ribozyme cleavage and the antisense effect to gene silencing to be 
determined. In some cases both mechanisms play a role (Steinecke et al., 1994), whilst in 
other cases inclusion of an active ribozyme domain does not increase gene-silencing ability.
Once a ribozyme has been demonstrated to function intracellularly, how can it be 
delivered to its target? Ribozyme expression has been demonstrated in vivo  in transgenic 
mice, though the development of a vector system is required for therapeutic use. 
Exogenously synthesised ribozymes have been delivered in cell culture using liposomes, 
though this is hampered by degradation by serum nucleases and by the poor transfection 
efficiency of untargeted liposomes. There has been some success in stabilising exogenously 
synthesised ribozymes by incorporating phosphorothioate linkages into the flanking 
sequences (Koizumi & Ohtsuka, 1991, Shimayama et al., 1993, Heidenreich et al., 1994). 
However, these have the same drawbacks as modified antisense oligonucleotides (see 
section 1.10.5). Retroviral vectors have been used to stably transfect CD4+ cell lines with 
anti-HIV hammerheads, rendering the cells resistant to HIV infection in a manner similar to 
that being used in the clinical trials of the hairpin ribozyme (see section 1.12.3f) (Rossi et 
al., 1993). Anti-HCV ribozymes have been successfully delivered to cultured human 
hepatocytes using an adenoviral vector (Lieber et al., 1996a). El-deleted replication-
incompetent adenovirus has been used to deliver an anti-human growth hormone (hGH) 
ribozyme to the livers of hGH transgenic mice. This led to a 96% reduction in hepatic hGH 
(Lieber et al., 1996b). Though this is encouraging for the potential gene therapy of chronic 
hepatitis, there have been problems with El-deleted adenoviruses eliciting inflammatory 
responses in human clinical trials.
Is there any way in which intracellular hammerhead activity can be increased? It has 
been proposed that the reason why so many promising ribozymes fail to function 
intracellularly is because they fail to enter the same compartments of the cell as their target. 
Addition of polyadenylation and splicing signals could forseeably allow a ribozyme 
transcript to pass through the same processing pathways as mRNA. Some viral targets have
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the additional advantage of packaging elements, which target viral transcripts to regions of 
the cell where virion formation occurs. Sullenger demonstrated that a hammerhead targeted 
against a lacZ reporter in a murine leukaemia retrovirus was inactive in cells. However, if 
the retroviral packaging signal was included in the ribozyme transcript, then expression of 
the lacZ reporter was reduced (Sullenger & Cech, 1994a).
1.12.4g Hammerheads and HBV
Initial in vitro studies demonstrated cleavage of a fragment of HBcAg mRNA by a 
single transcript containing three hammerhead motifs (von Weizsacker et al, 1992). All three 
active sites were simultaneously active, with cleavage occurring at a 1:1 molar ratio of 
ribozyme to substrate. The data suggest that the cleavage products dissociate independently 
from the ribozyme. This is probably why the long total flanking regions (45 bases) do not 
impair activity. The shotgun approach (see section 1.12.4e) has been used in vitro to cleave 
up to 80% of substrate (derived from the core region), with the substrate in excess of the 
ribozyme constructs (Ruiz eta l., 1997).
Beck and Nassal designed a series of hammerheads targeted against the encapsidation 
signal (see section 1.12.4d). They showed that highly structured substrates could be 
targeted by lengthening the flanking sequences of the hammerhead. Although their 
ribozymes functioned in vitro, they failed to work when transfected into HepG2 cells. 
Cleavage could be detected in cell lysates, but only if the lysates were supplemented with 
extra Mg2+ (Beck & Nassal, 1995).
Luber et al., (1997) have successfully targeted the X region with a hammerhead with 
asymmetric flanks up to a kilobase in length. This was shown to cleave the target efficiently 
in vitro. The hammerhead construct was cotransfected into HepG2 cells with HBV DNA, 
and was shown to reduce viral replication, as determined by measuring pgRNA, HBsAg in 
the supernatant and HBcAg. However, an inactive ribozyme mutant was shown to have the 
same inhibitory potential, suggesting that this construct operates purely by the antisense 
m echanism .
Despite the potential of ribozymes as antiviral agents having been demonstrated, 
work with anti-HBV ribozymes has not progressed as far as with anti-HTV constructs. In 
part this is due to the lack of an effective in vitro model for viral replication. The main 
problem is the safe, efficient targeting of gene therapy constructs to the liver. The 
development of hepatocyte-specific vectors is progressing, but as yet there is nothing 
approaching the rigorous safety specifications required for a vector for use in vivo in 
humans.
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2.1 MATERIALS
a) Plasmids
pGEM-3z Promega, Madison, WI
pRK5 ' Prof. H. Will, Hamburg
pRZ60, pY98 Dr. G. Sczakiel, Heidelberg
pZeo-5D Dr. A. Patel, Institute of Virology
b) Bacterial Strain and growth media
D H 5a Escherichia coli. Genotype: (J)80d/acZAM 15, recA 1, endA 1,
gyrA96, th i-\, h sd R \l(rK',m K), supEAA, relAX, deoR , A(lacZYA- 
argF) U169.
L-broth lOg bacto-tryptone, 5g bacto-yeast extract, 5g NaCl in 11 water
c) Radioisotopes
All radiolabelled compounds were obtained from Dupont-NEN.
Radiolabelled compound Activity (Ci/mmol)
oc35S-dATP 1250
a 32P-U TP 800
a 32P-dCTP 3000
y32P-ATP 6000
35S-L-methionine 1175
Radiolabelled nucleic acids and proteins were visualized on electrophoretic gels using Kodak 
X-OMAT film.
d) Enzymes
Restriction enzymes and buffers and calf intestinal alkaline phosphatase were 
purchased from Boehringer Mannheim; RNA polymerases, recombinant RNase inhibitor 
(RNasin) and ribonucleotides were obtained from Promega and Ambion; RNase A was 
purchased from Sigma Chemicals; T4 polynucleotide kinase, T4 DNA ligase and T4 RNA 
ligase were purchased from New England Biolabs; Taq DNA polymerase and 
deoxyribonucleotides for PCR were purchased from Gibco; terminal deoxynucleotidyl 
transferase was obtained from Promega.
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e) Labels and antibodies for ELISA
Biotin- 16-ddUTP, biotin- 16-dUTP, digoxigenin-16-ddUTP, digoxigenin-16-UTP, 
all purchased from Boehringer Mannheim/ Enzo Diagnostics.
Peroxidase-anti peroxidase and donkey anti-sheep IgG- peroxidase conjugate 
secondary antibodies were both purchased from Sigma Chemical Co.
f) Common Reagents
Manufacturer 
Beecham Research 
Biorad
Boehringer Mannheim 
Fluka
National Diagnostics
Oncor
Prolabo
Chemicals
Ampicillin
TEMED, Ammonium persulphate 
Agarose, Tris base 
Formaldehyde
Sequagel 6 and Protogel pre-prepared acrylamide 
solutions.
Deionized formamide
Boric acid, chloroform, ethanol, glacial acetic acid, 
glycerol, isopropanol, methanol
All other reagents and chemicals were purchased from Sigma-Aldrich Co.,Poole, UK or 
BDH Chemicals, Poole, UK.
g) Reagents and buffers for PCR, DNA sequencing and cloning
Acrylamide gel elution buffer 500mM CH3COONH4, lOmM M gCl2, 0.1% SDS,
ImMEDTA
10X PCR buffer 200mM Tris-HCl (pH 8.4), 500mM KC1
10X agarose gel loading buffer
IX  TBE, 1% SDS, 50% glycerol, 0.025% bromo- 
phenol blue.
100 mM each of dATP, dTTP, dCTP, dGTP 
89mM Tris-HCl (pH 8.0), 89mM H3B 0 3, Im M  EDTA 
0.1M Tris-HCl (pH 4.5 or pH 8.0), lOmM EDTA 
250mM Tris-HCl (pH 7.6), 50mM M gCl2, 5mM DTT, 
5mM ATP, 25% PEG 8000
10X dNTPs 
10X TBE, 
10XTE
10X ligase buffer
h) Reagents and solutions for small scale plasmid preparation
Solution I 25mM Tris-HCl (pH 8.0), lOmM EDTA, 50mM
glucose
Solution II 0.2M NaOH, 1 % (w/v) SDS
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Solution III 3M CH.COOK, 5M CH3COOH
i) Reagents and solutions for large scale plasmid preparation
These were purchased as part of a kit from QIAGEN, Crawley, UK,
Buffer PI 50mM Tris-HCl (pH 8.0), lOmM EDTA, lOOpg/ml 
RNAse A
0.2M NaOH, 1% (w/v) SDS 
3M CH3COOK, pH 5.5
750mM NaCl, 50mM MOPS (pH 7.0), 15% EtOH, 
0.15% triton X -100
1M NaCl, 50mM MOPS (pH 7.0), 15% EtOH 
1.25M NaCl, 50mM Tris-HCl (pH 8.5), 15% EtOH
Buffer P2 
Buffer P3 
Buffer QBT
Buffer QC 
Buffer QF
j) Reagents and solutions for in vitro  transcription, RNA gel shifts and 
ribozyme cleavage reactions
a) Small scale RNA synthesis
5X Transcription buffer 200mM Tris-HCl (pH 7.5), 30mM MgCl2,
lOmM spermidine, 50mM NaCl.
Nucleotide solutions lOmM ATP in H20 , (pH 7.0), lOmM CTP in
H20 , (pH 7.0), lO m M G TP in H20 ,  (pH 7.0), 
lOmM GTP in H20 , (pH 7.0)
b) RiboMAX system (Promega) fo r  large scale RNA synthesis
5X Transcription buffer 400mM HEPES-KOH (pH 7.5), 120mM M gCl2,
200mMDTT
Nucleotide mix 25mM each of ATP, CTP, GTP, TTP (pH 7.0)
c) Ribozyme analysis
1 OX Ribozyme hybridization buffer
200mM Tris-HCl (pH 7.5), 1M NaCl 
RNA gel shift stop solution 50mM Tris-HCl (pH 8.0), 50mM EDTA, 0.5% SDS,
0.5M urea, 0.025% bromophenol blue
Formamide gel loading buffer
90% formamide, IX  TBE
k) Reagents and solutions for ELISA
Cacodylate buffer 500mM cacodylate (pH 6 .8), 5mM CoCl2,0 .5m M  DTT
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All other buffers were all provided with Boehringer M annheim’s PCR detection ELISA kit.
1) In vitro translation
In vitro translation was performed using Promega’s TNT rabbit reticulocyte lysate 
coupled transcription-translation system. All reagents were provided with the kit.
Final concentrations of reaction components
lOmM creatine phosphate, 50|ig/ml creatine phospho- 
kinase, 2mM DTT, 50jig/ml calf liver tRNA, 79mM 
CH3COOK, 0.5mM (CH3COO)2Mg, 0.02mM haemin
m) Reagents and buffers for immunoprecipitation
Protein-A sepharose beads Purchased from Sigma. Resuspended in H20 .
Wash buffer 0.5M LiCl, 0 .1M Tris-HCl (pH 8.0)
Rabbit anti-HBcAg polyclonal antiserum
Purchased from Dako Corporation.
n) Reagents and buffers for SDS-PAGE and western blotting
4X stacking gel buffer 0.5M Tris base, 0.4% SDS, adjusted to pH 6.8
4X separating gel buffer 1.5M Tris base, 0.4% SDS, adjusted to pH 8.8 
1 OX SDS polyacrylamide gel running buffer
0.25M Tris base, 1.9M glycine, 1% SDS 
SDS sample buffer 20% glycerol,, 2% SDS, IX  stacking gel buffer, 5% (3-
mercaptoethanol, 0.25mg bromophenol blue 
Towbin buffer 25mM Tris-HCl (pH 8.3), 192mM glycine, 20%
CH3OH
5X TBS lOOmM Tris-HCl (pH 7.5), 2.5M NaCl.
TTBS IX  TBS, 0.05% Tween 20.
Rabbit anti-HBcAg polyclonal antisera was purchased from Zymed Laboratories or 
Dako Corporation. These were used at dilutions of 1:2 and 1:1000 respectively. Goat anti­
rabbit IgG whole molecule peroxidase conjugate was purchased from Sigma.
Hybond-N nylon membrane (also used for northern blotting) was purchased from 
Amersham.
o) Firefly luciferase reporter assay
The firefly luciferase reporter assay was performed using Promega’s Luciferase 
Assay System.
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Assay reagent 20mM tricine, 1.07mM (M gC 03)4M g(0H )25H20 ,
2.67mM M gS 04, 0.1 mM EDTA, 33.3mM DTT, 
270pM coenzyme A, 470pM  luciferin, 530|iM  ATP, 
(pH 7.8)
p) Reagents and solutions for northern blotting
10X MOPS buffer 
RNA sample buffer
Denhardt’s Reagent, 50X
20X SSC
Hybridization solution
0.4M MOPS, 0.1M CH3COONa, lOmM EDTA 
720jil deionized formamide, 160|ll1 10X MOPS buffer, 
260|il 37% formaldehyde. (Store -20°C, renew every 2 
weeks.)
5g Ficoll, type 400, 5g polyvinyl-pyrrolidone, 5g 
bovine serum albumin dissolved in DEPC treated water 
to give final volume of 500ml.
3M NaCl, 0.3M Na3C6H 50 7 (pH 7.2)
5X SSC, 50% deionized formamide, 1% SDS, 5X 
Denhardt’s reagent, 20pg/ml sonicated salmon sperm 
DNA.
q) Buffer for primer extension analysis
Promega’s MMLV-RT H' primer extension system was used.
M M LV-RT2X buffer lOOmM Tris-HCl, (pH 8.3), 150mM KC1, 6mM
M gCl2, 20mM DTT, ImM dATP, ImM dCTP, ImM 
dGTP, ImM dTTP
r) Buffers for radiolabelling nucleic acids
1 OX nick translation buffer 0.5M Tris-HCl, (pH 7.5), 0.1M M g S 0 4, ImM DTT,
500pg/ml bovine serum albumin 
10X polynucleotide kinase buffer
500mM Tris-HCl (pH 7.6), lOOmM M gCl2, 50mM 
DTT, ImM  spermidine.
10X calf intestinal alkaline phophatase buffer
500mM Tris-HCl (pH 9.3), lOmM M gCl2, ImM 
ZnCl2, lOmM spermidine
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s) Synthetic oligodeoxyribonucleotides
Table 2.1 Primers used for PCR construction of ribozymes. Restriction sites are 
underlined.
Primer Sequence Restriction
sites
RZ1 CTCACAGAATTCATGCTCAGCTGATGAGTCCGTGAGGACG
AAAGACTCTATGTTTATTGCAGCTTATAATGGTT
ZicoRI
RZ2 CTCACAGAATTCAGTATGGTCTGATGAGTCCGTGAGGACG
AAAGGTGAACTGTTTATTGCAGCTTATAATGGTT
EcoKl
RZ534 CTCACAGAATTCCGTCGTCTCTGATGAGTCCGTGAGGACG
AAACAACAGTTGTTTATTGCAGCTTATAATGGTT
EcoKl
RZ551 CTCACAGAATTCTTCTAGGGCTGATGAGTCCGTGAGGACG
AAACCTGCCTTGTTTATTGCAGCTTATAATGGTT
EcoRl
RZ556 CTCACAGAATTCTCTTCTTCCTGATGAGTCCGTGAGGACG
AAAGGGGACCTGTTTATTGCAGCTTATAATGGTT
EcoKl
RZ568 CTCACAGAATTCAGGCGAGGCTGATGAGTCCGTGAGGACG
AAAGTTCTTCTGTTTATTGCAGCTTATAATGGTT
EcoKl
RZ572 CTCACAGAATTCTGCGAGGCCTGATGAGTCCGTGAGGACG
AAAGGGAGTTTGTTTATTGCAGCTTATAATGGTT
EcoKl
CPI GTCACGACGTAAGCTTGTAAAACGACGGC H indlll
Table 2.2 Oligonucleotides used as run-off transcription templates.
Oligonucleotide Sequence
T7P AATTTAATACGACTCACTATAG
RZSUB TCGTCTGCGAGGCGAGGGAGTTCTTCTTCTAGGGGACCTGCCTCGT
CGTCTAACAACAGTAGCCCTATAGTGAGTCGTATTAAATT
RZ534T ACTGTTGTTTCGTCCTCACGGACTCATCAGAGACGACGAACCCTAT
AGTGAGTCGTATTAAATT
RZ551T AGGCAGGTTTCGTCCTCACGGACTCATCAGCCCTAGAAAACCCTAT
AGTGAGTCGTATTAAATT
RZ556T GGTCCCCTTTCGTCCTCACGGACTCATCAGGAAGAAGAAACCCTAT
AGTGAGTCGTATTAAATT
RZ568T GAAGAACTTTCGTCCTCACGGACTCATCAGCCTCGCCTAACCCTAT
AGTGAGTCGTATTAAATT
RZ572T AACTCCCTTTCGTCCTCACGGACTCATCAGGCCTCGCAAACCCTAT
AGTGAGTCGTATTAAATT
RZ572BT ACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCT
TTCGTCCTCACGGACTCATCAGGCTCGCAGACGACCCTATAGTGAG
TCGTATTAAATT
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2.2 METHODS
2.2.1 PCR, sequencing and cloning
a) Preparation of oligodeoxyribonucleotides
Oligodeoxyribonucleotides were synthesized in house using a Cruachem PS250 
oligonucleotide synthesizer. Oligodeoxyribonucleotides were eluted from the synthesis 
columns with 1.5ml concentrated ammonia, and deprotected by incubation at 55°C for 5 
hours. The oligos were recovered as lyophilized pellets by spinning the ammoniacal solution 
under vacuum overnight. The pellets were resuspended in 200jll1 H 20 . Oligos over 45 bases 
in length were further purified by polyacrylamide gel electrophoresis. 50|il of resuspended 
oligo were mixed with 50jll1 deionized formamide and run on a 15% polyacrylamide gel 
(30ml 30% Protogel (National Diagnostics), 6ml 10X TBE buffer, 0.6ml 10% (w/v) 
ammonium persulphate, 40|il TEMED, 23.4ml H 20 ). Bands were visualized by ultraviolet 
shadow-casting. The bands were cut out of the gel, placed in 1ml acrylamide gel elution 
buffer and incubated overnight at 37°C. The elution buffer was removed, phenol/chloroform 
extracted, and the oligo recovered by precipitation with 2 volumes EtOH at -20°C for 30 
minutes. The oligo was pelleted by spinning at 13,000rpm for 30 minutes in a Scotlab 
microfuge. The pellet was washed with 70% EtOH, dried under vacuum, then resuspended 
in 50jll1 H 20 . The oligo’s concentration was determined by measuring the optical density 
(OD) at 260nm of a 1:100 dilution, where 1 OD unit equals 50|ig/ml DNA.
b) Polymerase chain reaction (PCR)
PCR was used to generate ribozyme cassettes to clone into pGEM-3z and pRK5 
plasmids. Each reaction contained 5|il 1 OX PCR reaction buffer, 2p,l lOOmM M gCl2, IjllI of 
each primer to give a final concentration of 50pmol/|ll of each primer, lfil dNTP mix (each 
dNTP at 125fiM final concentration), 2 units Thermophilus aquaticus (Taq) DNA polymerase 
(Gibco), lOng target DNA and H20  to a final volume of 50|il. The reaction mix was overlaid 
with 50|LLl mineral oil to prevent evaporation. The reactions were performed on a Biometra 
TRIO Thermoblock using the following program; 95°C for 4 minutes followed by 5 
cycles of
95°C for 1 minute 
55°C for 1 minute
72°C for 1 minute, 30 seconds followed by 35 cycles of 
90°C for 1 minute 
55°C for 1 minute
72°C for 1 minute, 30 seconds followed by a final 4 minutes at 
72°C. Products were detected by agarose gel electrophoresis 
(see section 2 .2 .1.iv).
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c) Restriction digests
Cloning was confirmed by restriction digestion of miniprep plasmid DNA with 
appropriate restriction enzymes followed by agarose gel electrophoresis. A standard 
restriction digest typically consisted of 1.5pl 10X restriction buffer (Boehringer Mannheim), 
0.2 pi (2 units) of each appropriate restriction enzyme, 5fil miniprep plasmid DNA and H20  
to a final volume of 1 5jll1. Digests were incubated for 3 hours at 37°C. The same protocol 
was also used to prepare PCR products and plasmids for ligation and for generating templates 
for run-off in vitro transcription reactions.
d) Agarose gel electrophoresis
Agarose gel electrophoresis was used to analyse restriction digests of miniprep DNA, 
and also to prepare linearized plasm ids’for.; in .vitro transcription reactions. Gels were 
prepared by boiling lg  agarose (Boehringer Mannheim) in 100ml IX  TBE buffer. The 
solution was allowed to cool, and 50|J.l ethidium bromide (1 mg/ml) was added prior to 
casting the gel. Samples were prepared by adding 1 volume of agarose gel loading buffer, 
and run at 80V in IX TBE buffer. On completion of running, the bands were visualized on 
an ultra-violet transilluminator.
e) Gene-cleaning
PCR products, restriction digest products and linearized plasmids were isolated from 
agarose gels using the Geneclean kit (BIO 101 Inc.). Bands were located by visualizing the 
gel on an ultraviolet transilluminator. The correct bands were cut out and placed in 1.5ml 
eppendorf tubes with 4.5 volumes sodium iodide and 0.5 volumes TBE gel modifier and 
incubated at 55°C until the gel slice had melted. 6pl glassmilk was added to each tube. The 
tubes were vortexed and left on ice for 5 minutes. The tubes were spun briefly at 13,000rpm 
in a Scotlab microfuge, and the resulting glassmilk pellet washed three times with 1ml ice 
cold NEW wash. (NEW wash was prepared by adding 14ml concentrate provided with the 
Geneclean kit to 280ml distilled water and 310ml 100% ethanol.) Following the final wash 
the glassmilk pellet was airdried. The DNA was eluted from the glassmilk by resuspending 
the glassmilk pellet in 50jil H 20 ,  and incubating at 55°C for 5 minutes. The glassmilk 
suspension was spun at 13,000rpm for 5 minutes and the supernatant containing the eluted 
DNA was removed.
f) DNA ligations
Concentrations of vector and insert DNA were estimated by agarose gel 
electrophoresis with molecular weight markers of known concentration. Ligations were 
optimized by trying vector:insert ratios of 3:1, 1:1 and 1:3. Vector-insert DNA mixes were 
added to 2jil 5X T4 ligase buffer (BRL), 1 unit T4 ligase and H20  to a final volume of lOpl.
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Ligation reactions were incubated at room temperature for 3 hours and then transformed into 
competent bacteria.
g) Preparation of competent Escherichia coli cells
10(Lil of D H 5a glycerol stock was placed in 10ml L-broth, and incubated at 37°C 
overnight. 500(il of overnight culture was transferred to 50ml L-broth and incubated for a 
further 2 to 2.5 hours, until the OD600 of the culture was between 0.2 and 0.4. Cells were 
then placed into chilled 50ml Falcon tubes on ice for 10 minutes, and then spun at 2800rpm 
for 10 minutes at 4°C. The supernatant was decanted and the tube inverted to dry the pellet. 
The pellet was resuspended in 15ml ice cold lOOmM CaCl2 by vortexing and then left on ice 
for at least 30 minutes. The cells were respun, then carefully resuspended in 2.5ml lOOmM 
CaCl2. Competence was enhanced by leaving cells overnight at 4°C. Alternatively, cells 
were stored in 15% glycerol (v/v) at -70°C for up to 3 weeks.
h) Transformation of competent cells
IOjllI of ligation reaction was added to lOOjal of competent E. coli and then placed on 
ice for 30 minutes. Transformation efficiency was enhanced with a 90 second heatshock at 
42°C, followed by chilling bacteria on ice for a further 5 minutes. The bacteria were 
incubated with 1ml L-broth at 37°C for 1 hour. Cells were spun for 5 seconds at 13,000rpm. 
The supernatant was removed and the pellet resuspended in lOOpl L-broth. The resuspended 
cells were spread on L-agar/ ampicillin (lOOpg/ml) plates. The plates were inverted and 
incubated overnight at 37°C.
i) Small Scale Plasmid Preparations
Colonies were picked from L-agar/ ampicillin plates into 2ml L-broth and incubated at 
37°C for 6 hours. 1ml of this bacterial culture was decanted to a 1.5ml eppendorf tube and 
spun at 13,000rpm for 30 seconds, the supernatant removed and the tube inverted to dry the 
pellet. The pellet was resuspended by vortexing in lOOpl ice cold Solution I. 200jil freshly 
prepared Solution II was added, and mixed by inverting the tube several times. The tube was 
left on ice for 3 minutes. 150pl Solution III and 50|il phenol/chloroform were added and 
mixed in by gentle vortexing. The tubes were then spun at 13,000 rpm for 5 minutes. The 
aqueous phase was transferred to a fresh tube, and contaminating RNA removed by adding 
lp l RNase A (lOmg/ml) and incubating at 37°C for 30 minutes, followed by a 
phenol/chloroform extraction. Plasmid DNA was precipitated with 2 volumes 100% EtOH at 
-20°C for 15 minutes and recovered by centrifugation at 13,000rpm for 10 minutes. The 
supernatant was removed and the pellet washed with 500jll1 70% EtOH. The pellet was air 
dried and resuspended in 50|il H20 .
83
Chapter 2 Materials and Methods
j) Large Scale Plasmid Preparations
Large scale plasmid preparations were performed using the QIAGEN Plasmid Midi 
Kit. lOOpl of overnight bacterial culture was added to 50ml L-broth supplemented with 
lOOpg/ml ampicillin and incubated at 37°C overnight. This culture was spun at 3000rpm for 
10 minutes at 4°C. The supernatant was removed, and the pellet resuspended in 4ml buffer 
P I. 4ml buffer P2 was added and mixed gently by inverting the tube several times. 
Following a five minute incubation of the bacterial lysate at room temperature, 4ml buffer P3 
was added and mixed by inverting the tube. The bacterial lysate was then poured into a 
QIAfilter syringe and allowed to stand for 10 minutes. During this time a QIAGEN-tip 100 
was equilibrated with 4ml buffer QBT. The lysate was filtered through the QIAfilter syringe 
into the QIAGEN tip, and allowed to enter the tip resin by gravity flow. After all the lysate 
had passed through the QIAGEN tip, the tip was washed twice with 10ml wash buffer QC. 
The plasmid DNA was eluted from the resin with 5ml elution buffer QF, and precipitated 
with 0.7 volumes isopropanol. The precipitate was spun at 15,000rpm for 30 minutes at 
4°C. The supernatant was removed, the pellet washed with 70% EtOH, air-dried for 5 
minutes and resuspended in lOOpl HzO. DNA yield was determined by UV absorption.
k) Bacterial glycerol stocks
Glycerol was added to overnight bacterial cultures to a final concentration of 40%. 
Glycerol stocks were then snap-frozen in liquid nitrogen and stored at -70°C.
1) DNA sequencing
DNA sequencing was performed using the Sequenase version 2.0 DNA sequencing 
kit or the Sequenase PCR product sequencing kit (Amersham).
i) Template Preparation
Double stranded plasmid DNA was prepared using the QIAGEN Plasmid Midi Kit 
(see section 2.2.1.x). 5pg of plasmid DNA in 20jll1 H20  was denatured by adding 0.1 
volumes of 2M NaOH, 2mM EDTA and incubating for 15 minutes at 65°C. The mixture was 
neutralized by adding 0.1 volumes 3M sodium acetate and the DNA precipitated with 3 
volumes of ethanol (30 minutes at -70°C). The DNA was pelleted by spinning at 13,000rpm 
for 30 minutes. The DNA pellet was washed with 70% ethanol, dried under vacuum and 
resuspended in 7pi H20 .
PCR products were purified by adding lp l shrimp alkaline phosphatase (to remove 
unincorporated nucleotide triphosphates) and lp l exonuclease I (to remove primers) (both 
enzymes were supplied with the kit) to 5pl PCR reaction, and incubating for 15 minutes at 
37°C. The enzymes were then inactivated by incubating for 15 minutes at 80°C.
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Between 0.5-1.0 pmol of primer was used per sequencing reaction. 1 jllI primer and 
2pl 5X Sequenase buffer were added to 7|il template DNA, incubated for 10 minutes at 65°C 
and then cooled to room temperature.
ii) Sequencing Reactions
To each primed template in a volume of 10|Lil was added 2jll1 1:5 dilution of labelling 
mix, l |i l  0.1M dithiothreitol, 5jiCi [oc-35S]dATP (Dupont-NEN) and 2jll1 1:8 dilution 
Sequenase version 2.0 T7 DNA polymerase. The mixture was incubated at 20°C for 2 
minutes. 3.5pl of labelling reaction was added to each of four termination tubes containing 
2.5pl of one dideoxynucleotide (ddA, ddC, ddG or ddT) and incubated for a further 5 
minutes at 37°C. The termination reactions were ended by adding 4jil formamide stop 
solution. The completed reactions were incubated at 72°C for 2 minutes and then loaded onto 
a 6 % polyacrylamide sequencing gel. Following electrophoresis the gel was fixed in 10% 
methanol, 10% glacial acetic acid, then dried and exposed to autoradiography film.
2.2.2 RNA preparation
a) Preparation of nuclease-free water
Diethylpyrocarbonate (DEPC) (Sigma) was added to deionized water to a final 
concentration of 0.1%. Following incubation at 37°C for 30 minutes the DEPC treated water 
was autoclaved.
b) In vitro transcription
i) Template preparation
Plasmids containing templates to be transcribed were linearized with an appropriate 
restriction enzyme with a cleavage site at the 3 ’ end of the insert. 5pg of plasmid was 
incubated with 10 units of restriction enzyme for 3 hours at 37°C. Digests were then run 
against uncut plasmid on a 1% agarose gel to confirm cutting had occurred. The linearized 
plasmid band was excised from the gel and gene-cleaned.
Short RNAs (less than 80 bases) were generated from partially single-stranded 
oligodeoxyribonucleotide templates (Milligan et al, 1987). An oligonucleotide encoding the 
T7 phage promoter and the template was annealed to a second oligonucleotide complementary 
to only the promoter region. Both oligonucleotides were incubated together in water at a final 
concentration of 50pM at 95°C for 2 minutes, and then allowed to slowly cool to room 
temperature.
ii)Transcription reactions
Large scale transcription reactions were performed using Promega’s RiboMAX kit. 
Briefly, reactions were set up with 4|ll1 5X transcription buffer, 6 |il rNTP mix, 2 |il T7
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enzyme mix, l|LLg DNA template and nuclease free water to a final volume of 2 0 p l The 
reactions were incubated at 37°C for 3 hours, after which ljxl RQ1 RNAse free DNAse was 
added (supplied with kit), followed by a further 15 minute incubation at 37°C. RNA was 
extracted with TE-saturated phenol (pH 4.5) and precipitated with 0.1 volumes 3M 
ammonium acetate (supplied with kit) and 2.5 volumes EtOH at -70°C for at least 30 minutes. 
The precipitate was spun down at 13,000rpm at 4°C for 30 minutes, the pellet washed with 
70% EtOH, vacuum dried and resuspended in 50|il nuclease free water. RNA concentration 
was determined by measuring the OD260 of a 1:100 dilution of the purified RNA in nuclease 
free water, where 1 OD unit equals 40|ig/ml RNA.
High specific activity radiolabelled RNA was generated using Promega’s T7 RNA 
polymerase. 30|ll1 reactions were set up containing 6fil 5X transcription buffer, 1 .5jll1 each of 
lOmM rATP, rCTP, and rGTP (final concentration 0.5mM), 3|il lOOpM UTP (final 
concentration lOfiM), 5|il a 32P-UTP (Dupont-NEN) (final concentration 2. IjiM ), lfil 
recombinant RNAse inhibitor (Promega), l |i l  T7 RNA polymerase (Promega) and nuclease 
free water to final volume 30|il. Following incubation at 37°C for 1 hour, 0.5 volumes 90% 
w/v formamide gel loading buffer was added to the RNA, which was denatured at 95°C, 2 
minutes. The labelled RNA was run on a 10% acrylamide, 4M urea gel at 50mA for 1 hour 
in IX TBE buffer. The band corresponding to the labelled RNA was located by 
autoradiography and cut out. The RNA was eluted from the gel slice in acrylamide gel 
elution buffer overnight at room temperature. The elution buffer was removed, extracted 
with TE-saturated phenol (pH 4.5), and precipitated with 2.5 volumes EtOH at -70°C for at 
least 30 minutes. The RNA was then treated as for the large scale preparations as described 
above.
All RNA was stored in water at -70°C following purification.
2.2.3 In vitro ribozyme studies
a) RNA gel shifts
Labelled ribozyme RNA was incubated with an excess of unlabelled substrate RNA in 
IX  ribozyme hybridization buffer at 37°C in a volume of 20pl, with 20 units RNAsin 
(Promega). 2 |il aliquots were taken at time zero and subsequent points and quenched in 20|il 
stop solution. RNA complexes were analysed by polyacrylamide gel electrophoresis. The 
percentage of acrylamide and urea concentration in the gel varied depending on the extent of 
base pairing expected in the complex under study. Following electrophoresis, the dried gels 
were exposed to X-ray film (Kodak) for autoradiography, or alternatively to a 
phosphoroimager plate, and the resulting image analysed using the IMAGEQUANT package 
(Molecular Dynamics).
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b) In vitro ribozyme cleavage
Unlabelled ribozyme RNA and radioactively labelled substrate RNA were pre­
annealed by incubating at 95°C for 5 minutes, then cooling to 37°C in IX  ribozyme 
hybridization buffer. The cleavage reaction was started by adding MgCl2 to varying final 
concentrations in a final volume of 20pl. 2 |il aliquots were taken at time zero and subsequent 
points and quenched in 20jll1 stop solution. Cleavage products were separated by denaturing 
polyacrylamide gel electrophoresis. Following electrophoresis the dried gels were exposed to 
a phosphoroimager plate, and the resulting image analysed using the IMAGEQUANT 
package (Molecular Dynamics).
Cleavage reactions were also performed in which the ribozyme and substrate were not 
pre-annealed, although the remainder of the procedure was identical to that described above.
2.2.4 RNA ELISA
a) RNA endlabelling
RNA endlabelling was attempted using both T4 RNA ligase (Boehringer-Mannheim 
or New England Biolabs) and terminal deoxynucleotidyl transferase (TdT) (Promega).
T4 RNA ligase was used to ligate the BIO-1 biotinylated oligonucleotide (sequence 
dA18-BIO) to the 3’-end of Y98 RNA. Prior to ligation the BIO-1 oligonucleotide was 5 ’- 
phosphorylated with T4 polynucleotide kinase (New England Biolabs) and cold ATP, and 
the Y98 RNA was 5’-dephosphorylated using calf intestinal alkaline phosphatase 
(Boehringer-Mannheim). The ligation reactions were performed using IX  T4 RNA ligase 
buffer (50mM Tris-HCl, lOmM MgCl2, lOmM DTT, ImM ATP, pH 7.8). lOnM internally 
radiolabelled, alkaline phosphatase treated Y98 was incubated with varying concentrations of 
BIO-1 oligonucleotide and T4 RNA ligase at 37°C for 30 minutes. Ligation reactions were 
repeated using New England Biolabs RNA ligase with lOnM Y98 and ImM BIO-1 with 
varying concentrations of DMSO, in accordance with recommendations included in the 
protocol supplied with the enzyme.
RNA was 3 ’ endlabelled using TdT for the ELISA hybridization experiments with 
either biotin-11-ddUTP, digoxigenin-16-ddUTP or digoxigenin-16-UTP (Boehringer- 
Mannheim/ Enzo Diagnostics). 1 nmol RNA was end-labelled with either 1 nmole labelled 
ddUTP or 10 nmoles digoxigenin-16-UTP in a total reaction volume of 50|il containing IOjllI 
5X cacodylate buffer (Promega) and 10 units TdT. Reactions were incubated at 37°C for 60 
minutes, then at 70°C for 10 minutes to inactivate the enzyme. The labelled RNA was 
purified by precipitation with 0.1 volumes ammonium acetate, 20 |ig/ml glycogen 
(Boehringer-Mannheim) and 2.5 volumes EtOH (BDH) for at least 30 minutes at -70°C. The 
RNA was recovered as described in section 2.2.2.b.
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b) RNA-RNA hybridization ELISA
Components from Boehringer-Mannheim’s PCR-ELISA kit were used. RNA 3’ end- 
labelled with biotin-11-ddUTP was fixed to streptavidin wells in 200|il IX  ribozyme 
hybridization buffer or the hybridization buffer supplied with the kit at 4°C overnight. 
Unbound RNA was removed by washing five times with wash buffer. RNA 3’ end-labelled 
with digoxigenin-16-UTP was added to the wells in 200|il IX  ribozyme hybridization buffer, 
and incubated at 37°C for varying times. Unbound RNA was again removed by washing five 
times with wash buffer.
The signal was detected using a 1:100 dilution of anti-digoxigenin sheep Fab 
fragments conjugated with horseradish peroxidase. Following a 30 minute, 37°C incubation 
excess antibody was removed by washing five times with wash buffer. The ELISA was then 
either immediately developed using the chromogenic peroxidase substrate ABTS (2 ,2’- 
azinobis(3-ethylbenzthiazoline-6-sulfonic acid)), or probed again with a secondary antibody. 
Peroxidase-anti-peroxidase conjugate (Sigma) and donkey anti-sheep IgG-horseradish 
peroxidase conjugate (Sigma) were both investigated as potential secondary antibodies.
The ELISA was developed by adding 200|il ABTS per well, and incubating for 1 
hour at 37°C. The colour change was measured using a Titertek Multiwell plate scanner at 
405nm.
c) Ribozyme cleavage ELISA
Equimolar amounts of biotin-11-ddUTP 3’ end-labelled substrate and digoxigenin- 
16-UTP 3’ end-labelled ribozyme were incubated at 37°C for 3 hours in IX  ELISA 
hybridization buffer. The resulting complex was added to streptavidin coated wells, with 
20pmoles of complex in 200|il IX  ELISA hybridization buffer per well. The streptavidin 
coated wells were incubated overnight at 4°C to allow the ribozyme-substrate complex to bind 
to the well surface. Unbound ribozyme-substrate complex was removed from the wells by 
rinsing five times with wash buffer. IX ribozyme hybridization buffer supplemented with 
varying concentrations of MgCl2 was added to the wells, which were then incubated for 
varying periods of time. Cleavage products and unbound ribozyme was removed at the end 
of the incubations by rinsing five times with wash buffer. The ELISA was probed and 
developed as described in the previous section. The extent of cleavage was determined by 
comparing the reduction in the ABTS signal in wells where the ribozyme-substrate complex 
had been incubated in MgCl2 supplemented IX  ribozyme hybridization buffer with the ABTS 
signal in wells where no MgCl2 had been added.
2.2.5 In vitro translation
a) Rabbit reticulocyte lysate system
In vitro translation was performed using Promega’s TNT T7 coupled transcription- 
translation rabbit reticulocyte lysate system. Kit components were stored at -70°C, with the
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lysate being thawed rapidly by hand warming prior to use. Reactions in which proteins were 
either radiolabelled with 35S-methionine or left unlabelled were performed. For 
radiolabelling, 25|il TNT rabbit reticulocyte lysate was added to 2fxl TNT reaction buffer, l(il 
TNT T7 RNA polymerase, l |il ImM amino acid mixture minus methionine, 4jal 35S-L- 
methionine (Dupont-NEN), 40 units RNAse inhibitor (Promega), l|LLg DNA template and 
nuclease-free water to a final volume of 50|il. For unlabelled protein synthesis, the 35S-L- 
methionine was omitted from the reaction and replaced with lp.1 ImM complete amino acid 
mixture. Reactions were incubated at 30°C for 90 minutes. Alternatively, Promega’s 
TNTQUICK T7 coupled transcription-translation rabbit reticulocyte lysate systemwas used. 
To 20|il TNTQUICK lysate mix was added l |i l  35S-L-methionine (Dupont-NEN), 0.5jng 
template DNA and nuclease-free water and/ or ribozyme RNA to final volume 2 5 p l Lysates 
were analysed by acrylamide gel electrophoresis, western and northern blotting, 
immunoprecipitation and primer extension analysis.
b) Denaturing Gel Analysis of Translation Products
A 5jll1 aliquot of the translation reaction was added to 20fxl SDS sample buffer, and 
heated to 100°C for 2 minutes. IOjllI of the denatured sample was then loaded onto a 17.5% 
SDS-acrylamide gel.
17.5% separating gels were prepared using 1.12ml water, 4.38ml Protogel 30% 
stock acrylamide solution (National Diagnostics), 1.9ml separating gel buffer, 112|il 10% 
ammonium persulphate and 5\x\ TEMED (Biorad). 5% Stacking gels were prepared using 
1.0ml water, 444p,l stacking gel buffer, 300|il Protogel 30% stock acrylamide solution, 28|ll1 
ammonium persulphate and 5p.l TEMED. Electrophoresis was carried out at a constant 
current of 15mA in the stacking gel and 30mA in the separating gel. Gels were run in Tris- 
glycine buffer. Proteins were visualized either by autoradiography or by western blotting. 
Prior to autoradiography gels were fixed by soaking in 10% glacial acetic acid, 10% 
methanol, for 30 minutes. Fixed gels were soaked in Enhance (National Diagnostics) for 30 
minutes, then washed in water for 30 minutes. Gels were then vacuum dried and exposed 
for autoradiography.
c) Western blotting
Acrylamide gels were blotted onto Hybond-N nylon membrane (Amersham) using a 
Biorad Electroblotter running at 250mA for 3 hours in Towbin buffer. Icepacks were used to 
prevent the apparatus overheating. Following blotting, the membrane was blocked by 
incubating in 3% gelatin (Biorad) in TBS buffer overnight at 37°C. The blocked membrane 
was washed twice for five minutes in TTBS, and then incubated for 3 hours at room 
temperature with neat rabbit anti-HBc polyclonal antibody (Zymed). Following two 10 
minute washes in TTBS the membrane was incubated for 2 hours at room temperature with
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the secondary antibody, mouse anti-rabbit IgG-horseradish peroxidase conjugate (Dako). 
This secondary antibody was used at a 1:1000 dilution in 1% gelatin, TTBS. After four final 
washes of 15 minutes each in TTBS the blot was developed using ECL chemiluminescent 
peroxidase substrate (Amersham). The substrate was prepared by mixing 1ml of both 
solutions provided, and then placing this mixture directly onto the membrane. Following a 1 
minute incubation at room temperature the membrane was exposed to photographic film for 
15 seconds.
d) Firefly luciferase reporter assay
50|il room temperature luciferase assay reagent was dispensed into the required 
number of luminometer tubes. The luminometer was pre-programmed to perform a two 
second pre-measurement delay followed by a ten second measurement period. 2.5pl of 
rabbit reticulocyte lysate reaction was transferred to a luminometer tube containing assay 
reagent. The tube was mixed briefly, and placed in the luminometer to initiate a reading.
e) Northern blotting
Samples were run on 2% agarose gels. 3g agarose was boiled in 127.5ml water, and 
then allowed to cool for 10 minutes. 15ml 10X MOPS buffer, and 7.5ml 37% formaldehyde 
(Fluka) was added and the gel was cast. RNA samples were added to RNA gel loading 
buffer in the ratio 5 volumes RNA to 11 volumes buffer and heated to 95°C for 2 minutes 
prior to loading on the gel. Gels were run in IX  MOPS buffer at 40mA for 3 hours. 
Duplicate samples were loaded on each half of the gel.
Following electrophoresis the gel was washed twice for 10 minutes in DEPC treated 
water. The gel was then cut in half, with one half of the gel being used for blotting and the 
other half being stained with ethidium bromide. For ethidium bromide staining the gel was 
soaked in DEPC treated water containg 1 jig/ml ethidium bromide for 15 minutes. The gel 
was then rinsed and destained for 10 minutes in DEPC treated water. Bands were then 
visualized by ultra-violet transillumination.
The other half of the gel was capillary blotted overnight using 10X SSC onto 
Hybond-N nylon membrane (Amersham), which was presoaked with 10X SSC. On 
completion of blotting the membrane was rinsed in 2X SSC, air dried and then baked at 80°C 
for 2 hours. The baked membrane was blocked by incubation at 42°C for 3 hours in 50ml 
hybridization buffer. Following blocking the denatured probe was added directly to the 
hybridization buffer. Probes were prepared either by nick translating PCR products or by 
end-labelling synthetic oligonucleotides. The probe was allowed to hybridize to the blot 
overnight at 42°C.
Following hybridization, the probe was poured off, and the membrane washed for 30 
minutes in 300ml 2X SSC at room temperature, then for one hour at 65°C in 2X SSC + 1%
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SDS, and finally for 10 minutes at room temperature in 0.1X SSC. The membrane was 
wrapped in cling film and exposed for autoradiography at -70°C with an intensifying screen.
If the blot required reprobing, it was stripped of the original probe by placing the 
membrane in boiling 0.1% SDS and allowing to return slowly to room temperature. The 
stripped blot was then blocked and probed as before.
f) Immunoprecipitation
25pl of rabbit reticulocyte lysate in vitro translation reaction was diluted with H20  to 
give a final volume of 200pl. To this was added 25jll1 5M LiCl and 25pl protein-A sepharose 
beads (Sigma). The tubes were incubated whilst spinning end-over-end at 4°C for 2 hours. 
This incubation cleared any proteins from the lysate which bound non-specifically to the 
beads. The tubes were spun at 13,000rpm for 1 minute, and the supernatant removed to a 
fresh tube. 5pl of rabbit anti-HBcAg polyclonal antiserum (Dako) was added to the 
supernatant. The tubes were incubated whilst spinning end-over-end at 4°C for 3 hours. 
25pl of protein-A sepharose beads were added to each sample, which were then incubated at 
4°C for a further 1 hour. The tubes were spun briefly to pellet the protein-A sepharose 
beads. The pellet was resuspended in 500pl wash buffer (0.5M LiCl, 0.1M Tris-HCl, pH 
8.0), then repelleted. This washing procedure was repeated three times. The final pellet was 
resuspended in 30pl gel-loading buffer. The sample was boiled for 2 minutes, then loaded 
onto a SDS-polyacrylamide gel. The resulting gel was visualized by autoradiography.
g) Primer extension analysis
Primer extension analysis was used to detect ribozyme cleavage products in RNA 
extracted from rabbit reticulocyte lysate coupled transcription-translation reactions. 
Promega’s MMLV-RT H‘ primer extension system was used. RNA was extracted with TE- 
saturated phenol (pH 4.5) and precipitated with 0.1 volumes 3M ammonium acetate and 2.5 
volumes EtOH at -70°C for at least 30 minutes. The precipitate was spun down at 
13,000rpm at 4°C for 30 minutes, the pellet washed with 70% EtOH, vacuum dried and 
resuspended in 25|il nuclease free water.
A primer was chosen from laboratory stocks which bound at the 3’-end of the core 
ORF (primer C2, sequence GAGATTTCTCAAGGGATACTAACATTCA). The primer was 
5’ endlabelled as described (section 2.2.5.viii). lOOfmol ( lp l)  of labelled primer was added 
to 5pl MMLV-RT 2X buffer and 5pl RNA sample. The RNA and primer were annealled by 
heating the tubes at 95°C for 2 minutes, then allowing them to cool to room temperature. A 
master reverse transcriptase (RT) mix was prepared, containing 5pl MMLV-RT 2X buffer, 2 
units MMLV-RT H' and nuclease-free water to a final volume of 9pi per reaction. 9pi of the 
RT mix was immediately added to each reaction tube containing annealed primer and RNA. 
Reactions were incubated at 42°C for 30 minutes. 20pl formamide gel loading buffer was
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added to each tube. 20|il of each sample was loaded on a 10% denaturing polyacrylamide gel 
and run in IX TBE buffer.
h) Nick translation
0.5jig of the double-stranded DNA to be labelled was mixed with 2.5jll1 10X nick- 
translation buffer, 20nmoles each of unlabelled dATP, dTTP and dGTP, 16pmoles [ a 32P]- 
dCTP (Dupont-NEN) and water to 21.5pi. The reaction mixture was chilled to 0°C. 2.5jll1 
of DNase I (lOng/ml) (Boehringer-Mannheim) and 2.5 units DNA polymerase I were added. 
The reaction was incubated at 16°C for 60 minutes, after which it was stopped by adding ljil 
0.5M EDTA (pH 8.0). Labelled DNA was separated from unincorporated nucleotides by 
ethanol precipitation.
i) End-labelling nucleic acids
Prior to labelling, it is necessary to remove the 5 ’> phosphate group from RNA with 
calf intestinal alkaline phosphatase (CLAP) (Boehringer Mannheim). The RNA to be labelled 
was incubated in IX  CLAP reaction buffer with 2 units CIAP for 1 hour at 37°C. The 
reaction was stopped by adding 2mM EDTA. The'RNA was recovered by extraction with 
TE-saturated phenol (pH 4.5) and ethanol precipitation.
Synthetic oligonucleotides (synthesized without a 5 ’ phosphate group) or CLAP- 
treated RNA was mixed with 3|iT 1 OX kinase bu ffer,'5jil [y32P]-ATP (Dupont-NEN), 10 
units T4 polynucleotide kinase and water to 50jil and incubated at 37°C for 60 minutes. 
Labelled DNA or RNA was purified by phenol-chloroform extraction and ethanol 
precipitation.
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The aim of this study was to investigate the effects of substrate secondary structure 
on hammerhead ribozyme activity and how this could influence the design of anti-HBV 
ribozymes. The study can be divided into three sections: I) measuring ribozyme-substrate 
hybridisation rates, II) determining ribozyme cleavage rates under single-turnover conditions 
and III) assessing the ability of ribozymes to block protein synthesis in an in vitro translation 
system. However, before this work could begin, ribozyme target sites in the HBV RNAs 
had to be determined, and constructs made for the expression of the ribozyme and substrate 
RNAs in vitro.
3.1 DOES SUBSTRATE SECONDARY STRUCTURE AFFECT 
RIBOZYME-SUBSTRATE HYBRIDISATION RATES?
3.1.1 Choice of target site
As described in section 1.3.3, the entire HBV genome encodes RNA. Therefore any 
NUX triplet within the genome could theoretically be targeted with a hammerhead ribozyme 
resulting in the destruction of an RNA. It was decided to target the pre-core/ core open 
reading frame (ORF). HBcAg is translated from the pgRNA (Yaginuma et al., 1987). 
Cleavage within this region will not only destroy the pgRNA, a vital intermediate in genome 
replication, but will also block HBcAg production, which is important for capsid formation 
and minus-strand DNA synthesis. Figure 3.1 shows the sequence of the core region, with 
hammerhead ribozyme NUX target sites indicated (note that the NUX triplets do not have to 
be in frame with the HBcAg sequence). The pre-core/ core ORF has been targeted by 
hammerhead ribozymes in a previous study, von Weizsacker et al., (1993) demonstrated 
that a set of three ribozymes could cleave core mRNA either singly, or if all three ribozymes 
were in the same transcript. It was decided to use two of the three ribozymes from this study 
in our system as controls, cleaving after bases 220 (designated ribozyme RZ1) and 238 
(designated ribozyme RZ2) in the pre-core/ core ORF. The third ribozyme could not be used 
as its target site was mutated away from an NUX consensus triplet in the core sequence used 
as a transcription template in the current study.
It was important for the purposes of this study to know the secondary structure of the 
ribozyme substrate. The MFOLD computer program was used to determine the optimum 
and sub-optimum secondary structures of the HBcAg mRNA sequence 5D (figure 3.2). 
This program utilises the minimum energy algorithm developed by Jaeger et a l ,  (1989) to 
predict the most stable conformations assumed by an inputted RNA sequence. There was 
some variation between the optimum and sub-optimum structures, though one stem loop was 
conserved between all the structures generated. This lay between residues 525 and 585
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mu i i i in  u ii
1 ATGCAACTTT TTCACCTCTG CCTAATCATC TCTTGTTCAT GTCCTACTGT
'A a AGCCTC^: AAGCTGTGCC T^GGGTGGCT T^GGGGCATG GACATTGACC 
CTT^TAAAGA A'TtIt GGAGCT J c TGTGGAG'T t J c TCTC^TT T^T^GCCTTC^T
u 11 u  i n i l  i i i
GACTTCTTTC CTTCAGTACG AGATCTTCTA GATACCGCCG CAGCTCTGTA
i  u  11 1 11 1 1TCGGGAAGCC TTAGAGTCTC CTGAGCATTG TTCACCTCAC CATACTGCAC
i  UU 1 1 1 4TCAGGCAAGC AATTCTTTGC TGGGGGGAAC TAATGACTCT AGCTACCTGG
H U  1 1 1  1 4 I U
TA ATTTGGAAGA TCCAGCATCT AGAGACCTAG TAGTCAGTTA3 0 1  GTGGGTGT1 11 1 11 11 U1
3 5 1  TGTCAACACT AATATGGGCC TAAAGTTCAG GCAACTCTTG TGGTTTCACAn 111 1 1 1 HI 1 1 1 1 1
4 0 1  TTTCTTGTCT CACTTTTGGA AGAGAAACAG TTATAGAGTA TTTGGTGTCTui u 11 1 1
4 5 1  TTCGGAGTGT GGATTCGCAC TCCTMCAGCT TATAGACCAC CAAATGCCCC
H i  11 1 1 u
ATCCTATCA ACACTTCCGG AGACTACTGT TGTTAG5 0 1  T ACGA CGAGGCAGGT
5 5 1  CCCCTAGAAG AAGAACTCCC TCGCCTCGCA GACGAAGGTC^TCAATCGCCG1 1 1 1 1 1 1
6 0 1  CGTCGCAGAA GATCTCAATC TCGGGAATCT CAATGTTAG
Figure 3.1. Sequence of the 639 base pre-core/core open reading frame, Italian isolate 5Dr 
All 143 potential hammerhead ribozyme cleavage sites are indicated by arrows (NTX 
consensus). Base number 1 in this sequence corresponds to base 1814 in the HBV 
genome (numbered from the unique EcoRI restriction site in pre-S2). This sequence w as  
kindly provided by E. Dornan, Institute of Virology.
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RZ556
\
RZ551
   ^ GG CCUe GCCUCG C
A
I
A
A wG A A '
RZ568 RZ572
A -U
RZ534
UCA 5’
Figure 3.3. Detail of bases 526 to 585 from the pre-core/ core ORF. The predicted 
structure shown here was generated using the MFOLD computer program using just the 
sequence between bases 526 and 585 as the input sequence. Cleavage sites are 
indicated by arrows, with the target triplets highlighted in bold type. The ribozymes are 
named for the base after which they are designed to cleave.
RZ534
g a c a a c a a  c u g c u g c u
RZ551
u c c g u c c a  g g g a u c u u
RZ556
c c a g g g g a  c u u c u u c u
RZ568
c u u c u u g a  g g a g c g g a
RZ572
u u g a g g g a  c g g a g c g u
HBcAg mRNA seq u en ce
a c u g u u g u u a g a c g a c g a g g c a g g u c c c c u a g a a g a a g a a c u c c c u c g c c u c g c a g a c g u  
* *
526 585
Figure 3.4. The sequence of HBcAg mRNA between bases 526 and 585, corresponding 
to the stem loop shown in figure 3.3, and the flanking sequences of ribozymes RZ534, 551, 
556, 568 and 572. The ribozyme sequences are aligned with their complementary target 
sequences in the HBcAg mRNA. For clarity the conserved catalytic cores have been  
omitted. The sequence between bases 526 and 585 of 5D RNA corresponds to the 
sequence of the truncated ribozyme substrate, RZSUB.
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(figure 3.3). Five NUX triplets within this region were identified, and hammerhead 
ribozymes were designed to be targeted against them. Each ribozyme had a total of 16 bases 
in the flanking sequences, with 8 bases in each flank (figure 3.4). In addition to these 
ribozymes a positive control ribozyme, RZ60, and substrate, Y98, were obtained from Dr. 
G. Sczakiel, Heidelberg (figure 3.5).
3.1.2 Ribozyme-substrate hybridisation (I)
3.1.2a Construction of ribozymes
It was initially decided to produce ribozyme constructs by PCR (figure 3.6). The 
primers used for this are shown in table 2.1. The pRK5 mammalian expression plasmid 
was used as the substrate, allowing the SV40 polyadenylation signal to be incorporated into 
the PCR product. At this stage of the project it was hoped that the ribozyme constructs 
could have been used in cell culture experiments. It was decided to incorporate the poly­
adenylation signal into the ribozyme construct to limit the amount of exogenous vector 
sequence in the transcripts generated from the expression of the cloned PCR product.
EcoRI site Ribozyme core
RZ primer (5’)
CP1 primer (3’)
i
Flanking
sequence
HinD\\\ site
i
Flanking
sequence
RZ primer
pRK5 plasmid template
SV40 polyA
* * \ r
CP1 primer
Figure 3.6. Generation of ribozyme expression cassettes by PCR. The primers used are 
described in detail in table 2.1. The 5'-RZ primer contains the complete ribozyme sequence 
plus an EcoRI restriction site. The 3'-CP1 primer contains a H/nDIII restriction site. 
Incorporation of these restriction sites at the 5' and 3' ends of the PCR product allowed it to 
be cloned into the pGEM-3z plasmid. The resulting construct contains a complete 
hammerhead ribozyme domain at the 5' end and the SV40 polyadenylation signal at the 3’ 
end. The total length is 450 bases.
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The PCR product was cloned into the bacterial plasmid pGEM-3z. This plasmid has 
two bacteriophage promoters, T7 and SP6. The promoters were situated at opposite ends of 
the poly linker, with both promoters aligned to initiate transcription through the polylinker 
region. The ribozyme construct was under the control of the T7 promoter. Linearizing the 
plasmid at the H indlll site enabled run-off transcripts of the ribozyme-polyadenylation signal 
construct to be generated (figure 3.7).
+ve control 
Size (DNA (mouse RZ1 RZ2
bases) [3-actin)
2072 
1500 
600
100
Figure 3.7. Run-off in vitro transcripts obtained from PCR cassettes cloned into pGEM-3z 
plasmid. Transcripts were generated using T7 bacteriophage RNA polymerase. The 
resulting RNA was acid phenol/ chloroform extracted, ethanol precipitated and pelleted. 
The pellet was resuspended in 50pl H20 . 5pl of the dissolved RNA was added to 5pl 
agarose gel loading buffer. The resulting sample was run on a 1% agarose gel in 1X TBE 
buffer.
3.1.2b Gel sh ift assays
The interaction between ribozyme and substrate was studied by gel shift assay. 
Initially RZ1 and RZ2, constructs based on von Weizsacker’s study, were used. Both 
ribozyme and substrate were generated by in vitro transcription, with the ribozyme being 
internally labelled with a - 32P-UTP. The ribozyme and substrate were incubated together at 
37°C, with aliquots being taken at various time-points and placed in gel loading buffer. The 
gel loading buffer contained urea in order to remove any intramolecular structure from the 
ribozyme-substrate complex, whilst maintaining base-pairing between the ribozyme and 
substrate. This is to prevent the occurrence of any structural isoforms which could migrate 
different distances to give multiple bands, making analysis of the gel difficult. Therefore the 
concentration of the urea is critical. Too little and the final gel will have multiple bands, 
making it difficult to distinguish the ribozyme-substrate complex and the unbound ribozyme. 
Too much and the ribozyme-substrate complex will be broken apart. Concentrations of 1M 
urea or less should not denature RNA duplexes of 8 base-pairs in length (G. Sczakiel, 
personal communication).
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complex could be observed (figure 3.9). Using both gel loading buffer and acrylamide gels 
containing no urea did not change this result.
[Y98]=250nM [Y98]=500nM
RZ60
Time
(minutes)
Figure 3.8. Gel shift performed with radiolabelled RZ60 positive control ribozyme and an 
e x ce ss  of unlabelled Y98 positive control substrate. Both RNAs were incubated together 
in IX ribozyme hybridisation buffer at 37°C. Aliquots were taken at the times indicated and 
placed in gel loading buffer containing 1,0M urea. Samples were run on an 8% acrylamide, 
1 OM urea gel. Ribozyme-substrate complex (C) and unbound ribozyme (R) are indicated.
[5D]=0.5nM [5D]=1.5pM [5D]=0.5|laM [5D]=1 ,5hM
RZ1 RZ1
only 0 ’ 10’ 2 0 ’ 0 ’ 10’ 2 0 ’ only 0’ 10’ 20 ’ 0 ’ 10’
~ f  ~ r — H
0.5M urea 
gel loading buffer
1.0M urea 
gel loading buffer
Time
(minutes)
Figure 3.9. Gel shift performed with radiolabelled RZ1-SV40 polyadenylation signal and 
an ex cess  of unlabelled 5D RNA substrate (at a concentration of 0.5pM or 1.5pM). Both 
RNAs were incubated together in 1X ribozyme hybridisation buffer at 37°C. Aliquots were 
taken at the times indicated and placed in gel loading buffer containing either 0.5M or 1.0M 
urea as indicated. Samples were run in a 1 % agarose gel at 4°C. Even though this is the 
gentlest method for separating RNA species, no ribozyme-substrate complex is observed.
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It was considered that the extra sequence in the ribozyme construct derived from the 
SV40 polyadenylation signal may have been obscuring the ribozyme flanking sequences. 
The MFOLD program was used to generate predictions for the secondary structure of the 
RZ1-SV40 polyadenylation signal RNA (figure 3.10). Only a single predicted structure was 
generated, which showed that the ribozyme domain was trapped within a double-stranded 
region of the RNA.
90200
Figure 3.10. Prediction of RZ1-SV40 polyadenylation signal RNA secondary structure, 
generated by MFOLD program. The ribozyme domain lies between bases 1 and 40, 
which forms part of an almost entirely double-stranded region of the RNA. For clarity only 
bases 1 to 271 are shown. The transcript’s full length is 450 bases.
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Nucleic acid secondary structure which inhibits the binding of two complementary 
nucleic acid molecules can be removed by heating the nucleic acids to 95°C, which melts the 
secondary structure, and then snap-cooling the nucleic acids on ice. This snap-cooling step 
brings the nucleic acids back down to a temperature at which intermolecular hybridisation 
can occur before intramolecular secondary structure can form. Although it can be seen from 
figure 3.2 that the 5D RNA has long stretches of intramolecular helices, formation of these 
regions of extended secondary structure is slower than the formation of short helices, such 
as those formed between ribozyme and substrate. Therefore, denaturation followed by snap- 
cooling provides a window in which ribozyme-substrate hybridisation, if such a thing is 
possible, can occur.
A truncated version of RZ1 was produced, lacking the SV40 polyadenylation signal, 
by linearizing the RZ1-SV40 polyadenylation signal plasmid with a restriction enzyme 
cutting just after the ribozyme domain. This was then used as a template for radiolabelled in 
vitro transcription (figure 3.11). This truncated RZ1 was used in a denaturation-snap- 
cooling experiment. Figure 3.12 shows that this process allowed the formation of a complex 
between the positive controls RZ60 and Y98, but not between RZ1 (truncated) and 5D.
T7 p romoter BamH I
Ribozyme SV40 polyadenylation signal
domain
Figure 3.11. Generation of truncated RZ1. The RZ1-SV40 polyadenylation signal 
cassette contains a BamH\ site immediately after the ribozyme domain. The plasmid w as 
linearized at this BamH\ site and used as a template for run-off in vitro transcription, 
producing a 40-mer RNA.
3.1.2c Discussion
These initial results were a cause for concern. Although sequencing of the cloned 
PCR product showed that the complete ribozyme sequence was present, the RZ1 RNA did 
not appear to be binding to its complementary sequence in the substrate. Why should this 
be? The first possibility to consider is that the conditions in which the gel shift assay 
samples are analysed are too harsh. Whilst the RZ60-Y98 complex can withstand 0.5M 
urea, this is not a fair comparison with RZ1-5D. The RZ60-Y98 complex contains a total of 
60 intermolecular base-pairs compared to 16 in the predicted RZ1-5D complex. However, in 
other people’s experience: RNA duplexes of at least 8 base-pairs should be able to withstand 
0.5M urea (G. Sczakiel, personal communication). Both acrylamide and agarose gels were
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A B C D E F
RZ60-Y98
complex
Unbound
RZ60
Figure 3.12. Formation of ribozyme-substrate complexes after denaturation at 95°C 
followed by snap-cooling on ice in 1X ribozyme hybridisation buffer. Key to lanes: (A) 
RZ60 only; (B) RZ60 + Y98, 95°C 2’, snap-cooling; (C) RZ60 + Y98, 95°C 2’, slow cooling 
to room temperature; (D) RZ1 (truncated) only; (E) RZ1 (truncated) + 5D, 95°C 2’, snap- 
cooling; (F) RZ1 (truncated), 95°C 2’, slow cooling to room temperature. Despite 
degradation of the radiolabelled RNA by RNases (resulting in the smearing of the bands on 
the gel), RZ60-Y98 complex can be observed in lanes B and C.
used to try to separate RZ1-5D complex from unbound RZ1, though this made no 
difference.
Another possibility lies within the sequence of the constructs used. Secondary 
structure in the ribozyme and/or substrate RNAs could block hybridisation between the two 
RNAs. Although the secondary structure predictions do suggest this to be the case (figure 
3.10), the denaturation-snap-cooling experiment utilising the truncated RZ1 RNA does not 
support this hypothesis (figure 3.12). von Weizsacker et al. did not use the entire pre­
core/core ORF as a transcription template. It is possible that their RNA substrate had a very 
different secondary structure from the 5D RNA used in the current study. However, the 
region containing the cleavage sites for RZ1 and RZ2 does not appear to interact with any 
sequence from distant parts of the 5D RNA which were omitted from von W eizsacker’s 
substrate (figure 3.2).
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3.1.3 Ribozyme-substrate hybridisation (II)
It was decided to abandon trying to duplicate von Weizsacker’s work, and to focus 
on targeting ribozymes against the stem loop between bases 525 and 585 of the 5D RNA. 
This region has been shown to be accessible to large antisense molecules, thanks to the large 
loop between bases 550 and 570 (Patzel et a l., 1997), but is the same region accessible to 
small hammerhead ribozymes with total flanking regions of 16 bases?
3.1.3a Construction of ribozymes
For this work it was decided to use, in addition to the full length 5D RNA substrate 
(length 639 bases), a shorter substrate, 60 bases in length, corresponding to the region 
between bases 526 and 585 of 5D RNA (RZSUB, figure 3.3). Ribozymes would also be 
produced with the minimum of exogenous sequence. These ribozyme transcripts would 
have a total length of 40 bases.
When producing short RNAs by in vitro transcription, the rate limiting step is the 
association of the RNA polymerase with the promoter. To get adequate yields of RNA from 
the transcription reaction it is necessary to use a high concentration of DNA template. The 
amount of DNA which can be added to a transcription reaction cannot be so high that the 
reaction buffer becomes saturated with DNA. If the transcription template is contained 
within a plasmid, then most of the DNA will be non-coding vector sequence. Therefore it is 
better to limit the amount of non-coding sequence to increase the concentration of promoters 
in the reaction. It was decided to use partially double-stranded oligonucleotides as 
transcription templates (figure 3.13). This method allowed the generation of large amounts 
of small RNA (figure 3.14).
3.1.3b Gel shift assays
Initial experiments were discouraging. No binding was observed between labelled 
ribozymes and unlabelled 5D RNA, or between unlabelled ribozymes and labelled RZSUB. 
When RZSUB was examined by non-denaturing PAGE, two bands were visible. When 
RZSUB was incubated with an excess of ribozyme at 95°C for two minutes and then cooled 
rapidly to 37°C, a band was visible between the two RZSUB bands (figure 3.15). It was 
assumed that this band was the ribozyme^RZSUB complex, but what was the slow- 
migrating RZSUB band which lay above this proposed complex on the gel? There are two 
possible explanations. The first is that RZSUB preferentially formed homodimers during 
renaturation rather than binding ribozyme. Unfortunately no molecular weight markers were 
available to confirm whether the top RZSUB band had a molecular mass twice that of the 
lower band. When separating small RNAs by non-denaturing PAGE, the structures of the 
RNAs play a significant part in determining migration distance, making it impossible to make 
accurate estimation of molecular mass. The second possibility is contamination from DNA 
template left over from the transcription reaction, though RNA produced by in vitro
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Figure 3.14. (a) Run-off transcripts generated from partially single-stranded in vitro 
transcription templates. RNA from a 20pJ transcription reaction w as treated with 10 units 
DNase I for 15 minutes at 37°C. Following add phenol/ chloroform extraction the RNA w as 
ethanol precipitated and pelleted. The resulting pellet was resuspended in 50pJ H20 . 5pJ 
w as removed from each transcription reaction, added to 5pl agarose gel-loading buffer, and 
run on a 1% agarose gel in 1X TBE, which allows the bands to be visualised, but cannot 
resolve the small differences in length of such short RNAs. (b) Treatment of RZSUB 
partially single-stranded DNA transcription template and RZSUB with DNase I or RNase A. 
DNA or RNA w as incubated for 1 hour at 37°C in 1X transcription buffer with either 10 units 
DNase 1,10 units RNase A, or no addition. Reactions were then run on a 1% agarose gel 
in 1X TBE. It can be seen that whilst RNase A clearly degrades RZSUB RNA and DNase 
I degrades RZSUB DNA, treatment of RZSUB RNA with DNase I causes a reduction in 
band intensity. This could be due to contaminating RNase in the DNase I preparation, or 
some RZSUB DNA transcription template remaining after the initial DNase/ add phenol 
treatment immediately after transcription.
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RZ534 RZ551 RZ568 RZ572 RZSUB
only
a b  c a b c a b  c a b c
Figure 3.15. Initial gel-shift experiments performed with radiolabelled RZSUB and an 
excess of unlabelled RZ534, RZ551, RZ568 or RZ572. Unlabelled ribozymes were added 
in either (a) 100, (b) 300 or (c) 500-fold ex cess  over radiolabelied RZSUB. Reactions were 
incubated at 95°C for 2 minutes, then rapidly cooled to 37°C in 1X ribozyme hybridisation 
buffer. Reactions were incubated at 37°C for 30 minutes before being added to 0.5M urea 
gel-loading buffer. Samples were run on an 8% non-denaturing polyacrylamide gel in 1X 
TBE. Two bands (labelled I and III) are visible when RZSUB is incubated alone (far right- 
hand-side). However, when an ex cess  of ribozyme is added to the reaction, an 
intermediate band, labelled II, is seen.
transcription was treated with DNase and acid-phenol extracted (which should remove all 
DNA). 2 units DNase was added to gel-shift reactions. Analysis of these reactions showed 
a single RZSUB band, and formation over time of ribozyme-RZSUB complex. Addition of 
DNase also permitted the formation of complexes between labelled ribozymes and unlabelled 
5D RNA.
Whilst this work was proceeding, it was considered that perhaps the flanking 
sequences of the ribozymes (totalling 16 bases) were too short to allow rapid binding to the 
substrate. A new ribozyme, RZ572B, was designed, with total flanking sequences of 59
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bases (13 bases in the 5 ’ flank, 46 bases in the 3 ’ flank) (figure 3.16). This ribozyme was 
designed to bind to the entire length of RZSUB, and cleave RZSUB after base 572. 
Preliminary gel-shift experiments using dilution series of unlabelled RZSUB with 
radiolabelled RZ572B showed ribozyme-substrate complex formation at 37°C after 2 hours 
incubation (figure 3.17).
RZ572B seq u en ce
u g a c a a c a a u c u g c u g c u c c g u c c a g g g g a u c u u c u u c u u g a g g g a  c g g a g c g u c u g c a
5D RNA seq u en ce I
a c u g u u g u u a g a c g a c g a g g c a g g u c c c c u a g a a g a a g a a c u c c c u c g c c u c g c a g a c g u  
•  •
526 585
Figure 3.16. RZ572B flanking sequences lined up with their complementary sequences 
in 5D RNA. The region of 5D RNA shown corresponds to the whole sequence of RZSUB. 
For clarity the catalytic domain of RZ572B has been omitted. The cleavage point is 
indicated by an arrow.
[RZSUB], pM
o o a p o
—*■ CD r e _L o o
-s i a : CO -si 00 -p> r o 00 o
CO CO CJI CJI 00 -p* r o __L 00
Figure 3.17. Gel-shift experiment with radiolabelled RZ572B and an excess of unlabelled 
RZSUB (concentrations indicated), incubated for 2 hours in 1X ribozyme hybridisation 
buffer. Reactions were stopped in 0.5M urea gel-loading buffer. Samples were run on an 
8% non-denaturing polyacrylamide gel in 1X TBE. Ribozyme-substrate complex (C) and 
unbound radiolabelled ribozyme (R) are indicated.
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Gel-shifts were analysed by scanning the dried gels with a phosphorimager. The 
bands to be measured were boxed using the IMAGEQUANT package (see figures 3.18 and 
3.22). The boxes for all bands plus the background were all of the same size. The band 
intensity was determined as the volume of the box, the volume being defined as the sum of 
the signal intensities of each pixel within the box. Band intensities quantified in this way 
were used to determine the rate of formation of ribozyme-substrate complex. The amount of 
ribozyme-substrate complex was determined as a percentage of the total labelled RNA:
(ribozyme-substrate complex)
% binding = ------------------------------------------------------------------ X 100 (i)
(ribozyme-substrate complex) + (labelled RNA)
Percentage binding was plotted against time, and a best-fit linear curve was determined. 
This curve was used to calculate the t '/2 for the ribozyme-substrate hybridisation reaction.
The binding of two molecules is a second-order reaction, with the initial rate of 
complex formation being dependent on the concentrations of both molecules. The initial rate 
can be represented by:
Vj = k2 X [Ribozyme] X [Substrate] (ii)
where k2 is the second-order binding rate constant. In the gel-shift experiments in the 
current study, the unlabelled RNA is always in excess of the radiolabelled RNA. Therefore 
the concentration of the unlabelled RNA effectively does not change during the course of the 
experiment. This gives the binding reaction pseudo-first-order kinetics (hence the linear 
best-fit on the graphs) (Tomizawa & Som, 1984, Persson et a l., 1990). The best-fit curve 
was used to determine the pseudo-first-order rate constant, k ’,:
ln2
k’l = -----  (iii)
11/2
The constant k \  is related to the second-order rate constant, k2, as follows:
k2 = —  (iv)
[S]
where S is the unlabelled component in excess. Therefore only the concentration of the 
component in excess needs to be known, as k2 is independent of the molar ratio between the 
labelled and unlabelled components of the reaction. The rate constant k2 is an indication of 
the affinity the two molecules have for each other. The higher the value of k 2, the stronger 
the binding.
Results of gel-shifts performed with both RZSUB and 5D RNA substrates are 
shown in figures 3.18 to 3.27. In both groups of experiments, the ribozymes were 
radiolabelled, whilst RZSUB and 5D RNA were unlabelled. The results from all these 
experiments are summarised in table 3.1. In all cases experiments were repeated in triplicate; 
the data plotted on the graphs are the means of these experiments, with error bars showing
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the standard deviations. In some cases the experiments were repeated at different 
concentrations of the unlabelled RNA.
As the gel-shift reactions were subject to pseudo-first order kinetics, it was expected 
that the data plotted would lie approximately on a straight line. However, in many cases the 
data appeared to follow an exponential curve. This suggests that in certain cases there are 
two phases to ribozyme-substrate association; an initial burst of rapid hybridisation followed 
by a period of slower hybridisation. In these cases, linear best-fits were made for just the 
initial phase of hybridisation.
RIBOZYME % GC RZSUB 5D RNA
RZ534 50 - (9.8±3.2) X 10V M '1
RZ551 56.3 1 7 s1 M‘1 (10±4) X103s'1M‘1
RZ556 50 (4.1±1.4)s‘1M‘1 (8.2±1.8) X103 s'1M‘1
RZ568 50 - 0.72 X103 s'1M'1
RZ572 62.5 3.3s'1M'1 1.6 X103s*1M'1
RZ572B - (24±9)s'1M'1 0.76X103 s'1M'1
Table 3.1. Pseudo-first-order rate constants of association between ribozymes RZ534, 
RZ551, RZ556, RZ568, RZ572 and RZ572B and substrates RZSUB and 5D RNA. All 
rates shown are for the initial rapid phase of ribozyme-substrate complex formation. Gel- 
shift experiments performed using radiolabelled ribozymes, with the unlabelled substrate in 
excess. The derivation of these data is shown in figures 3.18 to 3.27. All rate constants 
are approximated to two significant figures. The percentage of GC residues in helices I and 
III of the ribozyme-substrate complex is also shown.
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Figure 3.18. Gel-shift experiment using radiolabelled RZ572 and an ex cess  of unlabelled 
RZSUB. (a) Gel, with unbound RZ572 (R) and RZ572-RZSUB complex (C) indicated. The 
boxes indicate the regions in which the signal volume w as determined. Note that all the 
boxes are of the same size. This process w as repeated for all other gels (figures 3.19 to 
3.21), though only the full gel is shown here. The background w as determined in a region 
of the gel away from the sample lanes, in this case  above the wells, (b) Rate of formation 
of ribozyme-substrate complex with 38.4pM RZSUB, with linear best-fit to initial rate 
shown (dashed lines), (c) best-fit line formula, t1/2, and k2 for initial rate.
Time (minutes)
iackground
1 11
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k’i (s'1) 0.0001
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Figure 3.19. Gel-shift experiments using radio la be I led RZ572B and an excess of 
unlabelled RZSUB. (a) Gel, with unbound RZ572B (R) and RZ572B-RZSUB complex (C) 
indicated, (b) Rate of formation of ribozyme-substrate complex with 5.675piM, 16.875pM 
or 33.75^iM RZSUB, with linear best-fit to initial rates shown (dashed lines), (c) best-fit 
line formula, t1/2, k’-, and k2 for initial rates in each set of experiments.
(a) Time (minutes)
0 2 4 8 16 32 64
(c)
4 0 1
30-
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k’i (s'1) 0.0005 0.0003 0.002
k2 (s'1ivr1) 15 20 37
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Figure 3.20. Gel-shift experiment using radiolabelled RZ551 and an ex ce ss  of unlabelled 
RZSUB. (a) Gel, with unbound RZ551 (R) and RZ551-RZSUB complex (C) indicated, (b) 
Rate of formation of ribozyme-substrate complex with 14.8pM RZSUB, with linear best-fit 
to initial rate shown (dashed lines), (c) best-fit line formula, 11/2, k’., and k2 for initial rate.
(a) Time (minutes)
4 8 16 32 64
1* ’ T-' ' *8* -
(c)
(b) 15-,
[RZSUB]=14.8pM
o -p
o on.1 Oro Oi-1
Time (minutes)
[RZSUB] 14.8 i^M
Best-fit line y=1.1x+1.2
t1/2 (seconds) 2830
k’i (s'1) 0.00025
k2 (s 1IVT1) 17
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Figure 3.21. Gel-shift experiments using radiolabelled RZ556 and an ex cess  of unlabelled 
RZSUB. (a) Gel, with unbound RZ556 (R) and RZ556-RZSUB complex (C) indicated, (b) 
Rate of formation of ribozyme-substrate complex with 13.2pM or 39.6pM RZSUB, with 
linear best-fit to initial rates shown (dashed lines), (c) best-fit line formula, t1/2, and k2 
for initial rates in each set of experiments.
(a) Time (minutes)
0 2 4 8 16 32 64
( c )
(b) 25
x , on <d £
£ CL 
8 TD
JB =  15
10
[RZSUB]=13.2pM
5or h
[RZSUB]=39.6pM
0
o o1—1 m
Time (minutes)
[RZSUB] 13.2pM 39.6|^M
Best-fit line y=0.3x+0.5 y=0.46x-0.3
t1/2 (seconds) 9550 6480
k’i (s'1) 0.000073 0.00011
k2 (s'1IVr1) 5.5 2.7
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Figure 3.22. Gel-shift experiment using radiolabelled RZ572B and an ex cess  of unlabelled 
5D RNA. (a) Gel, with unbound RZ572B (R) and RZ572B-5D RNA complex (C) indicated. 
The boxes indicate the regions in which the signal volume w as determined. Note that all 
the boxes are of the same size. This process w as repeated for all other gels (figures 3.23 
to 3.27), though only the full gel is shown here. The background w as determined in a 
region of gel away from the sample lanes (not shown), (b) Rate of formation of 
ribozyme-substrate complex with 263.5nM 5D RNA, with linear best-fit to initial rate shown 
(dashed lines), (c) best-fit line formula, t1/2, k^  and k2 for initial rate.
Time (minutes)
(a)
0 2 4 8 16 32 64
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(b) 4 0 1
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(c)
U TjJ-------
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k’i (s'1) 0.0002
k2 (s'1M'1) 760
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Figure 3.23. Gel-shift experiments using radiolabelled RZ534 and an ex cess  of unlabelled 
5D RNA. (a) Gel, with unbound RZ534 (R) and RZ534-5D RNA complex (C) indicated, (b) 
Rate of formation of ribozyme-substrate complex with 125nM or 375nM 5D RNA, with 
linear best-fit to initial rates shown (dashed lines), (c) best-fit line formula, 11/2, and k2 
for initial rates in each set of experiments.
(a) Time (minutes)
(b) 80n
ID 5  '
■n-z 6 0 -
£  DC 
8 TD
[RZ534]=125nM
[RZ534]=375nM
00
o or\i O o
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(c)
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Best-fit line y=7. x+10.6 y=10.9x+16
t1/2 (seconds) 430 280
k’i (s’1) 0.0016 0.0027
k2 (s 1IVT1) 13000 6700
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Figure 3.24. Gel-shift experiments using radiolabelled RZ551 and an ex ce ss  of unlabelled 
5D RNA. (a) Gel, with unbound RZ551 (R) and RZ551-5D RNA complex (C) indicated, (b) 
Rate of formation of ribozyme-substrate complex with 125nM or 375nM 5D RNA, with 
linear best-fit to initial rates shown (dashed lines), (c) best-fit line formula, t1/2, k’-, and k2 
for initial rates in each set of experiments.
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Figure 3.25. Gel-shift experiments using radiolabelled RZ556 and an ex cess  of unlabelled 
5D RNA. (a) Gel, with unbound RZ556 (R) and RZ556-5D RNA complex (C) indicated, (b) 
Rate of formation of ribozyme-substrate complex with 125nM or 375nM 5D RNA, with 
linear best-fit to initial rates shown (dashed lines), (c) best-fit line formula, t1/2, k’-, and k2 
for initial rates in each set of experiments.
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0 2 4 8 16 32
(b) 80-i
60 -
H Q
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k’i (s'1) 0.00125 0.0024
k2 (s 1IVT1) 10000 6500
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Figure 3.26. Gel-shift experiment using radiolabelled RZ568 and an ex ce ss  of unlabelled 
5D RNA. (a) Gel, with unbound RZ568 (R) and RZ568-5D RNA complex (C) indicated, (b) 
Rate of formation of ribozyme-substrate complex with 156nM 5D RNA, with linear best-fit 
to initial rate shown (dashed lines), (c) best-fit line formula, t1/2, and k2 for initial rate.
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Figure 3.27. Gel-shift experiment using radiolabelled RZ572 and an ex cess  of unlabelled 
5D RNA. (a) Gel, with unbound RZ572 (R) and RZ572-5D RNA complex (C) indicated, (b) 
Rate of formation of ribozyme-substrate complex with 312nM 5D RNA, with linear best-fit 
to initial rate shown (dashed lines), (c) best-fit line formula, t1/2) k\ and k2 for initial rate.
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3.1.3c Discussion
Before considering the data obtained from this set of experiments it is important to 
discuss the accuracy of the results. The determination of the location of the bands was very 
difficult, as a result of low band intensity in the set of experiments using RZSUB (figures
3.18 to 3.21) and degradation of the labelled RNA in all the experiments shown (figures
3.18 to 3.27). The location of the unbound ribozyme was taken to be level with the most 
intense band in the zero time-point lane. However, this was complicated in many cases by 
the gel ‘smiling’. In figure 3.18 it can be seen that in cases of gels ‘smiling’ an estimate of 
the position of the unbound ribozyme had to be made, taking into account the curvature of 
the gel. In the experiments using 5D RNA as the unlabelled substrate degradation of the 
labelled ribozyme was a problem, as can be seen from the smearing at the bottom of figures 
3.22 to 3.28. In these cases the top band in this region was taken as being the complete 
unbound ribozyme (figure 3.22). In the experiments using RZSUB, the signal intensity of 
the ribozyme-substrate complex was very low, with the complex only being seen in the later 
timepoints. Therefore the positions of the complex in earlier timepoints had to be estimated 
by placing the quantification box at the same height above the unbound ribozyme band in all 
lanes. It must be stressed though that location of the bands was easier than may be first 
imagined from seeing the figures presented here. This is because a computer monitor has 
better contrast than the output of an inkjet printer. Even so, the accuracy of these gel-shift 
experiments, especially those performed with RZSUB as the unlabelled substrate, is very 
low.
It was initially hypothesised that ribozymes targeted against regions of the substrate 
containing a high percentage of single-stranded sequence would bind more readily to their 
target sites than ribozymes targeted against double-stranded regions of the substrate. 
Therefore it was predicted that RZ551, RZ556 and RZ568 would bind more readily to both 
substrates than RZ534 and RZ572, whilst RZ572B, with its long flanking sequences, was 
predicted to bind most rapidly. These predictions were found to be partially true when 
RZSUB was used as a substrate. RZ572B was found to have the greatest rate of association 
(k2=24±9s'1M 1), with RZ551 having the greatest rate of association of the small ribozymes 
(k2=17s‘]M '’). There was no significant difference between RZ556 (k2=4.1±1.4s"‘M 1) and 
RZ572 ( k ^ J s  'M 1), whilst no ribozyme-RZSUB complex was detected when RZ534 and 
RZ568 were used. These results did not correlate with those obtained when 5D RNA was 
used as the substrate. The greatest rates of association were seen with RZ534 
(k2=[9.8±3.2]X 10V 1M 1), RZ551 (k2=[10±4]X 10V 1M '1) and RZ556 (k2=[8.2±1.8]X 10V  
'M"1), whilst the remaining ribozymes showed significantly reduced rates of association. 
However, given the lack of accuracy using this technique, it is impossible to draw any real 
conclusions from this data. The lack of correlation between the results obtained with the two 
different substrates, RZSUB and 5D RNA also supports the queries as to the validity of 
these experiments. The apparent greater affinity of the ribozymes for the larger 5D RNA
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compared to the shorter RZSUB RNA contradicts observations made in previous studies 
which have shown that ribozymes are up to a thousand-fold more active against short 
substrates than against full-length mRNAs (Campbell et a l., 1997). This is assumed to be 
because of the presence of more inhibitory secondary structure in the larger RNA. The 
current data shows the converse (table 3.1). It is impossible to say whether this huge 
discrepancy is entirely due to the inaccuracies of the technique, given that the study by 
Campbell et al (1997) looked at the ribozyme reaction as a whole, rather than just focusing 
on the ribozyme-substrate hybridization step as this current study does.
Although the primary concern regarding these experiments is the accuracy of the gel 
retardation technique, it is also important to consider the validity of the MFOLD predictions. 
It is likely that the secondary structure predictions for both substrates produced by the 
MFOLD program are incorrect. The algorithm used to produce these predictions only takes 
into account Watson-Crick and Hoogsteen base-pairing. It does not take into account non- 
base-pair hydrogen bonding, which can influence RNA tertiary structure, base-stacking in 
single-stranded regions, or allow for structures such as pseudoknots. Such variations 
between the structures of RZSUB and 5D RNA could contribute in part for the differences in 
hybridisation rates, though this would probably only become significant if the gel-shift 
technique could be refined to increase accuracy. In such circumstances it would be 
necessary to confirm the structures of RZSUB and 5D RNA by RNase probing. Different 
RNases have different target specificities; some cleave double-stranded RNA, whilst others 
cleave single-stranded RNA. Substrate sequence can also affect RNase activity. Knowledge 
of the different activities of RNases can allow the pattern of cleavage of a given RNA with 
different RNases to be interpreted to give a structural prediction. However, it is possible that 
the substrate RNAs used in the current investigation can assume several different structures 
with similar energies. This hypothesis is supported by the observation that the graphs 
produced with the data obtained from the gel-shift experiments are non-linear, even though 
the reactions have been set up to follow pseudo-first order kinetics. This is probably due to 
there being two phases of hybridisation; an initial rapid phase, followed by a period of 
slower association. This could arise from the presence of two isomers of either the ribozyme 
or the substrate RNA, with each isomer having different binding affinity for the 
complementary RNA. Although the non-linearity of the graphs could also be attributed to 
inaccuracies in the technique, this is unlikely given that this phenomenon appeared again and 
again in many different experiments.
Another serious problem encountered in this study was the lack of reproducibility 
between experiments, resulting in the large errors obtained when experiments were repeated 
with different concentrations of unlabelled RNA (i.e. RZ556 and RZ572B plus RZSUB and 
RZ534, RZ551 and RZ556 plus 5D RNA). This is not solely a result of the inaccuracies of 
the technique as these differences arose when different batches of RNA were used. 
Although all RNA was prepared in the same way, it is possible that some salt could have
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remained in the RNA preparations following the ethanol precipitation step: Monovalent 
cations have been shown to influence nucleic acid hybridisation and structure (Wang et a l., 
1995). This problem was reduced as the study progressed as an increased number of 70% 
ethanol washes were used to clean the RNA pellet after precipitation. Dialysis would offer a 
solution to this problem. However, this would require the RNA to be dissolved in a large 
volume, making the RNA too dilute to be used in the gel-shift experiments. In some 
instances no ribozyme-substrate complex was seen to form. It must be stressed though that 
in the cases where no rate of association was determined (RZ534 and RZ568, both with 
RZSUB), the experiment was repeated many times but no complex was seen to form.
In light of these difficulties arising from using gel-shift analysis, it was decided to 
develop an ELISA-based protocol for analysing ribozyme-substrate binding.
3.1.4 RNA-RNA ELISA 
3.1.4a Introduction
ELISA (enzyme-linked immunosorbant assay) is a well-established technique for 
detecting an interaction between two biological molecules. One molecule is fixed to a matrix 
(for example the bottom of a well on a microtitre plate), whilst the second molecule is added 
in solution into the well. After incubating for a period of time, any of the second molecule 
which has not bound to the first molecule is washed from the well. An antibody to the 
second molecule is used to detect if any of the second molecule has become bound to the 
first. This antibody is conjugated to an enzyme, such as horseradish peroxidase. Enzymes 
are chosen which have chromogenic substrates, thus producing a colour change which is 
which can be measured by spectrophotometry (figure 3.28). The intensity of the colour 
change is proportional to the amount of enzyme present.
Microtitre plates coated with streptavidin are commonly used in ELISAs. 
Streptavidin binds biotin very strongly. Biotin can be easily incorporated into proteins and 
nucleic acids by a number of methods, enabling these macromolecules to be firmly anchored 
in streptavidin-coated microtitre plates. It was decided to biotinylate the positive control 
substrate, Y98. The positive control ribozyme, RZ60, was to be labelled with digoxigenin. 
Digoxigenin is a commonly used ligand in ELISAs, and there is a wide range of antibody- 
enzyme conjugates targeted to digoxigenin available. It was decided to endlabel both the 
ribozyme and substrate. Internal labelling with biotin or digoxigenin could interfere with 
ribozyme-substrate binding. Microtitre plates, buffers and detection reagents were taken 
from a commercial PCR product detection ELISA kit (Boehringer-Mannheim).
125
Chapter 3 Results
Chromogenic 
peroxidase substrate
Anti-digoxigenin antibody/ 
peroxidase conjugate
<■' o *
ABTS
Ribozyme 
RNA
substrate 
RNA
Streptavidin-coated 
microtitre plate
Figure 3.28. The principle behind the ribozyme-substrate hybridisation enzyme-linked 
immunosorbant assay (ELISA). Substrate RNA is 3’-endlabelled with biotinylated 
nucleotide derivatives (BIO). The biotinylated substrate RNA is anchored in streptavidin- 
coated microtitre well plates by the strong interaction between biotin and streptavidin (S). 
Ribozymes 3’-endlabelled with digoxigenin-labelled nucleotide derivatives (DIG) hybridise 
with the anchored substrate in microtitre plate wells. Unbound ribozyme is washed away, 
ieaving ribozyme-substrate complex bound to the microtitre plate weii. The ribozyme- 
substrate complex is detected with an anti-digoxigenin antibody/ peroxidase enzyme 
conjugate. Any unbound antibody/ enzyme conjugate is removed by washing. The 
remaining antibody/ enzyme conjugate is bound to the ribozyme-substrate complex, and 
can be detected using a chromogenic peroxidase substrate, such as ABTS. The change in 
colour of ABTS, from colourless to green, produced by peroxidase activity can be 
quantified by spectrophotometry, and is proportional to the amount of ribozyme-substrate 
complex.
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3.1.4b RNA labelling
It was initially decided to endlabel the substrate RNA by using RNA ligase to ligate a 
biotinylated oligonucleotide, BIO-1, to the 3'-end of the substrate RNA (figure 3.29). RNA 
ligase requires a 5'-phosphate group in one substrate and a 3'-hydroxyl group in the other 
substrate to function (Uhlenbeck & Gumport, 1982). If a single-stranded nucleic acid has 
both a 5 ’-phosphate and a 3’-hydroxyl group it will be circularised by RNA ligase. 
Therefore it was necessary to use polynucleotide kinase to phosphorylate the 5'-end of the 
BIO-1 oligonucleotide and to use alkaline phosphatase to remove the 5'-phosphate from the 
substrate RNA. The ligation reactions were performed using IX  T4 RNA ligase buffer 
(50mM Tris-HCl, lOmM M gCl2, lOmM DTT, ImM ATP, pH 7.8). lOnM internally 
radiolabelled, alkaline phosphatase treated Y98 was incubated with varying concentrations of 
BIO-1 oligonucleotide and RNA ligase purchased from either Boehringer-Mannheim or New 
England Biolabs at 37°C for 30 minutes (figure 3.30a). Under these conditions no ligation 
was acheived. The ligation reactions were repeated using New England Biolabs RNA ligase 
with lOnM Y98 and ImM  BIO-1 with varying concentrations of DMSO, in accordance with 
recommendations included in the protocol supplied with the enzyme. Even with this 
modification no ligation was detected (figure 3.30b).
An alternative method of adding modified nucleotides to the 3'-end of single-stranded 
RNA utilises terminal deoxynucleotidyl transferase (TdT). This enzyme can be used to add 
homopolymer tails when NTPs or dNTPs are used, or can be used to add a single nucleotide 
when a ddNTP is used (Roychoudhury et al., 1976). The efficiency of TdT was examined 
by using it to endlabel radiolabelled RZ572 RNA. The biotinylated or digoxigen-labelled 
radiolabelled RZ572 RNA was resolved by electrophoresis (figure 3.31). Despite 
background degradation, it can be seen that TdT can be used to endlabel single-stranded 
RNA.
Could biotinylated nucleic acid bind to streptavidin-coated microtitre plates? This 
was investigated by incubating the BIO-1 oligonucleotide , which has the sequence (dA )18, 
overnight at 4°C in IX ribozyme hybridisation buffer in streptavidin-coated microtitre plates. 
Following incubation, unbound BIO-1 was removed by rinsing the wells with wash buffer. 
The oligonucleotide primer CPI was end-labelled with a 32P-dTTP using TdT. This gave 
CPI a radiolabelled oligo-dT tail that was complementary to the BIO-1 oligonucleotide 
bound to the streptavidin wells. The end-labelled CPI was added to the BIO -1-streptavidin 
wells in IX  ribozyme hybridisation buffer and incubated at 37°C for 3 hours. U nbound 
CPI was removed at the end of the incubation and quantified by liquid scintillation counting 
(figure 3.32). These results show that the BIO-1 oligonucleotide was bound to the 
streptavidin wells, and was able to capture a complementary single-stranded nucleic acid.
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Figure 3.29. Reaction scheme for ligation of substrate RNA and BIO-1 biotinylated 
oligonucleotide using T4 RNA ligase. T4 RNA ligase catalyses the ATP-dependent joining 
of 5'-phosphoryl-terminated nucleic acid donor to a 3'-hydroxyl-terminated nucleic acid 
acceptor. In this case the BIO-1 oligonucleotide is the donor and the substrate RNA is the 
acceptor. Before ligation both nucleic acids need modifying. The substrate RNA must have 
its 5'-phosphate RNA removed with alkaline phosphatase to prevent T4 RNA ligase 
circularising it, by ligating the 5'-phosphate and 3'-hydroxyl group from the same molecule, 
and to prevent head-to-tail multimerization (A). The synthetic oligonucleotide BIO-1 
requires the addition of a 5'-phosphate group. This is done using polynucleotide kinase 
and ATP (B). The 3'-hydroxyl group of the BIO-1 oligonucleotide must be blocked, again 
to prevent circularisation or multimerization. This is done by adding ddCTP, which itself 
lacks a 3-hydroxyl group, to the 3'-end of BIO-1 with terminal deoxynucleotidyl transferase 
(C). The modified substrates can then be joined by T4 RNA ligase (D). This reaction 
requires ATP, and generates, in addition to the ligated product, AMP and pyrophosphate
(PPi).
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Figure 3.30a. Testing efficacy of RNA ligase purchased from Boehringer-Mannheim (BM) 
and New England Biolabs (NEB). Y98, internally labelled with cx32P-UTP, was incubated 
with varying concentrations of oligonucleotide BIO-1 (A, 10pM, B, 1pM, C, 100nM, D, 10nM) 
at 37°C overnight. Samples were separated on a 10% denaturing polyacrylamide gel in 1X 
TBE buffer. No increase in size of the radiolabelled band is visible following incubation of 
Y98 with RNA ligase and BIO-1. Both Y98 and BIO-1 were treated as described in figure 
3.29 prior to the ligation reaction.
Y98 + BIO-1 + RNA ligase 
% DMSO _____
Figure 3.30b. Investigating the effects of dimethylsulphoxide (DMSO) on RNA ligase 
activity. DMSO has been widely reported to enhance RNA ligase activity. Varying dilutions 
of DMSO were used in ligation reactions with BIO-1 oligonucleotide and internally 
radiolabelled Y98. Reactions were incubated overnight at 37°C, with the products being 
separated on a 10% denaturing polyacrylamide gel in 1X TBE buffer. No increase in the 
size of the radiolabelled band is visible following incubation of Y98 with BIO-1 and RNA 
ligase.
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Figure 3.31. Radiolabelled RZ572 RNA was incubated with terminal deoxynucleotidyl 
transferase (TdT) at 37°C for 1 hour with a variety of modified nucleotides. Reactions 
were terminated in formamide gel-loading buffer, and samples were run on 7M urea, 12% 
polyacrylamide gel in 1X TBE buffer. All reactions contained 0.4 pmoles radiolabelled 
RZ572 plus the following additions; (A) 10 pmoles biotin-11-ddUTP, (B) 10 pmoles 
digoxigenin-16-ddUTP, (C) 50 pmoles digoxigenin-16-UTP, (D) 50 pmoles digoxigenin-16- 
UTP + 450 pmoles dCTP, (E) no additions. Despite the curving of the gel it is possible to 
see that the addition of the modified nucleotides by TdT has resulted in an increase in the 
size of RZ572 RNA, as indicated by the arrows. This is particularly apparent in lane C, 
where the use of digoxigenin-16-UTP has permitted the addition of multiple modified 
nucleotides to RZ572, and in lane D, where inclusion of dCTP in nine-fold excess over 
digoxigenin-16-UTP has resulted in a large increase in the size of RZ572. The ability to 
include multiple digoxigenin moieties at the 3'-end of the ribozyme RNA is very important, as 
this could allow an increase in the signal-to-noise ratio. It has been reported previously 
that inclusion of a non-labelled dNTP, as in lane D, can further increase the signal-to-noise 
ratio by spreading out the digoxigenin-modified residues in the 3-tail, thus reducing steric 
hindrance between antibody/ enzyme conjugates attempting to bind neighbouring 
digoxigenin moieties.
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Figure 3.32. Binding of radiolabelled poly-dT oligonucleotide to BIO-1 biotinylated 
oligonucleotide in streptavidin-coated microtitre wells. Varying dilutions of BIO-1 
oligonucleotide, stock concentration 1pM, were fixed in streptavidin-coated microtitre wells 
by incubation in 1X ribozyme hybridisation buffer at 4°C overnight. Unbound BIO-1 was 
removed by rinsing the wells with wash buffer. Oligonucleotide CP1 was 3'-endlabelled 
using TdT and a32P-dTTP, to give the oligonucleotide a 3'-poly-dT tail. Equal amounts of 
the a32P-dTTP-labelled oligonucleotide were added to each well in 1X ribozyme 
hybridisation buffer, and incubated for 3 hours at 37°C, allowing the oligonucleotide's poly- 
dT tail to hybridise with BIO-1 (sequence dA18). Following the incubation the wells were 
rinsed with wash buffer, with the washes being saved, and the radioactivity they 
contained being quantified by scintillation counting. These counts were subtracted from 
those obtained from the washes from wells containing no BIO-1 to give an estimate of how 
much a32P-dTTP-labelled oligonucleotide remained bound in the wells.
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3.1.4c Detection of ribozyme-substrate complex
Following confirmation that RNA could be end-labelled using TdT and that 
biotinylated nucleic acids could bind to streptavidin-coated microtitre plates and be detected 
by hybridisation with a radiolabelled probe, the next step was to try and detect binding of the 
positive-control ribozyme, RZ60, and substrate, Y98, in the ELISA system. The binding of 
the positive controls RZ60 and Y98 had already been confirmed by gel-shift assay (figure 
3.5). Although ELIS As are sensitive to pH and ion concentrations, it was considered to be 
important to keep conditions as close to a physiological environment as possible. Therefore 
IX  ribozyme hybridisation buffer was used as in the gel-shift assays. It should be noted that 
this buffer was M g2+-free, to prevent substrate cleavage, and the collapse of the ribozyme- 
substrate complex. A checkerboard was set up using varying dilutions of biotinylated Y98 
and digoxigenin-labelled RZ60 (figure 3.33). The results of this initial experiment are 
shown in figure 3.34.
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Figure 3.33. Layout of ELISA checkerboard experiment. Biotinylated Y98 (Y98-BIO) 
positive control substrate was fixed to streptavidin-coated microtitre plate wells in 1X 
ribozyme hybridisation buffer, incubated overnight at 4°C. Following removal of unbound 
Y98-BIO by rinsing the wells with wash buffer, varying dilutions of digoxigenin-labelled 
RZ60 positive control ribozyme were added. The plates were then incubated at 37°C for 3 
hours. Results are shown in figure 3.34.
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Figure 3.34. Results of ELISA checkerboard experiment. Varying concentrations of Y98 
positive control substrate, end-labelled with biotin-11-ddUTP, w as fixed to streptavidin- 
coated microtitre plates in 1X ribozyme hybridisation buffer. Following removal of unbound 
Y98 by washing, varying concentrations of RZ60, end-labelled with digoxigenin-16-UTP, 
were added to the wells in the pattern shown in figure 3.34. The microtitre plates were 
incubated on a rotary shaker at 37°C for 3 hours. Following incubation, unbound RZ60 
w as removed by washing. The ELISA plates were developed using an anti-digoxigenin 
antibody/ peroxidase conjugate and ABTS chromogenic substrate. The developed ELISA 
plates were quantified using a multiwell plate-scanner at 405nM. The absorbance values 
shown are measured from the background reading. The background w as determined by 
incubating 53pmoles RZ60 in duplicate wells containing no Y98, and then developing as all 
the other wells.
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Although a dose dependent response was seen, the readings taken by the microtitre 
plate scanner are all below 0.1 absorbance units (at 405nm). This is much too low for 
accurate information regarding intermolecular interactions to be obtained. Why should these 
readings be so low? When the positive control digoxigenin-labelled PCR product and 
biotinylated capture oligonucleotide supplied with the commercial kit were used, readings 
greater than 2 absorbance units (at 405nm) were routinely obtained. Could the labelled RNA 
be degrading? Samples of both Y98 and RZ60, endlabelled using TdT, were run on a 1% 
agarose gel (figure 3.35). No degradation was observed.
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Figure 3.35. Y98 positive control substrate RNA, end-labelled with biotin-16-ddUTP (Y98- 
BIO), and RZ60 positive control ribozyme, end-labelled with digoxigenin-11-UTP (RZ60- 
DIG), run on a 1% agarose gel in 1X TBE. Both RNAs were end-labelled using TdT. No 
degradation is apparent.
Is it possible that the ribozyme RZ60 is unable to bind its substrate Y98 when Y98 is 
anchored to the streptavidin-coated wells? This could be due to steric hindrance. This 
hypothesis was tested by preincubating RZ60 and Y98 together at 37°C for 4 hours, and 
then fixing the resulting complex to streptavidin-coated microtitre wells (figure 3.36). This 
also did not increase the signal. An alternative possibility was that the streptavidin-coated 
wells were not saturated with biotinylated substrate RNA. In the initial experiment, a 
maximum of 80.1 pmoles of biotinylated Y98 was added per well. The manufacturers claim 
that each well can bind a maximum of 20 pmoles of biotin. It is possible that not all the 
available biotin is binding streptavidin. However, increasing the amount of biotinylated Y98 
up to 800 pmoles per well did not increase the signal (figure 3.36).
Therefore it became apparent that the detection system was insufficiently sensitive 
enough to detect the small number of digoxigenin residues in the ribozyme-substrate 
complex. The positive control PCR product supplied with the kit was labelled throughout its 
length with digoxigenin. As described earlier, this was not possible with the ribozyme 
RNAs. It was decided to try using a secondary antibody to increase the ELISAs sensitivity.
Y98-BIO RZ60-DIG
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Figure 3.36. Increased [Y98-BIO] in ELISA. Even increasing [Y98-BIO] to 800 pmoles 
per well does not significantly increase the final signal. Equimolar amounts of Y98-BIO and 
RZ60-DIG were prehybridised overnight at 37°C, prior to addition to the streptavidin- 
coated microtitre plates. The ribozyme-substrate complex was allowed to bind to the 
plates for 3 hours at 37°C. After washing to remove unbound complex the ELISA w as  
developed as previously described.
3.1.4d RNA-RNA ELISA using secondary antibodies
The sensitivity of any antibody-based detection system can be enhanced by utilising a 
secondary antibody chosen to bind to the primary antibody which itself binds directly to the 
ligand o f interest. The digoxigenin detection system provided with the PCR product 
detection ELISA kit utilised anti-digoxigenin Fa^ fragments generated in sheep conjugated to 
horseradish peroxidase. Two secondary antibodies were tried: an anti-sheep antibody- 
peroxidase conjugate (developed in donkey) and a peroxidase-anti-peroxidase (P-AP) 
conjugate.
Using a secondary antibody increases the likelihood of high background readings. 
Therefore trial experiments utilising combinations of blocking agents and washes were 
performed in order to limit this problem. An initial experiment was performed using Y98- 
BIO and RZ60-DIG with P-AP conjugate being used as a secondary antibody. 1% BSA in
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IX  ribozyme hybridisation buffer was used as a blocking agent (figure 3.37). It can be seen 
from this data that although P-AP does increase the signal, there is considerable background. 
Although addition of 1% BSA does reduce the background, the signal-to-noise ratio is still 
too low to enable this system to be used.
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Figure 3.37. Results of ELISA performed using Y98-BIO and RZ60-DIG. Fixing of RNA 
complex to the streptavidin wells was performed in 1X ribozyme hybridisation buffer (1X 
Hyb) either with or without 1% BSA at 4°C overnight. The ELISA was probed using either 
just a primary antibody (1° Ab; sheep anti-digoxigenin Fab fragments conjugated to 
horseradish peroxidase, 1:100 dilution), primary and secondary antibodies (2° Ab; 
peroxidase anti-peroxidase conjugate, 1:200 dilution), primary and secondary antibodies 
plus 1% BSA and with no antibody. Although use of the peroxidase anti-peroxidase 
conjugate as a secondary antibody clearly increases signal strength, there is considerable 
background even when 1% BSA is used as a blocking agent. All antibody incubations 
were at 37°C for 3 hours. Wells were rinsed five times for at least 30 seconds with wash  
buffer after each incubation. The ELISA was developed using ABTS, with absorbance 
being measured at 405nm.
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Further experiments were performed using 5D-BIO and RZ572B-DIG RNAs. These 
experiments utilised both P-AP and donkey anti-sheep IgG secondary antibodies. 1% 
gelatine and a 1:100 dilution of mouse IgG-FITC conjugate were used as blocking agents. 
The absorbances obtained from these experiments are shown in table 3.2 and in figure 3.38. 
The absorbances are again far too low to be of any use. Neither blocking agent increases the 
signal to noise ratio, with considerable peroxidase activity being seen even when no 
RZ572B-DIG has been added to the wells, suggesting that a significant proportion of the 
background is coming from non-specific binding of the anti-digoxigenin primary antibody.
Blocking agent no 2° Ab P-AP anti-sheep
IgG
no block 0.118 0.374 0.283
5D-BIO+ 1° Ab 1 % gelatine 0.12 0.277 0.198
1:100 mouse IgG 0.144 0.799 0.311
no block 0.092 0.252 0.199
5D-BIO - 1° Ab 1 % gelatine 0.099 0.23 0.145
1:100 mouse IgG 0.093 0.678 0.199
5D-BIO + no block 0.11 0.302 0.214
RZ572B-DIG 1% gelatine 0.098 0.174 0.176
-Q<O+ 1:100 mouse IgG 0.117 0.62 0.214
5D-BIO + no block 0.098 0.264 0.195
RZ572B-DIG 1% gelatine 0.099 0.194 0.14
JQ<o1 1:100 mouse IgG 0.094 0.63 0.195
Table 3.2. Results of ELISA performed using 5D-BIO and RZ572B-DIG RNAs to a s s e s s  
efficacy of secondary antibodies, peroxidase anti-peroxidase conjugate and donkey anti­
sheep IgG-peroxidase conjugate. 5D-BIO was fixed to streptavidin plates in 1X ribozyme 
hybridisation buffer at 4°C overnight. 1X ribozyme hybridisation buffer was supplemented 
with either 1% gelatine, 1:100 dilution of mouse IgG-FITC conjugate (both being used as  
blocking agents) or had no addition. Half the wells containing 5D-BIO had RZ572B-DIG 
added in 1X ribozyme hybridisation buffer with the addition of blocking agents in wells 
where they had been used previously. Following addition of RZ572B-DIG the wells were 
incubated for 3 hours at 37°C. Following this incubation the wells were rinsed with wash  
buffer, after which half the wells were incubated with the primary antibody (1° Ab), sheep  
anti-digoxigenin Fab fragment-peroxidase conjugate for 3 hours at 37°C. Following this 
incubation the wells were rinsed with wash buffer, and incubated with a secondary 
antibody for 3 hours at 37°C, as shown in the table. Following this incubation the wells 
were again rinsed with wash buffer, and the ELISA was developed using ABTS. The 
table shows the absorbance of the contents of the wells at 405nm.
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Figure 3.38. Results of ELISA performed using 5D-BIO and RZ572B-DIG RNAs to 
a sse s s  efficacy of various secondary antibodies and blocking agents. The data for this 
graph was obtained from table 3.2 by subtracting the absorbances obtained in incubations 
performed with no primary antibody from the absorbances obtained in incubations identical 
accept for the use of the primary antibody. Key to columns: (1) 5D-BIO plus 1° Ab, no 2° 
Ab, (2) 5D-BIO plus RZ572B-DIG and 1° Ab, no 2° Ab, (3) 5D-BIO plus 1° Ab and P-AP, 
(4) 5D-BIO plus RZ572B-DIG, 1° Ab and P-AP, (5) 5D-BIO plus 1° Ab and donkey anti­
sheep IgG, (6) 5D-BIO plus RZ572B-DIG, 1° Ab and donkey anti-sheep IgG. Incubations 
were performed using either no blocking agent, 1% gelatine or 1:100 dilution of mouse-lgG- 
FITC conjugate.
3.1.5. Discussion
Although ELISA could provide a rapid, efficient method of screening many 
ribozymes for binding activity simultaneously, it has been shown that the system tried in the 
current study was not sensitive enough to allow accurate determination of ribozyme-substrate 
binding kinetics. Despite demonstrating that nucleic acid binding could be detected by 
radioactive labelling in microtitre wells (figure 3.32), and that the digoxigenin detection 
system could follow ribozyme-substrate hybridisation in a dose-dependent fashion (figure
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3.34), it was clear that using end-labelled RNA would not provide enough binding sites for 
the anti-digoxigenin antibody.
This conclusion was reached after examining a number of other possibilities that 
could have explained the low readings. The RNA was clearly being endlabelled by TdT 
(figure 3.31), and was not degrading through the labelling process (figure 3.35). However, 
it was not demonstrated whether the RNA was degraded in the microtitre wells during the 
ELISA process. Increasing the quantity of RNA did not increase the signal, suggesting that 
the wells were saturated (figure 3.36). The ribozyme binding site in the substrate was not 
occluded by binding the biotinylated substrate to the streptavidin -coated wells, as binding 
pre-formed ribozyme-substrate complexes into the streptavidin-coated wells did not increase 
the signal (figure 3.36).
Two different secondary antibodies, P-AP and donkey-anti-sheep IgG, were used in 
an attempt to increase the signal. Although both of these antibodies did increase the signal, 
the signal to noise ratio was very low. Three different blocking agents were used to try and 
increase the signal to noise ratio; 1% BSA, 1% gelatine and 1:100 dilution of mouse IgG- 
FITC conjugate. None of these blocking agents appreciably increased the signal to noise 
ratio. In conclusion the ELISA based system did not prove to be an effective method for 
assessing ribozyme-substrate hybridisation. As stated earlier, ELISAs are sensitive to pH 
and ionic concentrations. Altering these parameters may allow the RNA-RNA ELISA to 
work. However, it was considered important to use the same conditions as have been used 
previously in in vitro ribozyme studies which have been shown to allow ribozyme-substrate 
binding and ribozyme-mediated substrate cleavage in non-ELISA systems.
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3.2 DOES THE CHOICE OF TARGET SITE AFFECT CLEAVAGE 
EFFICIENCY?
3.2.1 What factors affect ribozyme cleavage?
Section 3.1 detailed how ribozymes directed to different parts of a stem-loop of pre­
core/ core RNA hybridise with their target sequences at different rates. Is binding the rate 
determining step of a cleavage reaction, with cleavage happening at the same rate irrespective 
of the target sequence? It is often assumed that cleavage fails because of substrate binding 
failure. However, in cell culture, ribozyme constructs can block gene expression even when 
no cleavage products can be detected (or when the ribozyme domain is inactivated by 
mutation). This implies that ‘inactive’ ribozymes are able to bind to their target sequences 
and block gene expression by an antisense mechanism.
Why should these ribozymes be able to bind to their target sites but be unable to 
cleave their substrate? Here, the ribozymes targeted against the stem-loop between bases 
526 and 585 of the pre-core/ core ORF RNA were studied under single-tumover conditions 
in vitro to determine whether the rate of substrate cleavage differed between ribozymes. By 
splitting the ribozyme reaction into two parts, ribozyme-substrate hybridisation and substrate 
cleavage, it should be possible to determine whether hybridisation guarantees substrate 
cleavage.
3.2.2 Choice of substrate
Initial cleavage experiments were performed using 5D RNA. However, as these 
experiments consisted of incubations lasting up to 24 hours, the bulk of the 5D RNA 
degraded due to RNase activity, making it impossible to detect any ribozyme-generated 
cleavage products. Therefore it was decided to use the 60 base substrate RZSUB for all 
cleavage experiments.
3.2.3 Initial experiments
To determine whether any substrate cleavage could be detected, radiolabelled 
RZSUB was incubated with either a 100-fold excess, a 10-fold excess, or an equimolar 
amount of RZ534, RZ551, RZ556, RZ568, RZ572 or RZ572B. The ribozyme and 
substrate RNAs were incubated in IX ribozyme hybridisation buffer supplemented with 
25mM MgCl2 (final concentration) at 37°C for 5 hours (figure 3.39). Under these 
conditions, RZ556 cleaved 69% RZSUB when RZ556 was in a 100-fold excess over 
RZSUB. Both RZ572 and RZ572B cleaved approximately 60% RZSUB when both 
ribozymes were in a 100-fold excess over RZSUB (table 3.3).
A longer incubation at a lower MgCl2 concentration was performed to investigate 
whether these ribozymes would still be active under physiological conditions. Ribozyme 
and substrate RNAs were incubated in IX  ribozyme hybridisation buffer supplemented with 
5mM M gCl2 (final concentration), and incubated at 37°C for 24 hours (figure 3.40).
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Figure 3.39. 5 hour ribozyme incubation with 25mM MgCU Radiolabelled RZSUB w as  
incubated with either a 100-fold or a 10-fold ex ce ss  of each individual ribozyme, or with 
an equimolar amount of each individual ribozyme, in 1X ribozyme hybridisation buffer 
supplemented with 25mM MgCl2 (final concentration). RZSUB w as also incubated in 1X 
ribozyme hybridisation buffer supplemented with 25mM MgCl2 (final concentration) in the 
absence of any ribozymes. Reactions were incubated for 5 hours at 37°C. Following 
incubations, an equal volume of formamide gel loading buffer w as added to each reaction, 
which were then boiled for 2 minutes. Samples were run on a 10% denaturing 
polyacrylamide gel in 1X TBE buffer. Cleavage products are visible in the 100-fold ex cess  
lanes with RZ556 and RZ572B, and in both the 100-fold and 10-fold ex ce ss  lanes with 
RZ572.
Ribozym e RZ556 RZ572 RZ572B
RZ:RZSUB 100:1 10:1 1:1 100:1 10:1 1:1 100:1 10:1 1:1
% C leavage 69 - 57 49 59 -
Table 3.3. Extent of cleavage of RZSUB by RZ556, RZ572 and RZ572B after 5 hours 
incubation in 1X ribozyme hybridisation buffer supplemented with 25mM MgC  ^ (final 
concentration). These data were derived by quantifying the gel shown in figure 3.39 with 
the phosphorimager.
RZ551, RZ556, RZ572 and RZ572B all showed cleavage activity when incubated with 
RZSUB. RZ534and RZ568 failed to generate any cleavage products. These observations 
tie in with the gel-shift experiments described in section 3 .1 .3b, in which RZ534 and RZ568 
failed to hybridise with RZSUB. RZ551 and RZ556 both exhibited similar activities (table 
3.4). The greatest amount of cleavage was seen with RZ572 which, when in 100-fold 
excess, cleaved 90% of RZSUB and, when in 10-fold excess, cleaved 83% of RZSUB.
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Figure 3.40. 24 hour ribozyme incubation with 5mM MgCU Radiolabelled RZSUB w as  
incubated with either a 100-fold or a 10-fold ex ce ss  of each individual ribozyme, or with 
an equimolar amount of each individual ribozyme, in 1X ribozyme hybridisation buffer 
supplemented with 5mM MgC  ^ (final concentration). RZSUB w as also incubated in 1X 
ribozyme hybridisation buffer supplemented with 5mM MgCh (final concentration) in the 
absence of any ribozymes. Reactions were incubated for 24 hours at 37°C. Following 
incubations, an equal volume of formamide gel loading buffer w as added to each reaction, 
which were then boiled for 2 minutes. Samples were run on a 10% denaturing 
polyacrylamide gel in 1X TBE buffer. Cleavage products are visible in the 100-fold ex ce ss  
lanes with RZ551 and RZ556, and in all three lanes with RZ572 and RZ572B.
Ribozym e RZ551 RZ556 RZ572 RZ572B
RZ: RZSUB 100:1 10:1 1:1 100:1 10:1 1:1 100:1 10:1 1:1 100:1 10:1 1:1
% Cleavage 69 23 - 55 21 - 90 83 31 38 35 17
Table 3.4. Extent of cleavage of RZSUB by RZ551, RZ556, RZ572 and RZ572B after 24 
hour incubation in 1X ribozyme hybridisation buffer supplemented with 5mM MgCb (final 
concentration). These data were derived by quantifying the gel shown in figure 3.40 with 
the phosphorimager.
This suggests that approximately 10% of RZSUB is resistant to cleavage. This resistance 
could be due to substrate secondary structure, or the formation of inactive ribozyme- 
substrate complexes. In contrast, an excess of RZ572B, which cleaves RZSUB at the same 
point as RZ572, only cleaved 35% of RZSUB. This is despite RZ572B having a 13-fold 
greater affinity for RZSUB than RZ572. In multiple turnover experiments, ribozymes with 
high substrate affinities have low cleavage rates due to the slow release of cleavage products.
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Here, large excesses of ribozymes are being used which should ensure single turnover 
conditions where the rate of product dissociation is irrelevant.
Duplicating this experiment with lOmM EDTA added to the IX  ribozyme 
hybridisation buffer resulted in no cleavage products being detectable, confirming that the 
cleavage products seen in the previous two experiments were the result of the addition of 
MgCl2 (figure 3.41).
RZ534 RZ551 RZ556 RZ568 RZ572 RZ572B
oo  o §  o o  o 10
0
10 1 o  o
oo  o
N
oc
Figure 3.41. 24 hour ribozyme incubation with 10mM EDTA. Radiolabelled RZSUB w as  
incubated with either a 100-fold or a 10-fold ex ce ss  of each individual ribozyme, or with 
an equimolar amount of each individual ribozyme, in 1X ribozyme hybridisation buffer 
supplemented with 10mM EDTA (final concentration). RZSUB w as also incubated with no 
ribozyme added. Reactions were incubated for 24 hours at 37°C. Following incubations, 
an equal volume of formamide gel loading buffer w as added to each reaction, which were  
then boiled for 2 minutes. Samples were run on a 10% denaturing polyacrylamide gel in 1X 
TBE buffer. After 24 hours incubation in the presence of the Mg2+ chelator, EDTA, no 
cleavage products are seen, thus demonstrating that the cleavage products seen in 
figures 3.39 and 3.40 are the result of a Mg2* dependent reaction.
3 .2 .4  S ingle turnover timecourse
Following the demonstration of ribozyme cleavage the rate of cleavage was 
determined in a timecourse experiment. A large excess of ribozyme over substrate was used 
to ensure single turnover conditions.
The ribozyme and substrate RNAs were pre-annealed in IX ribozyme hybridisation 
buffer overnight at 37°C, to allow all the accessible ribozyme binding sites to become 
occupied; the cleavage reaction was started by adding M gCf to a final concentration of 
5mM. The reaction was stopped in formamide gel loading buffer and samples separated on a 
12% denaturing polyacrylamide gel (figure 3.42).
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RZ551 RZ572 No RZ
Time (minutes)
Figure 3.42. Single-turnover ribozyme cleavage timecourse performed with RZ551 and 
RZ572. 100-fold ex ce ss  ribozyme w as incubated with radiolabelled RZSUB in 1X 
ribozyme hybridisation buffer overnight at 37°C. Following this incubation, MgCk w as  
added to a final concentration of 5mMto initiate ribozyme cleavage. Aliquots were taken at 
various time-points and added to formamide gel-loading buffer. Samples were heated at 
95°C prior to running on a 12% denaturing polyacrylamide gel. The multiple bands seen  
across all three samples are the result of non-specific RNase degradation of RZSUB. 
However, the strong bands unique to the ribozyme incubations (indicated by arrows) are 
the result of specific ribozyme-mediated cleavage. Key to bands: (A), undigested RZSUB; 
(B) major product of RZ572 cleavage of RZSUB; (C) major product of RZ551 cleavage of 
RZSUB.
There was the same degree of cleavage of RZSUB at the zero and end timepoints. 
There are three possible explanations. The first is that the reaction continued in the 
formamide gel loading buffer; this is unlikely given that the ribozyme-substrate complex 
would rapidly break down. The second is that the preannealing reaction was contaminated 
with Mg2+ left over from the in vitro transcription reactions, or from the gel elution buffer 
which was used in the purification of the radiolabelled substrate RNA. Dialysis would solve 
this problem, but would require large volumes, which would then need to be concentrated. 
Nucleic acids are generally concentrated by ethanol precipitation in the presence of high 
concentrations of a monovalent cation, leading to the possibility of salt contamination of the 
dialysed RNA. The third possibility is that the ribozyme cleavage reaction is virtually 
instantaneous, given that the zero time-point is actually approximately five seconds after the
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true start of the reaction, as a result of the time needed to pipette Mg2+ into the reaction, and 
to take out a sample. The experiment was repeated, but with lOmM EDTA (final 
concentration) in the overnight preannealing reaction. This amount of EDTA was more than 
sufficient to bind all the Mg2+ in the transcription reaction. The reaction was then started by 
adding M gG 2 to a final concentration of 20mM, resulting in a final concentration of Mg2+ of 
at least lOmM. Over a 4  hour time course at 37°C, no detectable cleavage was seen, 
implying that the ribozyme cleavage reaction was not instantaneous (figure 3.43).
RZ572 RZ551 No RZ
Time (hours)
O  O  t-  CM CO O O  CM CO o  c\i co
Figure 3.43. Single-turnover ribozyme cleavage timecourse performed with RZ551 and 
RZ572. 100-fold ex ce ss  ribozyme w as incubated with radiolabelled RZSUB in 1X 
ribozyme hybridisation buffer supplemented with EDTA (final concentration 10mM) 
overnight at 37°C. Following this incubation, MgC  ^ w as added to a final concentration of 
20mMto initiate ribozyme cleavage. Aliquots were taken at various time-points and added 
to formamide gel-loading buffer. Samples were heated at 95°C prior to running on a 12% 
denaturing polyacrylamide gel. The multiple bands seen across all three samples are the 
result of non-specific RNase degradation of RZSUB. Because of this degradation, no 
evidence of ribozyme cleavage can be seen.
It can be seen that there is a large amount of degradation of the radiolabelled RNA in 
both of these experiments. Because of exposure to RNase degradation during the overnight 
pre-incubation of ribozyme with substrate in the absence of Mg2+, it was decided to simply 
start the ribozyme reactions by mixing purified ribozyme and substrate RNAs in IX 
ribozyme hybridisation buffer supplemented with 5mM MgCl2. This does not allow the 
cleavage reaction to be separated from the ribozyme-substrate hybridisation reaction. 
However, by performing the reactions under single turnover conditions, the only steps 
which could potentially influence the cleavage rate are ribozyme-substrate hybridisation and
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substrate cleavage. As the rate of ribozyme-substrate hybridisation has been determined by 
gel-shift assay (see section 3.1.3), any differences seen between the rate of ribozyme- 
substrate hybridisation and the rate of cleavage, as determined under single turnover 
conditions, must be attributable to the phosphodiesterase reaction catalysed by the ribozyme 
core.
Cleavage reactions were performed with at least a 50-fold excess of ribozyme over 
substrate. The quantity of ribozyme was increased until the rate of cleavage did not increase 
with further addition of ribozyme. In all cases this was achieved with a 100-fold excess of 
ribozyme over substrate. Experiments were repeated in triplicate, with cleavage products 
being analysed by denaturing polyacrylamide gel electrophoresis (figures 3.44). Band 
intensities were quantified using the phosphorimager. Percentage cleavage was determined 
using the formula
I" Product 1 1  _j_ [" Product 2 "1
L no. U residuesJ L no. U residuesj
[ Product 1 "I _|_ I" Product 2 "1 ^  I” Uncleaved substrate"! no. U residuesj L no. U residuesj L no. U residues J
(v)
where the intensities of each band are normalised by dividing the intensity obtained from the 
phosphorimager by the number of radiolabelled U residues in the RNA. Note that only one 
band is visible in the RZ572 and RZ572B timecourse cleavage gels (figures 3.44b and 
3.44c). This is because the smaller cleavage product only contains a single U residue, and is 
therefore not labelled to a sufficiently high specific activity to be detectable.
Despite repeated attempts, it was not possible to get RZ551 working in the single 
turnover timecourse experiments. Therefore only data is presented for RZ556, RZ572 and 
RZ572B (figure 3.45). It can be clearly seen that RZ556 and RZ572B have similar cleavage, 
rates (2X1 O'2 fmol/min and 3X 10 2 fmol/min respectively), whilst RZ572 cleaves 5-fold 
faster (14.6X10'2 fmol/min).
3.2.5 Multiple turnover
The main argument put forward favouring ribozymes over antisense is that 
ribozymes are predicted to be able to cleave multiple substrates through successive cycles of 
ribozyme-substrate hybridisation followed by substrate cleavage and the subsequent 
dissociation of the cleavage products. In contrast, one antisense oligonucleotide can only 
inactivate one target RNA. Antisense inhibition also has the potential to be reversible, with 
the antisense oligonucleotide dissociating from its target. The ability of ribozymes to cycle 
can be tested by incubating the ribozymes with an excess of substrate, and determining 
whether the quantity of cleaved substrate exceeds the quantity of ribozyme. In the present 
study it was found to be impossible to detect any cleavage products under such conditions.
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Figure 3.45. Ribozyme cleavage timecourses. The data presented are the averages of at 
least five experiments, with standard deviations shown. Ribozyme cleavage w as  
performed under single-turnover conditions, with ribozymes in 100-fold ex ce ss  over 
substrate RZSUB. Cleavage rates were determined from linear best fits made to each plot 
(dotted lines). Calculated cleavage rates are: RZ556, 2X10'2 fmol/min; RZ572B, 3X10'2 
fmol/min; RZ572,14.6X1 O'2 fmol/min.
Ribozyme RZ556 RZ572 RZ572B
k2 (4.1±1.4)s'1iy/T 3.27 s'1 M"1 (23.9±9.2)s'1M'1
Cleavage rate 2X1 O'2 fmol/min 14.6X1 O'2 fmol/min 3X1 O'2 fmol/min
Table 3.5. Comparison of pseudo-first order ribozyme-substrate hybridisation rate 
constant (k2) and single-turnover cleavage rates for ribozymes RZ556, RZ572 and 
RZ572B and substrate RZSUB.
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3.2.6 Discussion
The gel-shift assays described in section 3.1.3 showed that only ribozymes RZ534 
and RZ568 failed to bind to RZSUB. These observations were supported by the 24 hour 
ribozyme cleavage incubations in 5mM MgCl2 (figure 3.40) which showed that RZSUB was 
cleaved by all the ribozymes except RZ534 and RZ568. A comparison of ribozyme- 
substrate association constants and rates of cleavage is shown in table 3.5.
The most interesting observation made in the single-turnover timecourse experiments 
was the difference in cleavage rates between RZ572 and RZ572B. RZ572B was designed to 
cleave at the same point in RZSUB as RZ572. Despite RZ572B having a 13-fold greater 
affinity for RZSUB than RZ572 (see section 3.1.3c), RZ572B was only able to cleave, 
when in excess, 35% of RZSUB. As the catalytic core is the same in both ribozymes, and 
both are cutting at the same triplet (thus eliminating the variable cleavage efficiencies seen at 
different NUX triplets) it is surprising that there is such a large difference in cleavage 
efficiencies. Long-flank ribozymes have been shown to have reduced cleavage rates in 
multiple turnover experiments compared to short-flank ribozymes targeted against the same 
point. However, in the current study, a large excess of ribozyme was used. It is assumed 
that all accessible ribozyme binding sites in the substrate become occupied by ribozyme, after 
which the substrate is cleaved. As all the substrate is cleaved in one cycle of ribozyme 
activity, dissociation of products from the ribozyme does not influence the rate of cleavage. 
It is the rate of product dissociation which is reduced by lengthening the ribozyme flanking 
sequence.
Why should the seemingly identical catalytic cores of ribozymes RZ572 and RZ572B 
cleave RZSUB at different rates? Clearly the long flanking sequences of RZ572B are 
influencing the cleavage rate, possibly by inducing changes in the structure of RZSUB. 
Analysis of the three-dimensional structure of hammerhead ribozymes reveals that the 
scissile bond is twisted away from the normal bond angle for a phosphodiester linkage (see 
section 1.12.4c). It is believed that this twisting enables the hammerhead ribozyme to lower 
the activation energy of the phosphodiesterase reaction and, in so doing, catalyse the 
cleavage of the substrate RNA. It would appear that inducing mechanical stress at the 
scissile bond promotes cleavage.
RZ572 binds between bases 564 and 580 of RZSUB whilst RZ572B binds to the 
entire length of RZSUB (figure 3.46). Therefore when RZ572 binds to RZSUB the double­
stranded region formed between bases 530 to 534 and bases 581 to 585 should be 
maintained. This will keep RZSUB in a stem loop structure. In contrast when RZ572B 
binds to RZSUB, the stem loop structure of RZSUB will be lost (figure 3.47). It is 
hypothesised that the phosphodiester linkages in the single-stranded region of the stem loop 
form of RZSUB will be under more strain than those in the linear form of RZSUB bound to 
RZ572B. This extra strain should favour an increased rate of cleavage of the stem-loop form 
of RZSUB.
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Figure 3.46. T he binding of RZ572 to RZSUB. The stem -loop of RZSUB, corresponding 
to b a s e s  526 to 585 of the pre-core/ core O RF is show n in light type. T he flanking 
s e q u e n c e s  of RZ572 (both 8 b a s e s  long) are show n in bold, underlined type. The 
c leavage  point for ribozym es RZ572 and  RZ572B is indicated by an arrow, and  the target 
triplet, CUC, is highlighted in bold type. RZ572 binds betw een  b a s e s  564 and 580 of 
RZSUB, whilst RZ572B (total length of flanking se q u en ces  59 b a se s )  binds to the entire 
length of RZSUB.
To confirm this hypothesis it is necessary to confirm the structure of the ribozyme- 
substrate intermediates formed between RZ572 and RZSUB and RZ572B and RZSUB. 
This could be achieved by RNase mapping, as described in section 3.1.3c. However, this 
could be difficult because of the presence of ribozyme and substrate RNAs which are not 
part of a ribozyme-substrate complex. It may be necessary to stabilise any ribozyme- 
substrate complex using intercalating agents such as psoralen or acridine (see section 1. 10), 
and then purify the stabilised complex by gel electrophoresis prior to RNase probing.
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(a) (b)
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Figure 3.47. Hypothetical changes in the structure of RZSUB on the binding of ribozymes 
(a) RZ572 and (b) RZ572B. RZSUB (bold line) is predicted to assume a stem-loop 
structure (shown in detail in figures 3.3 and 3.45). The stem is kinked as the result of bases 
535 to 539 being single-stranded. Both ribozymes are represented as narrow lines, with 
the conserved catalytic core shown as a loop. RZ572 is designed to bind between b a ses  
564 and 580 of RZSUB. This is predicted to partially disrupt the double-stranded stem of 
RZSUB, though the double-stranded region formed between bases 530 to 534 and b a ses  
580 to 585 should be maintained, with the result that the RZSUB portion of the 
RZ572:RZSUB complex should maintain a stem-loop structure (a). In contrast, RZ572B is 
designed to bind to the entire length of RZSUB, between bases 526 and 585. It is 
predicted that this should completely destroy the stem-loop structure of RZSUB. The 
resulting RZ572B:RZSUB complex is predicted to be linear and completely double­
stranded (b). It is proposed that the differences described here between the ribozyme- 
substrate complexes explain the differences in cleavage rates between RZ572 and 
RZ572B. The increased rate of cleavage observed with RZ572 is believed to result from 
increased torsional stress at the scissile bond as a result of the substrate being twisted into 
a stem-loop.
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3.3 CAN RIBOZYMES BLOCK PROTEIN SYNTHESIS?
3.3.1 Intracellular ribozyme activity.
Despite the large number of in vitro studies which have successfully demonstrated 
ribozyme-mediated cleavage of a wide variety of mRNA substrates, there has been limited 
success in repeating these results in cell culture. This can be attributed in part to the 
intracellular environment, which is very different from the conditions used in vitro. RNA 
binding proteins could block ribozyme binding sites either by blocking ribozyme target 
sequences, or by changing the substrate secondary structure. These proteins could also bind 
to the ribozyme RNA itself. Substrate and ribozyme RNAs could be localised to different 
intracellular compartments, though inclusion of appropriate signal sequences in the ribozyme 
RNA can get around this problem (see section 1.12.4f). Intracellular ribozyme activity could 
even be affected by the medium in which cells are cultured. In vitro studies have shown that 
hammerhead ribozyme activity can be inhibited by neomycin, an antibiotic widely used in the 
establishment of mammalian cell lines (Murray & Arnold, 1996).
Although many early studies claimed to have observed inhibition of protein synthesis 
due to intracellular ribozyme activity, the majority failed to use the correct controls to confirm 
that this was mediated by ribozyme cleavage. There are two methods for confirming 
intracellular ribozyme activity. The first is to use a ribozyme containing an inactivating point 
mutation in its conserved catalytic core. This inactive mutant ribozyme will still be able bind 
to, but not cleave, its target. Therefore any inhibition of protein synthesis observed when 
this mutant ribozyme is used can be attributed to an antisense mechanism. Studies utilising 
such controls have revealed that, across a range of substrates and cell types, some or all of a 
ribozyme’s inhibitory potential is attributable to antisense effects. The second method to 
search for cleavage products. As most target mRNAs are at very low abundance, this is very 
difficult, and few studies have demonstrated cleavage of endogenous transcripts. It is easier 
to detect transcripts expressed to high copy number from transfected plasmids, or which 
have been transcribed in vitro and introduced into cells by microinjection.
Because of time constraints, it was not possible to test the efficacy of ribozymes 
RZ534, RZ551, RZ556, RZ568, RZ572 and RZ572B in transfected human hepatoma cells. 
Therefore it was decided to use the rabbit reticulocyte lysate in vitro coupled transcription- 
translation system (Promega). This allowed the constructs used for generating ribozyme and 
substrate RNAs for the in vitro ribozyme-substrate hybridisation (section 3.1) and ribozyme- 
mediated cleavage (section 3.2) to be used. DNA templates are transcribed in the reticulocyte 
lysate by T7 bacteriophage RNA polymerase, generating RNAs for translation. In addition 
to the plasmid p5D, which encoded HBcAg, a second plasmid pBL, encoding firefly 
luciferase, was used as an internal control in all ribozyme reactions.
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3 .3 .2  Expression o f ribozymes and proteins in rabbit reticulocyte lysate.
All constructs used contained a T7 bacteriophage promoter. All incubations were 
performed at 30°C for 2 hours in accordance with the users manual.
Ribozymes were expressed from partially single-stranded oligonucleotide templates 
(figure 3.13). Expression was confirmed and quantified by northern blotting (figure 3.48), 
with ribozyme RNA produced at a concentration of approximately 4pM  in the rabbit 
reticulocyte lysate system when 0.1  lp g  of oligonucleotide template was used.
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Figure 3.48. Northern blot of RZ572B RNA. Dilutions of partially single-stranded 
oligonucleotide transcription template RZ572B w ere added to 30pl rabbit reticulocyte lysate 
coupled transcription-translation reactions. Reactions were incubated at 30°Cfor 2 hours. 
RNA w as extracted by phenol/ chloroform extraction followed by ethanol precipitation. 
The resulting RNA pellets were resuspended in 15pl H2O. 5pl of the resuspended RNA 
w as run on a 2% agarose, 1% formaldehyde gel in 1X MOPS buffer. In addition, a dilution 
series of RZ572B RNA generated by in vitro transcription w as run on the same gel. The 
gel w as blotted onto Hybond-N nylon membrane in 10X SSC buffer. The blot w as probed 
with oligonucleotide RZ572BT 5’-endlabelled using y32P-ATP and T4 polynucleotide kinase. 
Band intensities were determined by phosphorimager scanning. Accurate determination 
w as impossible due to the diffusion of the RNA bands during the blotting process. This 
w as a result of the extremely small size of the RZ572B RNA (82 bases), which reduces 
the transfer and binding efficiencies of the RNA to the nylon membrane.
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Production of HBcAg mRNA was confirmed and quantified by northern blotting 
(figure 3.49). HBcAg mRNA was produced at a concentration of approximately 0.8pM  in 
the rabbit reticulocyte lysate system when 0 .5pg of template DNA was used.
in vitro transcribed 
5D RNA (pmoles)
Figure 3.49. Northern blot of core mRNA. 0.5pg of p5D plasmid DNA w as added to a 30pl 
rabbit reticulocyte lysate coupled transcription-translation reaction. Following incubation at 
30°Cfor 2 hours, RNA w as extracted by phenol/chloroform extraction followed by ethanol 
precipitation. The resulting RNA pellet w as resuspended in 15pl H2O. 5pJ of resuspended 
RNA w as run on a 1% agarose, 1% formaldehyde gel in 1X MOPS buffer (HBcAg mRNA). 
In addition, a negative control lysate (-ve) in which no translation had occurred w as  
phenol/ chloroform extracted, and a dilution series of in vitro transcribed 5D RNA were run 
on the same gel. The gel w as blotted onto Hybond-N nylon membrane in 10X SSC buffer. 
The blot w as probed with core ORF PCR product, labelled by nick translation with a32P- 
dCTP. Despite RNase degradation, HBcAg mRNA could be detected in rabbit reticulocyte 
lysate following coupled transcription-translation reactions. The greater size of the 
transcripts in the lysate reactions results from the template being a circular plasmid rather 
than a linearized plasmid as in in vitro run-off transcription. With a circular template the T7 
polymerase has to scan further along the plasmid to reach the transcription termination 
signal.
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Is this mRNA translated to produce protein? Addition of 3>S-L-methionine to the 
rabbit reticulocyte lysate reaction allows the radiolabelling of proteins, and their subsequent 
detection by SDS-PAGE and autoradiography. Bands corresponding to the correct sizes for 
HBcAg and luciferase were detected (figure 3.50). Western blotting was used to confirm the 
identity of the postulated HBcAg band. No band was visible when a rabbit anti-HBcAg 
polyclonal antibody was used (figure 3.51). Instead, a broad, pale band was visible at the 
same point where HBcAg was expected to lie. This broad band is due to globin from the 
rabbit reticulocyte lysate which has a similar molecular weight to HBcAg (24kD). The great 
excess of globin over HBcAg blocks the anti-HBcAg antibody from binding to the HBcAg.
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Figure 3.50. Expression of HBcAg and luciferase in rabbit reticulocyte lysate coupled 
transcription-translation system. 1pg of plasmid DNA template (p5D encoding HBcAg, pBL 
encoding luciferase) were added to rabbit reticulocyte lysate supplemented with 35S-L- 
methionine. Reactions were incubated at 30°C for 2 hours. Samples were separated by 
SDS-PAGE and visualised by autoradiography. The bands shown are of the sizes  
expected for HBcAg and luciferase.
In order to separate any HBcAg away from the globin background 
immunoprecipitation was used. Anti-HBcAg polyclonal antibody was added to rabbit 
reticulocyte lysate following completion of the transcription-translation reaction. The 
resulting antibody-antigen complexes were pulled down using protein A-sepharose beads. 
Protein A is a bacterial protein which binds the F c portion of IgG antibodies. The 
radiolabelled protein is removed from the beads by boiling, and is visualised by SDS-PAGE 
followed by autoradiography. Use of this technique allowed the detection of HBcAg (figure 
3.52). The presence of luciferase was confirmed by performing an enzyme activity assay 
(figure 3.53)
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Figure 3.51. Western blot of HBcAg produced in rabbit reticulocyte lysate coupled 
transcription-translation system. Samples were separated by SDS-PAGE in Tris-glycine 
buffer. The gel w as blotted onto Hybond-N nylon membrane in Towbin buffer using a 
Biorad electroblotter. The blot w as probed with a rabbit anti-HBcAg polyclonal primary 
antibody and a sheep anti-rabbit secondary antibody/ peroxidase conjugate. The blot w as  
developed using the ECLchemiluminescent system (Amersham). The long exposure used 
here (1 minute) show s pale regions at 46 and 21.5 kD in both the positive and negative 
lanes. These are regions were protein in the sample has blocked the antibodies used to 
probe the blot from binding non-specifically to the membrane. The region at 21.5 kD can be 
attributed to globin from the reticulocyte lysate. This is approximately the same relative 
molecular weight as HBcAg, and masks any HBcAg present.
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Figure 3.52. Immunoprecipitation of HBcAg from rabbit reticulocyte lysate coupled 
transcription-translation reactions confirms HBcAg is being produced. Radiolabelled 
HBcAg w as expressed from the p5D plasmid during a 2 hour incubation at 30°C in rabbit 
reticulocyte lysate supplemented with 35S-L-methionine. On completion, the lysate w as  
cleared with protein A-sepharose beads. The beads were removed by centrifugation, and 
rabbit anti-HBcAg polyclonal antibody w as added and incubated at 4°C for 3 hours. The 
resulting antibody-HBcAg complexes were pulled down with fresh protein A-sepharose 
beads. HBcAg w as removed from the beads by boiling. Samples were separated by 
SDS-PAGE, and visualised by autoradiography.
156
Chapter 3 Results
250
CD (D > .
CD 0
O Oo
+
CD
Oo
Figure 3.53. Confirmation of luciferase activity after in vitro translation reactions. Rabbit 
reticulocyte lysate reactions were set up with either no DNA template (-ve), plasmids p5D 
and pBL (HBcAg and luciferase templates respectively) and p5D only. Active luciferase is 
clearly produced during cotranslation of p5D and pBL. Luciferase activity is measured in 
arbitrary luminescence units.
After demonstrating that all the constructs were being expressed in the rabbit 
reticulocyte lysate, reactions were set up containing plasmids p5D and pBL, plus individual 
ribozyme templates. 0.25jig of each template DNA were added to each reaction. In addition 
to the ribozyme reactions, a control reaction containing only p5D and pBL with no ribozyme 
template plus a negative control containing no added DNA were also set up. Reactions were 
incubated at 30°C for 2 hours, with samples being visualised by SDS-PAGE (figure 3.54). 
It was necessary to limit the amount of ribozyme template DNA, as translation appeared to be 
sensitive to high concentrations of oligonucleotide. This effect may be sequence dependent, 
as it was particularly pronounced with oligonucleotide RZ572BT (figure 3.55). However, 
this inhibition of translation was not a result of an antisense effect, as both luciferase and 
HBcAg production were inhibited.
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Figure 3.54 SDS-polyacrylamide gel of rabbit reticulocyte lysate reactions producing 35S- 
L-methionine labelled luciferase and HBcAg. HBcAg w as co-expressed with ribozymes 
RZ534, RZ551, RZ556, RZ568, RZ572 and RZ572B. Luciferase w as used as an internal 
control. Band intensities were quantified by phosphorimager scanning.
co
a>
X
CO
£>
8
■»o
3
o S
8 %
+ T1+ a) c
"ge
oc
ID
5 , 8 a
□J O 4-
x  3
CD I— + GO CD □0 ® CM
3  I  f tm o 
x  3 *
8
Figure 3.55. Inhibition of translation by oligonucleotide RZ572BT. Initial experiments 
showed a loss of both HBcAg and luciferase expression in rabbit reticulocyte lysates 
when the partially single-stranded oligonucleotide template for RZ572B (composed of 
annealed oligonucleotides T7P and RZ572BT) w as used. Coupled transcription-translation 
reactions were performed using both HBcAg and luciferase templates. In addition, the 
partially single-stranded template for RZ572B and oligonucleotides T7Pand RZ572BT were 
added. A negative control in which no DNA w as added w as also included (-ve). 
Translation of both HBcAg and luciferase were inhibited when either the partially single­
stranded template or oligonucleotide RZ572BT were used. Lowering the concentration of 
the partially single-stranded template allowed translation to proceed. Addition of RZ572B 
RNA did not affect translation.
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Gels were scanned with the phosphorimager, and the band intensities quantified as 
previously described (see section 3.1.3b). The level of HBcAg was expressed as the ratio 
between the intensity of the HBcAg band to the intensity of the luciferase band. These 
results were then expressed as a percentage of the control (luciferase and HBcAg only, no 
ribozyme). The mean results obtained from five experiments are shown in figure 3.55. The 
only significant variation is seen with RZ534 (p<0.05, Student’s t-test).
1.5 -i
Figure 3.56. Mean results from five ribozyme/ rabbit reticulocyte lysate reactions. The 
quantity of HBcAg is expressed as the ratio of HBcAg to luciferase, as determined by  
phosphorimager scanning. The data from all five experiments was normalised relative to 
the negative control (no RZ). The only significant variation was seen with RZ534 (p<0.05, 
Student’s t-test).
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Is this variation the result of ribozyme activity? Primer extension analysis was used 
to detect the presence of cleavage products. This method utilises a radiolabelled 
oligonucleotide primer which binds to the 3’ region of an RNA. Reverse transcriptase is 
used to extend from the primer to the 5’-end of the RNA. If the RNA has been cleaved by a 
ribozyme then the primer extension should be prematurely terminated (figure 3.56).
Full length RNA Ribozyme-cleaved RNA
a) Radiolabelled primer ___ * ___ *
b) Reverse transcription
............................ .................* ______ *
c) Radiolabelled cDNA
-------------* ---------- *
Full length cDNA
Truncated cDNA 
(from ribozyme- 
cleaved RNA)
Figure 3.57. Detection of ribozyme cleavage products using primer extension analysis. 
Primer extension analysis allows the precise mapping of the 5’ ends of RNA molecules, (a) 
A radiolabelled oligonucleotide primer is annealed near the 3’ end of the RNA of interest. In 
order to detect ribozyme cleavage products the oligonucleotide must bind on the 3’ side of 
the putative ribozyme cleavage point, (b) Reverse transcriptase is used to extend from 
the primer, using the RNA as a template, (c) Extension terminates at the 5’ end of the RNA. 
If the RNA has been cleaved by a ribozyme, then the resulting cDNA is shorter than that 
produced from full length RNA. (d) Resolution of radiolabelled cDNAs by polyacrylamide 
gel electrophoresis.
d) Electrophoresis
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RNA was acid-phenol extracted from rabbit reticulocyte lysate ribozyme reactions, 
and annealed to radiolabelled C2 primer. This primer, obtained from laboratory stocks, is 
designed to bind to the extreme 3 ’-end of the core ORF. Extension was performed using 
MMLV reverse transcriptase, and the products were separated by SDS-PAGE (figure 3.58). 
No ribozyme cleavage product was seen, only radiolabelled cDNA corresponding to the 
complete HBcAg mRNA as generated from the plasmid DNA template p5D.
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Figure 3.58. Primer extension of HBcAg mRNA ex tracted  from rabbit reticulocyte lysate 
ribozyme reactions, using radiolabelled primer C2. In all lanes  the  expected  cDNA product 
from full-length HBcAg mRNA is se e n  (approximately 640 b a ses ) . If ribozyme c leavage 
had occurred  it would be expected  that a  product of approximately 100 b a s e s  in length 
would be se en . This is not the c a se . The d e n se  band at the  bottom of the  gel is due to 
unextended primer. This band is higher up the  gel than would be expected  for a  28 -b ase  
long primer. This is possibly due  to there  being too much primer added  to the reaction, 
causing the  primer in the  sam ple to sm ear on the  gel.
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It was considered that perhaps this experiment was asking too much of the 
ribozymes. Rather than transcribing both the ribozymes and substrate simultaneously in the 
rabbit reticulocyte lysate it was decided to add ribozymes previously prepared by run-off in 
vitro transcription to rabbit reticulocyte lysate reactions in which HBcAg and the luciferase 
control were being transcribed and translated. Based on the estimated levels of HBcAg 
mRNA in the lysate reactions (0.8pM , see figure 3.49), a forty-fold excess of each 
individual ribozyme over substrate was added to the reticulocyte transcription-translation 
reactions. Initial reactions showed poor levels of HBcAg. This was thought to be due to 
insufficient non-coding sequence at the 5 ’-end of the HBcAg transcript. A second core 
construct containing a 5 ’ untranslated region was obtained (pZeo-5D), and was found to 
express large quantities of HBcAg (figure 3.59). This construct was used in subsequent 
ribozyme reactions. Following a 90 minute incubation at 30°C, the reactions were analysed 
by SDS-PAGE (figure 3.60). No inhibition of HBcAg production on addition of the 
ribozymes to the coupled transcription-translation can be seen. As a result of this it was 
decided not to proceed with analysis of the HBcAg mRNA.
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Figure 3.59. Comparison of expression of 35S-methionine labelled HBcAg from p5D and 
pZeo-5D in rabbit reticulocyte lysate coupled transcription-translation reactions. 0.5pg of 
each plasmid w a s added to a 12.5pl reaction, which w as incubated at 30°C for 90 
minutes. Samples were analysed by SDS-PAGE, using a 17.5% polyacrylamide gel. The 
wide protein band is the result of translation being initiated from multiple start codons.
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Luciferase
HBcAg
Figure 3.60. 17.5% SDS-polyacrylamide gel of luciferase and HBcAg expressed in rabbit 
reticulocyte lysate coupled transcription-translation reactions in the presence of 40pM anti- 
HBcAg ribozymes. The ribozymes were generated by in vitro transcription from partially 
single-stranded oligonucleotide templates, and were purified by phenol-chloroform 
extraction followed by ethanol precipitation. Individual ribozymes were added to 
transcription-translation reactions to a final concentration of 40pM. Reactions contained 
0.5|xg pZeo-5D (HBcAg template) and 0.025pg luciferase template. Reactions w ere  
incubated at 30°C for 90 minutes.
3 .3 .3  D iscussion
Of the six ribozymes used in the current study, only RZ534 appeared to produce a 
reduction in HBcAg levels in the rabbit reticulocyte lysate in vitro translation system. 
Although overloading the translation reactions with partially single-stranded oligonucleotide 
template was shown to reduce translation (figure 3.55), this was not the case with RZ534, as 
the luciferase internal control was not affected (figure 3.56).
Was this reduction in HBcAg expression by RZ534 the result of ribozyme cleavage 
of the 5D RNA. Primer extension analysis failed to detect any cleavage products in RNA 
extracted from any of the rabbit reticulocyte lysate ribozyme reactions (figure 3.58). On the 
basis of this data it appeared that RZ534 was functioning by an antisense mechanism. 
However, repeating this experiment with pre-synthesised ribozyme RNA, rather than 
transcribing the ribozyme in the coupled transcription- translation reaction, showed that non 
of the ribozymes caused a significant decrease in HBcAg production. Therefore the 
reduction seen with RZ534 in the initial set of reticulocyte reactions was probably a result of 
the oligonucleotide template.
The rabbit reticulocyte lysate system is not an ideal system for studying ribozyme 
activity. In vitro translation systems are designed to rapidly produce large quantities of
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protein. It has already been shown in sections 3.1 and 3.2 that the ribozymes used in this 
study have slow rates of hybridisation and cleavage. Northern blotting suggests that the 
ribozymes could be expressed from the partially single-stranded templates to give a five-fold 
excess of ribozyme over substrate. However, it is possible that the ribozymes, even when in 
excess over the substrate, are not being transcribed at a sufficient rate to enable them to keep 
up with the rapid rate of transcription and translation of HBcAg in the reticulocyte lysate 
system, and therefore cannot cause an appreciable reduction in protein synthesis. Even so, 
adding a large excess of pre-synthesised ribozyme RNA to the reticulocyte lysate reactions 
did not have any effect on HBcAg production (figure 3.60). The in vitro translation 
reactions only last for 90 minutes and are incubated at 30°C, whilst in section 3.2 it was 
shown that appreciable cleavage of the truncated substrate RZSUB took up to 10 hours at 
37°C. It is possible that the ribozymes used here may cause appreciable reduction of HBcAg 
synthesis in cell culture, as such experiments are likely to take at least 24 hours, and levels of 
target RNA are likely to be lower than those seen in the reticulocyte lysate system. 
However, such studies would have to take into account the problems associated with 
intracellular localisation and processing of RNAs.
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Despite the availability of an efficacious vaccine for twenty years, hepatitis B is still a 
major public health problem. Although the introduction of global vaccination would 
eventually lead to the eradication of HBV, there are still over 300 million chronic carriers 
around the world. There is an urgent need for cheap, efficacious antiviral agents to either 
clear the virus from these carriers, or to reduce their infectivity. Current antivirals, reviewed 
in sections 1.7 and 1.8, include immune system modulators and inhibitors of HBV 
polymerase. This study has investigated an alternative approach using hammerhead 
ribozymes to specifically cleave HBV transcripts. The main goal was to try and deduce how 
substrate secondary structure is involved in determining the susceptibility of different regions 
of RNA to ribozyme cleavage. Although there have been a number of studies addressing 
this question in the past, the current study has divided the ribozyme reaction into two parts; 
ribozyme-substrate hybridisation, and substrate cleavage, and investigated how substrate 
secondary structure affects both of these steps in turn.
4.1 DOES SUBSTRATE SECONDARY STRUCTURE AFFECT RIBOZYME 
ACTIVITY?
Previous studies performed with both antisense and ribozymes have come up with 
varying answers, due in part to differences in the reaction conditions used. Nucleic acid 
hybridisation is particularly sensitive to ionic concentrations (Wang et al., 1995). Also, 
ribozymes may bind to, but fail to cleave, their substrate. This does not mean that they will 
fail to work as gene-silencing agents, as they may still function in vivo  as antisense agents. 
This has been observed in some studies in which ribozymes have failed to work in vitro but 
have inhibited protein synthesis in cell culture (Crisell et al., 1993), though of course the 
converse is also true (Cotten & Bimstiel, 1989, Cameron & Jennings, 1994). For this 
reason it was decided to look at the two steps of the ribozyme reaction separately in vitro, 
then to see if these results could be duplicated in a cell-free translation system. In order to 
determine the effects of substrate secondary structure, a stem-loop was identified using 
computer modelling in the pre-core/core ORF which contained five potential ribozyme 
cleavage sites.
Ribozyme-substrate hybridisation was studied using a gel-shift assay system. Two 
different substrates were used: 5D RNA, corresponding to the entire pre-core/ core ORF, 
and RZSUB, a tmncated substrate corresponding to the stem-loop to which the ribozymes 
were targeted. A truncated substrate was used as this was less prone to RNase degradation. 
As described in section 3.1, the accuracy of this technique was very poor. The hybridisation 
constants differed between the two substrates used, with much stronger binding being seen 
when 5D RNA was used. This does contradict earlier observations in which ribozymes
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cleave shorter substrates more readily than longer substrates (Campbell et al., 1997), which 
does lead to questions about the validity of the data. However, the initial experiments do 
suggest that RZSUB tends to associate with itself to form aggregates rather than binding the 
ribozyme, which could have played a part in producing this unusual observation. Even with 
the large inaccuracies in the current study, this does have interesting implications for much of 
the in vitro work that has been performed with ribozymes. Many studies have utilised 
truncated substrates rather than full-length mRNAs simply due to ease of handling shorter 
RNAs. The differences observed here in the hybridisation constants of the ribozymes with 
each substrate (for example, RZ534 fails to bind to RZSUB, but binds strongly to 5D RNA) 
obtained in this study implies that the conclusions reached in earlier studies are questionable 
in their relevance to physiological conditions. The current study is also flawed in this respect 
as it has not used the full-length substrate for these ribozymes. In an HBV infected cell, the 
core protein is translated from the 3.5kb pgRNA, which contains the 639 base pre-core/ core 
ORF. It was not possible to use the pgRNA as a substrate, as it is necessary to work in 
category 3 containment facilities when using this potentially infectious RNA and such 
facilities were not available.
The inaccuracies arising in the quantification of the gel-shifts led to a large amount of 
variability between repeated assays performed with the same ribozyme and substrate. This 
lack of reproducibility was cause for concern. In addition to analytical problems, the RNA- 
RNA gel-shift assay system is very sensitive to fluctuations in experimental conditions. The 
biggest problem in this area lies with variability between different batches of RNA generated 
by in vitro transcription. This arises from salt contamination during the purification process. 
Although much care was taken with repeated ethanol washes of the precipitated RNA, it 
would probably have been better to use one of the ion exchange resin spin-column systems 
which are now available for purifying and desalting the RNA. Another problem arose from 
repeating the gel-shifts with different concentrations of unlabelled substrate. As the substrate 
was in excess over the radiolabelled ribozyme the hybridisation reaction should have been 
under pseudo-first order kinetics, and the resulting hybridisation constants should have been 
virtually the same. However, this was not the case (figures 3.20, 3.22, and 3.23). This 
suggests that the reaction was still following second-order kinetics (i.e. was dependent on 
the concentrations of both components) and a higher concentration of unlabelled RNA was 
needed for pseudo-first-order kinetics to be achieved. Many of the graphs produced from 
the gel-shift data (figures 3.18 to 3.27) do not follow straight lines. This suggests an initial 
phase of rapid hybridisation followed by a period of slower binding. This could occur as a 
result of one or both of the RNAs assuming more than one conformation. Although, again, 
many of these problems can be attributed to the inaccuracies of the technique, this is unlikely 
to be the sole cause of the non-linearity of the data sets, or the variability of the hybridisation 
constants. Given that the non-linearity was seen in multiple data sets, and that the errors
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associated with hybridisation constants within each group of experiments with the same 
RNA concentrations were small, it is unlikely that the observations described are artifactual.
With the problems arising from the gel-shift assay system, it was decided to develop 
an ELISA-based RNA-RNA hybridisation system (section 3.1.4). This would have the 
advantage of being able to screen many ribozymes at once, or a single ribozyme in a variety 
of reaction conditions. However, the ELISA failed to have sufficient sensitivity or 
reproducibility to serve as a successful assay system.
Do the results obtained in the gel-shift assays correlate to ribozyme-mediated 
cleavage activity? Only the truncated substrate, RZSUB, was used in the cleavage 
experiments due to the instability of the 5D RNA. An excess of ribozyme over substrate was 
used to ensure single-tumover conditions. Under such conditions the cleavage reaction, 
rather than hybridisation, would be the rate determining step. The results showed that a high 
hybridisation constant did not necessarily guarantee rapid substrate cleavage (table 3.5). The 
variation between RZ556 and RZ572 cleavage rates can be attributed to the differences in the 
target NUX triplet (CUA for RZ556 and CUC for RZ572), which has already been shown 
to affect ribozyme activity (Zoumadakis et al., 1995). However, the difference in cleavage 
rates between RZ572 and RZ572B is more interesting. Both ribozymes were designed to 
cleave at the same target triplet. RZ572 has total flanking sequences of 16 bases, whilst 
RZ572B has total flanking sequences of 60 bases. Because of its longer flanking sequences, 
RZ572B binds more strongly to RZSUB than does RZ572. It has long been known that 
ribozymes with longer flanking sequences bind more strongly than those with shorter flanks; 
this observation is not dependent on the gel-shift assays described earlier. However, RZ572 
cleaves RZSUB more rapidly under single-tumover conditions. This eliminates the 
problem, seen with ribozymes with long flanking sequences, of slow product dissociation 
reducing cleavage rate. As described in section 3.2.6, it is hypothesised that the flanking 
sequences alter the secondary structure of the substrate, and in doing so alter the rate of 
cleavage. This implies that a highly structured substrate may be beneficial to ribozyme 
activity, provided that the ribozyme is able to hybridize with the substrate. The 
phosphodiester bonds in RNA stem-loops are under considerable torsional stress, which it is 
proposed makes them more susceptible to ribozyme cleavage.
4.2 DO RESULTS OBTAINED IN VITRO CORRELATE WITH THOSE 
OBTAINED IN A CELL-FREE TRANSLATION SYSTEM?
As described previously, many studies have failed to convincingly duplicate in vitro 
results in cell culture. Either ribozymes which cleaved their substrate in vitro failed to 
function in cell culture, or else inhibition of protein synthesis was observed but the lack of 
adequate controls made it impossible to attribute this inhibition to ribozyme cleavage. Due to 
time constraints it was not possible to test the ribozymes designed in this study in cell 
culture. Instead it was decided to use the rabbit reticulocyte lysate coupled transcription-
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translation system, which would enable the same constructs used in the earlier part of the 
study to be used.
A plasmid expressing firefly luciferase was used as an internal control to ensure that 
any inhibition of protein synthesis by the constructs used was specific to HBcAg. 
Following the reticulocyte ribozyme reactions, 35S-L-methionine labelled proteins were 
visualised by SDS-PAGE and the bands quantified by phosphorimager scanning. The 
quantity of HBcAg was expressed as the ratio of HBcAg band intensity to luciferase band 
intensity. Initially non-specific inhibition of all protein synthesis was observed if too much 
oligonucleotide transcription template was used. However, once the system was optimised it 
was seen that only RZ534 caused a significant drop (20%) in HBcAg levels. Primer 
extension analysis of the RNA from these reactions failed to detect any ribozyme cleavage 
products in any of the reactions. This suggests that the reduction seen with RZ534 is the 
result of an antisense mechanism. As RZ534 is an RNA, it may be assumed that protein 
synthesis is stopped prematurely by the ribosome stalling on the mRNA when it reaches the 
ribozyme. If this hypothesis is correct then an inactive mutant RZ534 should produce the 
same effects, though lack of time prevented this experiment from being performed. 
However, it is difficult to draw any realistic conclusions from this work, as the hybridisation 
and cleavage kinetics of the ribozymes used in this study may prevent them from causing any 
appreciable inhibition Of HBcAg expression in the rabbit reticulocyte lysate system, which is 
designed to rapidly produce very large quantities of mRNA and protein. It was decided to 
add ribozyme RNA synthesised by in vitro transcription to the reticulocyte lysate reactions. 
Under these conditions no inhibition of protein synthesis was seen with any of the 
ribozymes. This suggests that the inhibition seen with RZ534 was caused by the 
oligonucleotide transcription template for this ribozyme. It would be preferable to study 
ribozyme activity in cell culture, with HBcAg being expressed under the control of its 
endogenous promoter, in order to determine if these ribozymes are efficient enough to affect 
a natural HBV infection.
4.3 FUTURE PROSPECTS FOR RIBOZYMES
Will ribozymes live up to their early high expectations and find a place in medicine? 
Antisense oligonucleotides have survived the recent questions surrounding their safety and 
mechanism of action (see section 1.11.5), with a number of protocols currently in clinical 
trials. However, these antisense protocols are all based on chemically modified 
oligonucleotides which are synthesised exogenously and delivered as conventional 
pharmaceuticals (Bayever & Iversen, 1994, Bishop et al., 1996). Although chemically 
modified active ribozymes have been constructed, it will be preferable for many applications 
to express unmodified ribozymes from genes delivered to the target tissue.
Despite early enthusiasm, the field of human gene therapy has stalled due to the 
requirements for safe, efficient vectors. A number of different approaches have been
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investigated. These can be divided into non-viral and viral methods. Non-viral methods 
have focused on cationic liposomes (Song et a l., 1997). The DNA of interest wraps around 
the liposome. The lipid component of the DNA-liposome complex fuses with the plasma 
membrane and deposits the DNA into the endosome. Because of the digestive enzymes in 
the endosome most of the DNA delivered in this fashion is destroyed. Therefore this method 
has very low efficiency in vivo as demonstrated in early trials of corrective gene therapy for 
cystic fibrosis (Caplen eta l., 1995). Liposomes also have no target cell specificity, though 
current studies are attempting to target liposomes by embedding ligands for cell surface 
receptors into the liposome (Feigner, 1996). An alternative cationic DNA carrier is poly-L- 
lysine (Martinez-Fong eta l., 1994). This can be covalently linked to proteins to enable cell 
targeting. Numerous experiments have utilized poly-L-lysine-asialoglycoprotein conjugates, 
which are targeted to hepatocytes. This has enabled antisense oligonucleotides (both 
unmodified and with phosphorothioate backbones) to be successfully targeted against 
transient transfections of HBsAg in hepatocytes (Wu & W u, 1991) and against W HV in 
woodchucks (Bartholomew eta l., 1995). Another alternative is to conjugate DNA to native 
lipoproteins called chylomicrons which are targeted to the liver (Rensen et al., 1995).
Viral vectors come in several categories; retroviruses, adenoviruses and adeno- 
associated virus. Retroviruses are widely used for transduction of mammalian cells, though 
they do have a limited coding capacity (though this is not a problem for small antisense and 
ribozyme constructs) and concerns have been raised about the possibility of recombination 
with endogenous human retroviruses. Because of this only murine retroviruses have been 
used for human applications to date, and these are only licensed for ex vivo  use, as in the 
trials of the anti-HIV-1 hairpin ribozyme (section 1.12.3b) (Ho e ta l.,  1994, Rosenzweig et 
al., 1997). Although retroviruses can integrate into the host chromosomes, thus stably 
transducing target cells, they can only do this in dividing cells. Future protocols are likely to 
be based on lentiviruses which are capable of infecting non-dividing cells. Target specificity 
can be altered either by chemical modification of surface glycoproteins (Neda et al., 1991) or 
by generating pseudotyped viruses containing surface proteins from a source other than the 
parent retroviral strain (Freedman & Yee, 1995). Adenoviruses have a large coding 
capacity, and the ability to efficiently infect a wide variety of cell types. The penton base 
protein in the viral capsid allows viral DNA to be delivered into the cytoplasm from the 
endosome (Seth, 1994). Adenovirus vectors have been successfully used to transfect human 
hepatocytes with anti-HCV ribozymes (Lieber eta l., 1996a) and to target anti-human growth 
hormone ribozymes to the livers of transgenic mice (Lieber et a I., 1996b). However, safety 
issues concerning lack of tissue specificity and possible immune reaction make adenoviruses 
unattractive vectors. This follows the development of pneumonia in a number of patients in 
a phase I clinical trial utilizing adenovirus vectors in corrective therapy for cystic fibrosis 
(Wilmott et al., 1994, Wilmott et al., 1996). There is also the possibility of an immune 
response being raised against the vector. This is likely to be mediated by memory cells as
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the vast majority of the population has been infected at one time or another with at least one 
strain of human adenovirus. Because of this it is likely that adenoviruses from other 
mammalian species will be used in future (Klonjkowski et al., 1997). The adeno-associated 
virus, which is a satellite virus of human adenoviruses, is able to insert into a specific site in 
chromosome 19, which does not disrupt any proto-oncogenes (which is a risk of using 
randomly integrating retroviruses). Adeno-associated virus is not associated with any 
disease. However, the limited coding capacity and also the potential to recombine with other 
parts of the host DNA at low frequency do pose problems (Linden et al., 1996).
The problems of delivery mean that initial ribozyme therapy protocols (and indeed 
gene therapy protocols in general) are likely to fall into three groups. The first involves ex 
vivo modification of tissues which are then replaced into the patient. The most obvious 
application is in the area of haematological disorders. This is already happening with the 
anti-HTV-1 hairpin ribozyme trial. It has been proposed to use antisense oligonucleotides to 
purge the bone marrow of leukaemia patients of malignant cells (Bishop et al., 1997). The 
treated bone marrow would then be returned in an autologous transplant back to the patient. 
The ex vivo approach allows a specific cell population to be exposed to a vector which may 
not have a high tissue specificity without exposing non-target tissues to transduction. The 
modified cells can be screened before return to ensure all vector has been removed. The 
second area concerns the treatment of solid tumours. Vectors can be injected directly into the 
tumour, removing the need for the vector to circulate around the body searching for its 
target. This approach has already been used with El-negative adenoviruses (Kirn et al., 
1997). These are only able to grow in cells where the p53 tumour suppressor is inactive, 
producing a lytic infection which destroys tumour cells, but leaves healthy tissue untouched. 
The final area involves treatments of external disorders. These are almost entirely 
dermatological, and could include papillomavirus infection and melanoma. Antisense 
oligonucleotides targeted against human papillomavirus strains 16 and 18 (implicated in 
cervical cancer) have blocked viral expression in cultured cells taken from genital warts 
(Baker & Tyring, 1997). Such therapies are likely to be delivered in a liposome cream 
preparation, with uptake possibly enhanced by the addition of dimethylsulphoxide.
Clearly none of these approaches are suitable for the long-term treatment of viral 
hepatitis. As described above, both viral and non-viral delivery systems have been used in 
animal models to target ribozymes or antisense to the liver. W hether these approaches would 
be suitable for long-term treatment is unknown. Repeated administration with such vectors 
could lead to an immune response which could at best lead to failure of therapy or, at w orst, 
lead to a range of immune complex disorders. It would be more desirable to use a retroviral 
or lentiviral vector which could stably integrate into hepatocytes and produce a population of 
HBV-resistant hepatocytes. An alternative approach would be to use HBV itself as a vector. 
Inclusion of an HBV encapsidation signal and direct repeats DR1 and DR2, into a vector 
construct would enable the therapeutic RNA to be encapsidated by viral proteins present in
170
a) Cell-line of in terest
G ene-X / G FP  fusion retrovirus
LTR Gene-X LTR
b) Stably tran sd u ce  
cell-line with retrovirus
c) Clone library of 
random  oligonucleotides 
into p lasm ids
d) T ransien t transfection  
of G ene-X / G FP cells
e) FACS selection
f) N on-fluorescing cells. Extract plasm ids, 
retransform  into bacteria . Grow up bac te ria  
and re-ex tract p lasm ids.
g) T ransfect into cells tran sd u ced  
with G FP  control retrovirus. Control retrovirus
LTR LTR
h) FACS selection 
& k) Extract p lasm ids, 
perform  m utagen ic  
P C R ,rec lone  back 
into plasm ids.
i) D iscard non-fluorescing 
cells. Library construct 
inhibiting G FP O RF
j) Fluorescing cells. Library 
construct inhibiting gene-X , 
but not G FP  O R F REPEAT
Chapter 4 Conclusions
Figure 4.1. Proposed scheme for intracellular selection of gene-silencing RNAs. a) For 
the initial round of selection the cell-line of interest must be stably transduced with an 
appropriate reporter construct (b). This can be rapidly acheived using a retrovirus 
containing a fusion of the gene of interest (gene-X) and the jellyfish green fluorescent 
protein (GFP) ORFs. It must be ensured that such a fusion protein still has the GFP 
fluorescence activity.
c) A library of random synthetic double-stranded oligonucleotides is cloned into 
plasmids under the control of an appropriate mammalian promoter. The oligonucleotides 
could have either an entirely random sequence, or a ribozyme catalytic domain could be 
included in the centre of the oligonucleotide and be flanked by random sequences, d) The 
library is transiently transfected into the gene-X/ GFP cells. The amount of plasmid DNA 
added to the cells should be such that on average each transfected cell contains one 
plasmid, e) Some of the cells will contain plasmids which are expressing RNAs that block 
expression of the gene-X/ GFP fusion protein. These cells will fail to fluoresce, and can be 
separated from the rest of the cells by fluorescence activated cell sorting (FACS) 
scanning, f) Plasmids are extracted from the non-fluorescing cells. These can be 
amplified by retransforming the plasmids back into bacteria, growing up the bacteria, then 
re-extracting the plasmids.
Some of the constructs which inhibited fluorescence in the first round of selection 
could have been acting by ribozyme or antisense mechanisms on the GFP ORF rather than 
the gene-X ORF. These must be removed from the selected plasmids, g) The plasmids are 
transfected into cells stably transduced with a retrovirus only expressing GFP. h) The 
transfected cells are again sorted by FACS. I) The non-fluorescing cells are discarded. 
The constructs in these cells are inhibiting GFP directly rather than by targeting the gene-X 
portion of the fusion transcript, j) The fluorescing cells have been transfected with 
constructs which, although they can target the gene-X ORF, do not affect the GFP 
transcript directly, k) The plasmids are extracted from the fluorescing cells. The selected  
plasmids can be further enriched by repeating the process back at step (d). The selected  
plasmids can be mutagenized by PCR, enabling mutations with enhanced inhibitory activity 
to be evolved. Selection pressure can be increased by increasing the stringency of 
selection by FACS. This can be done by altering the cut-off point between fluorescing and 
non-fluorescing cells.
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the patient’s liver. It would be necessary to include the polymerase gene, as the polymerase 
becomes associated with the encapsidation signal in the pgRNA from which it was 
translated, though the core, surface and X ORFs would be truncated, and therefore inactive. 
This would ensure that the vector could only be propagated in cells already infected with 
wild-type HBV. Once the vector construct was in the liver, it would produce a second 
generation of vectors which would go on to infect more HBV-infected hepatocytes. Such an 
approach is attractive in that only one initial injection of vector is required, after which the 
vector continues to multiply in the patient until all the wild-type HBV is cleared. Once the 
wild-type virus has been cleared there are no more proteins to package the vector, and the 
vector disappears. The main concern with this approach is that of safety, as the vector could 
foreseeably spread from the patient and infect other people. Although the vector should only 
replicate in people infected with HBV, such a possibility is not likely to be entertained by the 
current legislation concerning the release of genetically modified organisms. Although 
ribozymes and antisense could rapidly suppress HBV gene expression, the cccDNA would 
still be present. There are no therapies currently available which target the cccDNA. The 
only potential treatment would be triplex forming oligonucleotides, especially those 
conjugated to a chemically modifying group (see section 1.10). Initial cell culture studies 
utilizing HBV promoter/ luciferase reporter constructs have been encouraging (Ito et al., 
1997), though care would be needed to ensure that such oligonucleotides had sufficient 
specificity. It is unlikely that any form of gene therapy will be used in the foreseeable future 
for the treatment of chronic HBV given the current therapies available. Combination 
therapies consisting of such treatments as interferon, lamivudine, famciclovir and ganciclovir 
are proven to be effective, and are cheaper than a potential gene therapy treatment. Given 
that vector production would need to be closely monitored, would require extensive 
mammalian cell culture (if a viral method was used), and that patients would need close 
observation, it is unlikely that gene therapy would be practical outside of the developed 
world. As most of the world’s HBV carriers are in the developing world a cheap treatment 
requiring a minimum of doses is required. From this standpoint it appears that therapeutic 
vaccination is probably the most cost-effective and practical method of managing chronic 
HBV infection (section 1.7.7).
Although ribozymes are probably not going to find a place treating HBV, they could 
still be used in a variety of other applications. These are likely to be in dominant negative 
genetic disorders such as osteogenesis imperfecta (Marini & Gerber, 1997), where genes 
need to be silenced rather than replaced and in the treatment of tumours. An important factor 
to consider is the choice of ribozyme target site. It is clear from many studies, including this 
one, that in vitro studies do not necessarily correlate with those seen in cell-free translation 
systems and in cell culture. It can also be seen from the present study that ribozyme activity 
and substrate accessibility (as predicted by computer modelling) do not correlate. Therefore 
it is proposed that in future ribozymes should be designed by a method of intracellular
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selection, as detailed in figure 4.1. This method enables inhibitory RNAs to be selected in 
the environment in which they are ultimately supposed to function. By using a library of 
entirely randomised sequence not only ribozymes, but antisense and RNase P external guide 
sequences could potentially be selected. By performing multiple rounds of selection 
interspersed with rounds of mutagenic PCR, the initial selection from the library can be 
evolved through several generations to obtain the optimum inhibitor.
It is rapidly becoming clear that designing ribozymes purely by guesswork, as has 
been the case in nearly all ribozyme research to date, is far from being the best approach to 
coming up with gene-silencing tools. In vitro work has failed to progress successfully to 
cell culture and in vivo applications, leaving many groups disheartened with the ribozyme 
approach and writing it off as a dead end. Ribozymes will in the future have a place in the 
gene therapy armoury, though probably only in certain applications. The use of intracellular 
selection procedures will allow the rapid screening of RNA libraries and the identification of 
effective gene-silencing RNAs. However, for these constructs to become useful therapies, it 
will be necessary for safe and efficient delivery systems to be developed.
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